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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
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General introduction
Endometrial carcinoma in general
Endometrial carcinoma is the sixth most common cancer in females and the second most 
common gynecologic cancer worldwide after carcinoma of the cervix. An estimated number 
of 287,100 new cases are diagnosed each year. In the western world, it is the most common 
gynecologic cancer.1 In the Netherlands, it accounts for over 1900 newly diagnosed patients 
each year, and approximately 400 patients die as a consequence of the disease.2 Two of 
the most important prognostic factors are tumor grade, and stage of the disease according 
to the 2009 FIGO staging system (International Federation of Gynecology and Obstetrics) 
(Table 1).3,4 In general, endometrial carcinoma patients have a favorable prognosis, with a 
five-year overall survival rate of 80%. This relatively good prognosis can be partly attributed 
to the early presentation of the disease with postmenopausal vaginal blood loss or irregular 
premenopausal vaginal bleeding.5 
Table 1: FIGO 2009 Staging System.
FIGO stage Grade Characteristics
I
     A
     B
G123
G123
Carcinoma confined to uterus
     No myometrial invasion or less < 50%
     Myometrial invasion > 50% 
II G123 Invasion of the cervical stroma
III
     A
     B
     C1
     C2
G123
G123
G123
G123
Metastases in the pelvic cavity
     Involvement of adnexa
     Involvement of the vaginal wall
     Involvement of pelvic lymph nodes
     Involvement of para-aortic lymph nodes 
IV
     A
     B
G123
G123
Distant metastases
     Abdominal metastases outside the pelvic cavity
     Thoracal metastases
G1: 5% or less of a nonsquamous or nonmorular solid growth pattern
G2: 6-50% of a nonsquamous or nonmorular solid growth pattern
G3: more than 50% of a nonsquamous or nonmorular solid growth pattern
Notable nuclear atypia inappropriate for the architectural grade, raises a grade 1 or grade 2 tumor by one grade
Clearcell adenocarcinoma and serous adenocarcinoma are grade 3 tumors
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The appearance of normal endometrium 
The endometrium in premenopausal women shows a cyclic pattern of proliferative, 
secretory, and declining endometrium.6 The endometrial lining in postmenopausal women is 
expected to be atrophic.7-10 However, only few papers report on the appearance of “normal” 
postmenopausal endometrium. In addition, proliferative endometrium to some extent has 
been reported in a significant part of asymptomatic postmenopausal women.11 In order 
to understand the carcinogenesis of endometrial carcinoma, it seems necessary to know 
the normal appearance of both pre- and postmenopausal endometrium, and to determine 
the nature of the background endometrium found in the histologic specimens of uteri with 
endometrial carcinoma.
Histopathology and carcinogenesis
In endometrial carcinoma several histopathologic types are distinguished: endometrioid 
adenocarcinoma, mucinous adenocarcinoma, serous adenocarcinoma, clear cell 
adenocarcinoma, undifferentiated carcinoma, and mixed carcinoma (composed of more 
than one type, with at least 10% of each component).5 These histopathologic classifications 
are grouped in two different subtypes. This widely accepted dualistic model of endometrial 
carcinogenesis was proposed by Bokhman in 1985.12 He based the subdivision of endometrial 
carcinoma in two different types on observations of clinical behavior and histopathologic 
presentation of the carcinoma. 
Type I carcinoma, representing 80% of all endometrial carcinomas, occurs around an 
average age of 60 years and bears in general a good prognosis. These carcinomas are linked 
to unopposed estrogen stimulation caused by obesity, nulliparity, and exogenous hormone 
use. Unopposed estrogen stimulation may result in the development of simple hyperplasia 
of the endometrium, which may progress to atypical hyperplasia, and ultimately results 
in endometrioid endometrial carcinoma (EEC). Type I carcinomas are characterized by ER 
(estrogen) and PR (progesterone) expression, Micro Satellite Instability, and alterations in 
K-Ras, CTNNB1, PTEN, and the WNT-pathway.13-19 
Type II carcinomas, on the contrary, occur at an average age of 70 years, and bear a relatively 
poor prognosis. These carcinomas show non-endometrioid histology like serous and clear 
cell type, and are not linked to estrogen stimulation. The background endometrium of these 
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patients appears atrophic, and carcinomas are characterized by aneuploidy, p53 and Her2/
neu expression, and loss of E-cadherin expression.13-19 Table 2 shows an overview of the 
clinical and pathologic features in type I and type II carcinomas.
However, about 20% of the individual cases does not fit into this dualistic model, represented 
by endometrioid endometrial carcinomas with poor prognosis.14,20,21 Is has been suggested 
that a third type endometrial carcinoma exists: EEC with atrophic background endometrium 
and poor prognosis.21
Table 2: Clinical and pathologic characteristics in type I and type II endometrial carcinomas.
Type I Type II
60 years 70 years
Estrogen stimulated Not estrogen stimulated
Endometrioid type Non-endometrioid type
Good prognosis Poor prognosis
Hyperplasia of background endometrium Atrophy of background endometrium
Surgical treatment 
The cornerstone of endometrial carcinoma treatment is surgery. The standard treatment 
for clinical FIGO stage I disease includes hysterectomy and bilateral salpingo-oophorectomy. 
The further extent of the surgical treatment, and mainly the extent of lymphadenectomy has 
been a matter of debate for decades. In two large randomized multicentre trials, no survival 
benefit of routine lymphadenectomy could be demonstrated in apparently FIGO stage I 
endometrial carcinoma patients.22,23 However, many critical comments on the methodology 
of these trials have been expressed, and the last word has not been said in this worldwide 
controversy.24 
In the Netherlands, the guidelines of endometrial carcinoma treatment have recently 
been updated.2 For endometrioid endometrial carcinomas, with tumor grade 1 or 2, only 
hysterectomy with bilateral salpingo-oophorectomy is recommended. For tumor grade 3 
endometrioid carcinomas complete surgical staging is to be considered. For serous and clear 
cell carcinomas a complete surgical staging procedure is recommended. Complete staging 
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includes total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic washings, 
bilateral pelvic and para-aortic lymph node sampling and omentectomy or omental biopsy.25 
Adjuvant treatment 
The most important adjuvant therapeutic strategy in endometrial cancer treatment is 
radiotherapy, for which in the Netherlands, the PORTEC criteria are leading.26,27 The PORTEC 
I trial revealed that FIGO stage I patients, with two out of three risk factors (age above 
sixty years, tumor grade 3 and myometrial invasion more than 50%) do benefit from 
external beam radiotherapy for loco-regional control of disease.26 In addition, the PORTEC 
II trial revealed that vaginal brachytherapy is equally effective in preventing loco-regional 
recurrence when compared to external beam radiotherapy, with fewer gastrointestinal toxic 
effects.27 In patients with stage III or IV disease, or serous or clear cell histologic type, (neo)
adjuvant platinum based chemotherapy can be considered.28  
Individualized treatment 
Individualization of treatment is more and more important in this carcinoma with a relatively 
favorable prognosis, but with individual cases that present with an aggressive clinical course. 
It is challenging to identify those patients that need a more aggressive treatment, without 
over-treating the patients who are sufficiently treated with standard management. This way, 
recurrence of disease due to under-treatment, and morbidity and side-effects caused by 
unnecessary treatment can be prevented. To make accurate treatment decisions it is of great 
importance to be able to predict the clinical behavior of a carcinoma. Prediction of clinical 
behavior can be guided by histopathologic and immunohistochemical or molecular markers. 
These markers can be helpful both in preoperative and postoperative decision making.
 
Clinicopathologic markers
The decision of the extent of surgical therapy is primarily based on the histopathologic 
characteristics of the pre-operative biopsy of the endometrium. Biopsies can be obtained 
in the outpatient department using pipelle, or in a clinical setting by Dilatation & Curettage 
or hysteroscopy.29 It is obligatory to determine tumor type and tumor grade of the 
endometrial carcinoma in the biopsy. However, making the correct diagnosis based on 
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often small biopsies can be challenging. A second risk of misclassification is the possible 
heterogeneity of the tumors, when only a part of the tumor is represented in the biopsy. 
The postoperative reproducibility of the tumor grade based on preoperative endometrial 
biopsies obtained with pipelle, Dilatation & Curettage, or by hysteroscopy varies from 59% 
to 96% in literature.30-33 Therefore, for a substantial part of the patients the extent of surgical 
treatment may possibly not be chosen correctly. 
A second tool, which can be of possible help in the pre-operative setting, is cervical cytology. 
It has been proposed by several authors that cervical cytology can give direction in the 
diagnostic work-up of endometrial carcinoma patients. Malignant endometrial cells found 
in cervical cytology are associated with parameters of poor prognosis like more advanced 
FIGO stage and high tumor grade.34-36 Some authors suggest that positive cervical cytology is 
associated with serous or clear cell histologic type.37,38    
In addition, surgical therapy is based on clinical estimation of the FIGO stage of disease. 
Risk estimation for the presence of extended disease is challenging as well. For instance, 
in FIGO stage II disease, for which more extended surgery with pelvic lymphadenectomy is 
recommended, the pre-operative determination of cervical involvement may be complex. 
MRI is the most accurate way of defining cervical invasion, but does not show an acceptable 
sensitivity.39 Equally, MRI is the most accurate way of assessing myometrial invasion pre-
operatively. However, due to its low negative predictive value, it is not a useful screening 
tool in determining the absence of myometrial invasion.40 The identification of stage III or 
IV disease, i.e. metastases in lymph nodes or other distant metastatic sites, with imaging 
techniques is also prone to misinterpretation. CT and MRI are equivalent in terms of 
evaluating nodal metastases, but neither is sensitive enough to replace surgical lymph node 
assessment.5 An algorithm which predicts the presence of lymph node metastases has been 
developed by examination of myometrial invasion, tumor grade, and tumor diameter intra-
operative.41 However, this setting during operation bears logistic challenges, and it may not 
be implemented widely.    
Additionally, serum markers have been studied for their prognostic value in endometrial 
carcinoma. CA125 (cancer antigen 125), the most common used marker in endometrial 
cancer has been found to be elevated in 25% of the patients, providing information on 
potential extended disease outside the uterus.42 A more promising serum marker may be 
HE4 (human epididymis protein 4). HE4 can be helpful in predicting myometrial invasion and 
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high tumor grade. However, a correlation with the presence of lymph node metastases has 
not been proven, yet.43 Potentially, a combination of both tumor markers may better predict 
the presence of metastatic disease than either one alone.44 
Finally, as mentioned before, in the postoperative setting myometrial invasion and tumor 
grade are crucial in determining adjuvant treatment strategy.26 For tumor grading, the pre-
operative diagnosis needs to be evaluated on the hysterectomy specimen. In case of doubt 
about the diagnosis, immunohistochemical markers can be of additional help, which will be 
discussed later in this chapter. The assessment of myometrial invasion bears a substantial 
deal of intra-observer variability. Irregular endomyometrial junctions, exophytic tumors, 
smooth muscle metaplasia, and adenomyosis make the assessment of myometrial invasion 
challenging.45 In literature, other, possibly better, reproducible ways of assessing myometrial 
invasion have been proposed.46-48      
Immunohistochemical markers 
Many immunohistochemical markers and changes of molecular pathways are known to be 
predictive for clinical outcome in endometrial carcinoma patients. Some of these markers 
have been known for years already. Surprisingly, these markers are still not used to give some 
direction in correctly diagnosing and treating patients with suspicion of endometrial cancer, 
like in breast cancer for example. The best known markers in the prediction of disease free- 
and overall survival in endometrial carcinoma patients are the expression of p53, MIB1, 
and loss of ER and PR expression.49-53 Other identified markers are changes in expression of 
β-catenine, a gain in expression of stathmin and PIK3CA, and loss of MLH1, E-cadherin, p21, 
and p16 expression.14,15,20,51,54-58 In addition, expression of L1CAM has been identified to be a 
promising marker in endometrial carcinomas.59-61 L1CAM has recently shown to be a strong 
predictive marker in a large cohort of early stage EEC patients.62 
Most of these markers are also known to be helpful in the distinction between type I and 
type II carcinomas, again reflecting the prognostic information.63 All markers associated with 
type II carcinomas are associated with poor prognosis as well. Table 3 shows an overview of 
the changes of several pathways and markers in type I and type II carcinomas. An overview 
of the best studied pathways in endometrial carcinoma is shown in Figure 1.14
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Table 3: Immunohistochemical and genetic changes in type I and II endometrial carcinomas.
Marker Function Type I Type II
Microsatellite 
instability
Defect mismatch repair genes, accumulation mutations 
microsatellites
20-40% 0-5%
K-RAS mutation Ras-raf-MAP/ RAS signaling, oncogene, signal 
transduction, cell proliferation
13-40% 0-10%
B-RAF mutation Ras-raf-MAP/ RAS signaling, mediates cell growth and 
malignant transformation
23% 11%
↓MLH1, MSH2 Mismatch repair genes 20-40% 0-10%
↓PTEN PI3Kinase pathway, tumor suppressor gene, regulation 
cell cycle
30-60% 0-11%
↑PIK3CA PI3Kinase pathway, oncogene, mutations co-existing 
with PTEN mutations 
24-36% 24-36%
↑Stathmin PI3Kinase pathway, oncoprotein, promotes proliferation in aggressive EC*
↑/↓β-catenine WNT pathway, specification cell fate, regulation 
proliferation, dual function in cell signaling and adhesion
14-44% 0-5%
↑p53 Tumor suppressor gene, cell proliferation and apoptosis 5-20% 71-90%
↑/↓p21 Downstream effector in P53 pathway in aggressive EC
↑/↓p16 Tumor suppressor gene, cell cycle regulator 10% 10-40%
↑HER-2/neu Oncogene, epidermal growth factor receptor, cell growth 
and differentiation
3-10% 18-80%
↑L1CAM Transmembrane cell adhesion molecule in aggressive EC
↓E-cadherin Transmembrane cell adhesion molecule 10-43% 57-90%
↓ER/PR [14] Steroid receptor, transcription factors 70-73% 19-24%
↑MIB1 (Ki-67) Proliferation marker 53% 62%
↑Insulin Like 
Growth Factor 
Normal growth/development, mediating steroid 
hormone actions
in aggressive EC
↑VEGF Vascular endothelial growth factor in aggressive EC
*Endometrial Carcinoma
Mechanisms of metastasizing 
To be able to predict which patient actually has or will develop metastatic disease, 
more insight in the mechanisms of metastasizing in endometrial carcinomas is needed. 
Endometrial carcinoma spreads by exfoliation of cells that are shed through the fallopian 
tubes, lymphatic dissemination and/or hematogenous dissemination. The metastatic 
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process starts with the direct invasion of the tumor in the surrounding tissue: the 
myometrium. For this process to occur, epithelial tumor cells need to undergo an epithelial 
to mesenchymal transition (EMT).64 In EMT, epithelial cells lose their polarity and cell-cell 
contacts, undergoing a dramatic remodeling of the cytoskeleton end acquiring a migratory 
phenotype.65 This process has been extensively described in other types of cancer, and the 
cellular and molecular steps required for metastasis may be similar for all cancer cells.66 
Recently, few insights have been given in EMT in endometrial carcinoma. Some hallmarks 
of EMT have been reported in endometrial carcinoma either at the level of E-cadherin loss 
or the induction of its repressors.64,67 In addition, other molecular alterations are correlated 
with carcinomas with expression of EMT hallmarks. For example, L1CAM expression is 
correlated with loss of E-cadherin expression.61 After invasion of the myometrial tissue, and 
possibly the lymphatic or blood vessels, cancer cells need to arrive and grow in sites distant 
Figure 1: The RAS signaling, AKT signaling and Wnt signaling pathway in endometrial carcinoma.
From: Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS. 
2009;117(10):693-707. Epub 2009/09/25.
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from the primary tumor.68 Also, for this step in the metastatic process few markers have been 
reported in endometrial carcinoma. For example, the expression of vascular endothelial 
growth factor (VEGF) and Insuline-like growth factor-1 receptor (IGF-1R) were associated 
with aggressive phenotype and lymph node metastases in endometrial carcinoma.69,70 
Taking all this together, although some markers in the metastatic process of endometrial 
carcinoma have been identified, essential parts of the mechanisms behind the metastatic 
process in endometrial carcinoma are still poorly understood.      
Aims of the thesis
Decades of research on endometrial carcinoma have given us clinical and histopathologic 
tools to decide on the appropriate treatment for the individual patient. Nevertheless, 
the individual course of disease of a patient can (unexpectedly) be more aggressive than 
predicted based on these tools. Therefore, more research is needed in histopathologic 
and immunohistochemical characteristics of endometrial carcinoma for a more accurate 
guidance of decision making in the surgical and adjuvant treatment of these patients. 
In addition, to be able to investigate the pathologic condition of the endometrium, the 
appearance of the normal endometrium should be exactly known as a reference. The aims 
of this thesis were therefore:
• To accurately study and describe the endometrium in asymptomatic pre- and 
postmenopausal women.
• To accurately study and describe the endometrium adjacent to carcinoma.
• To investigate the prognostic value of pathologic markers.
• To gain more insight in the pathologic and immunohistochemical markers in patients 
not fitting in the dualistic model of Bokhman.
• To assess the prognostic value of immunohistochemical markers in endometrioid 
endometrial carcinoma.
• To gain more insight in the metastatic process of endometrioid endometrial carcinoma. 
General introduction and outline of the thesis
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Outline of the thesis
In Chapter 2, a detailed description of the endometrium in pre- and postmenopausal women 
without symptoms of endometrial disease is given. To this end, the entire endometrium of 
patients who underwent a hysterectomy because of uterine prolapse was systematically 
sampled according to the SEE-END protocol.
In Chapter 3, the prevalence and clinical value of endometrial cells found in cervical smears 
of a cohort of endometrioid endometrial carcinoma patients and a cohort of uterine 
papillary serous carcinomas is investigated.
In Chapter 4, the prognostic value of the depth of myometrial invasion in absolute millimeters 
is evaluated and compared to the currently used cut-off value of invasion of more or less 
than 50% of the myometrium.
In Chapter 5, the background endometrium of endometrioid endometrial carcinomas is 
reviewed. The prognostic value of the background endometrium is evaluated. Since the 
findings of the study show a subgroup of patients not fitting in the dualistic model of type 
I and type II carcinomas the existence of a third type endometrial carcinoma is proposed.
In Chapter 6, the expression of a set immunohistochemical markers and the mutation 
analysis of three genes is performed in a group of type I, type II and the proposed type III 
endometrial carcinoma, to find evidence to support the theory of the existence of a third 
type endometrial carcinoma.
In Chapter 7, an immunohistochemical comparison is made between endometrioid 
endometrial carcinomas with and without metastases to be able to identify markers 
associated with metastatic disease.
In Chapter 8, the prognostic value of the relatively new immunohistochemical marker 
L1CAM in endometrioid endometrial carcinoma is investigated.
In Chapter 9, findings are discussed in the light of the current understanding of the 
pathogenesis of tumor progression in (endometrioid) endometrial carcinomas, and 
the possibilities this understanding gives us to predict the clinical course of endometrial 
carcinoma patients.      
18
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Abstract
Objective: Knowledge on the nature of the endometrium in women without symptoms of 
endometrial disease is poor. Therefore, the aim of this prospective study was to describe the 
endometrium of a cohort of asymptomatic women. 
Methods: The entire endometrium of pre- and postmenopausal women was embedded 
for histologic examination. All included patients underwent a hysterectomy on indication 
of uterovaginal prolapse, from July 2011 to October 2012, in three hospitals in the South of 
The Netherlands. Exclusion criteria were symptoms of postmenopausal vaginal blood loss, 
or premenopausal disordered vaginal bleeding. 
Results: Sixty-eight women were included in the study, 48 women were postmenopausal and 
20 were premenopausal. In the endometrium of ten women simple hyperplasia was found 
(15%), in one complex hyperplasia (2%), in two simple atypical hyperplasia (3%), in two 
complex atypical hyperplasia (3%), and in two a small focus of intramucosal endometrioid 
endometrial carcinoma (3%). In general, the endometrium was heterogenous and the 
majority of the lesions were not present in the entire endometrium. 
Conclusion: after examining the entire endometrium, a remarkable high prevalence of 
endometrial pathology was found in asymptomatic women. The clinical meaning of these 
lesions is not yet clear, but endometrial pathology may frequently exist without symptoms.
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Introduction
Endometrial carcinoma is the most common gynecologic malignancy in the Western 
population.1 Endometrial carcinogenesis is thought to be a combination of genetic 
predisposition and environmental influences.2 The majority is of endometrioid histology 
and arises in hyperplastic endometrium. In this type of endometrial carcinoma unopposed 
estrogenic stimulation leads to orderly progression from endometrial proliferation to 
hyperplasia, atypical hyperplasia, and finally to endometrioid endometrial carcinoma.3 In 
about a quarter of women diagnosed with endometrial atypical hyperplasia development 
into endometrioid endometrial carcinoma occurs, within a time period of around four 
years.4,5 
During the reproductive years, the endometrium is dynamic and undergoes hundreds 
of cycles of proliferation, differentiation and shedding. In premenopausal women the 
endometrium is expected to be proliferative or secretory, depending on the phase of the 
menstrual cycle. However, in postmenopausal women it is expected that the decline of 
estrogen production of the ovaries will result in atrophic endometrium.6 However, excessive 
and unopposed estrogenic stimulation after menopause is described, and an unspecified 
proportion of menopausal women retain a weak proliferative pattern for many years.7 
So far, the prevalence of endometrial lesions is mainly investigated in symptomatic women 
with abnormal bleeding. A limited number of studies investigated endometrial tissue 
in asymptomatic women. Based on review of biopsies, dilatation & curettage tissues or 
pathology reports from hysterectomies, hyperplasia was reported in 0.6-5.5%, atypical 
hyperplasia in 0.5-1.1% and carcinoma in 0.3-0.5% of the reviewed cases.8-13 Yet, these 
studies are limited by the fact that endometrial sections of the hysterectomies were not 
reviewed, and embedding of the endometrium was performed according to routine protocol, 
including only one or two sections of the endometrium. It is known from literature that 
endometrial pathology can present focally, and is therefore easily missed if not the entire 
endometrium is embedded and reviewed.14 Hence, routine sampling leaves the possibility 
that endometrial pathology will be missed. 
The aim of the current study is to improve knowledge on the nature of the endometrium in 
pre- and postmenopausal women without symptoms of endometrial disease. Therefore, the 
prevalence of endometrial pathology is determined in asymptomatic patients who received 
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a hysterectomy for uterovaginal prolapse. The endometrium was entirely embedded in all 
cases for extensive histologic assessment.  
Materials and Methods
Patient selection
In this prospective, multicentre study, women were included that were treated for 
uterovaginal prolapse with a vaginal, laparoscopically assisted, or abdominal, hysterectomy. 
All women were treated in the Radboud University Nijmegen Medical Centre from July 2011 
to October 2012, or in the TweeSteden Hospital, and St. Elisabeth Hospital, Tilburg, from 
February 2012 to October 2012. Exclusion criteria were uterus myomatosus, abdominal 
pain, or any signs or symptoms of endometrial disease (menorrhagia, metrorrhagia, or 
postmenopausal vaginal bleeding). Of the included women, clinical data including age, body 
mass index, menopausal status, parity, medical history, and use of hormone replacement 
therapy were extracted from the medical records. 
Sampling of the endometrium
After formalin fixation overnight, the uterus was sectioned for diagnostic purposes following 
routine protocol, including one or two endometrial sections for histologic assessment. The 
diagnostic process was completed by a pathologist, before the remaining endometrium was 
entirely sampled according to the SEE-End protocol (Sectioning and Extensively Examining 
the Endometrium) shown in Figure 1. The endometrium was cut transversely at 2 mm 
intervals before embedding in paraffin. All sections were stained with hematoxylin and 
eosin for histologic examination. 
Viewing and reviewing of the endometrium
All endometrial sections were reviewed blindly by three of the authors (MM, YG, JB). In 
case of discrepancies, the case was discussed by all three authors and consensus was 
reached. Review was performed systematically by checking the following items: the 
nature of the endometrium, the presence of additional pathology in the endometrium 
(e.g. polyp, endometrial intra-epithelial carcinoma, or carcinoma), the presence of 
adenomyosis or leiomyomas, and measurement of endometrial and myometrial thickness. 
Histopathologic assessment of the entire endometrium in asymptomatic women
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Figure 1: Sampling of the endometrium according to the SEE-END protocol.
The endometrium was sampled entirely embedded following the SEE-End protocol (Sectioning and Extensively 
Examining the Endometrium). After completing the diagnostic process, the remaining endometrium was sectioned 
in transverse direction with intervals of 2 mm. Redundant myometrium was removed to enable the display of 
several endometrial sections in one section.
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The endometrium was grouped in eight categories: proliferative endometrium, secretory 
endometrium, atrophy, disordered proliferative endometrium, simple hyperplasia (SH), 
complex hyperplasia (CH), simple atypical hyperplasia (SAH), complex atypical hyperplasia 
(CAH), and endometrial carcinoma. The categories simple and complex hyperplasia, simple 
and complex atypical hyperplasia and carcinoma were considered as endometrial pathology.
Atrophic endometrium was defined as shallow endometrium with a thin basalis, and with 
a few tubular glands lined by inactive epithelium.6 Proliferative or secretory endometrium 
was defined as widely spread, sometimes tortuous, tubular glands that show mitotic activity, 
pseudostratification of the nuclei, and abundant stroma.6 Proliferation in the endometrium 
of postmenopausal patients is defined as disordered proliferative. This diagnosis was 
considered when some of the glands showed proliferative activity, and the gland:stroma 
ratio was slightly increased, but did not meet the criteria for hyperplasia.14,15 Endometrial 
hyperplasia was defined as proliferation of glands with an increase in gland:stroma ratio of 3:1 
and a variety of abnormal architectural patterns.14 Cytologic atypia was defined as enlarged, 
rounded, polymorphic nuclei with loss of polarity, prominent nucleoli, chromatin clumbing, 
and an increased nuclear to cytoplasmic ratio.15 Hyperplasia was categorized according to 
the World Health Organization (WHO) classification system for hyperplasia, which is based 
on the study of Kurman and colleagues.4 When focal areas of hyperplasia or disordered 
proliferation were identified, the percentages of the entire endometrium containing this 
pathologic feature was estimated. The diagnosis of hyperplasia was only made when present 
in more than 10% of the total endometrial surface. Endometrial thickness was measured in 
all areas containing a pathologic lesion and in all areas with a non-pathologic diagnosis of 
the endometrium to enable comparison. At least two measurements were performed for 
each specific area of the endometrium.  
Statistical analysis
For comparison between the groups of women with or without endometrial pathology the 
Pearson’s chi-Square (χ2) test, or the Fisher’s exact test, when appropriate, were used. For 
comparison of continuous variables between both groups the Mann-Whitney U test was 
used. 
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Ethical committee approval 
The study protocol was approved to be in accordance with the applicable rules concerning 
the review of research ethics committees and informed consent by the Research Ethics 
Committee of the Radboud University Nijmegen Medical Centre, and the Medical Ethical 
Test Committee of both the Elisabeth Hospital, and the TweeSteden Hospital, Tilburg. 
Results
Patient characteristics
A total of 68 women who underwent a hysterectomy for uterovaginal prolapse were included 
in the study. Clinical characteristics are shown in Table 1. The mean age was 61 years (range 
33-89) and 71% (48/68) was postmenopausal. In the vast majority of the women a vaginal 
hysterectomy was performed, and in a few an abdominal hysterectomy. The mean body mass 
index of these women was 25.9 kg/m2 (range 19.6-39.8), and a minority had comorbidity 
like diabetes mellitus or hypertension. Twelve per cent (8/68) used hormone replacement 
therapy, estrogen suppletion opposed with progesterone, for menopausal complaints. 
None of the women had a history of tamoxifen use. Further, 9% (6/68) of the women used 
contraceptives, three used an intra-uterine device and three oral contraceptives. The mean 
number of deliveries in the studied group was 2.7 (range 1-8). None of the women were 
diagnosed with a malignancy or premalignancy in the past. 
Histology
The mean number of endometrial sections available for review, after applying the SEE-End 
protocol, was 6, including a mean number of two sections embedded for standard diagnostic 
examination. (Sections contained several small areas with endometrial tissue for histologic 
examination.) Results of assessment of the endometrial sections are shown in Table 2. 
Examples of all diagnosed categories in the endometrium are shown in Figure 2. Endometrial 
pathology was observed in 25% (17/68 ) of the reviewed cases: simple hyperplasia in 15% 
(10/68), complex hyperplasia 2% (1/68), simple atypical hyperplasia in 3% (2/68), complex 
atypical hyperplasia in 3% (2/68) and endometrioid endometrial carcinoma in 3% (2/68) 
of cases. The remaining 75% of cases were diagnosed without endometrial pathology. 
Proliferative endometrium was found in 15% (10/68) of cases, secretory endometrium in 
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7% (5/68), and atrophic in 46% (31/68). Further, in 17 (25%) cases a polyp was found in 
the endometrium. One of these polyps was diagnosed with atypical hyperplasia, that was 
located both in the polyp as well as in the adjacent endometrial tissue. In all other polyps no 
atypical hyperplasia was identified. 
Results were specified for premenopausal and postmenopausal women (Table 2). In the 
postmenopausal women 10% (5/48) showed disordered proliferative endometrium. 
Of the premenopausal women 20% (4/20) had atrophic endometrium, and all four used 
contraceptives. 
Table 1: Clinical characteristics of all included women (N=68).
Characteristic Mean/N (range/%)
Age (years) (N=68) 60.5 (33-89)
BMI (kg/m2) (N=41) 25.9 (19.6-39.8) 
Parity (N=47) 2.7 (1.0-8.0)
Menopausal Status
     Premenopausal
     Postmenopausal
20 (29.4)
48 (70.6)
Diabetes Mellitus
     No
     Yes
     Unknown
58 (85.3)
6 (8.8)
4 (5.9)
Hypertension
     No
     Yes
     Unknown
49 (72.1)
15 (22.1)
4 (5.8)
Use contraceptives
     Oral
     Intra-Uterine Device
     No or Unknown
 3 (4.4)
 3 (4.4)
 62 (91.2)
Use HRT
     No
     Yes
     Unknown
56  (83.3)
8 (11.8)
4 (5.9)
Type of operation
     Vaginal Hysterectomy
     Laparoscopic Assisted Hysterectomy
     Abdominal Hysterectomy
     Unknown
62 (91.3)
2 (2.9)
2 (2.9)
2 (2.9)
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The prevalence of endometrial pathology was significantly different in postmenopausal and 
premenopausal women, 33% and 5% respectively. Furthermore, in the group of women 
with endometrial pathology 13% (2/15) used hormone replacement therapy. One of these 
two women had simple hyperplasia, and one had complex atypical hyperplasia. In the group 
of women without endometrial pathology also 12% used hormone replacement therapy 
Table 2: Pathologic characteristics after review for the total group (N=68), and for premenopausal 
women (n=20) compared with postmenopausal women (N=48).
Characteristic Total 
(N=68)
Premenopausal 
(N=20)
Postmenopausal 
(N=48)
N (%) N (%) N (%)
Endometrial diagnosis
     Proliferative                                                     
     Secretory
     Atrophic
     Disordered proliferative 
     Simple hyperplasia (SH)
     Complex hyperplasia (CH)
     Simple atypical hyperplasia (SAH)
     Complex atypical hyperplasia (CAH)
     Endometrioid endometrial carcinoma (EEC) 
10 (14.7)
5 (7.4)
31 (45.6)
5 (7.4)
10 (14.7)
1 (1.5)
2 (2.9)
2 (2.9)
2 (2.9)
10 (50.0)
5 (25.0)
4 (20.0)
-
1 (5.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
-
-
27 (56.3)
5 (10.4)
9 (18.8)
1 (2.1)
2 (4.2)
2 (4.2)
2 (4.2)
Additional identified lesions
     Polyp
          No 51 (75) 18 (90.0) 23 (68.7)
          Yes, benign 15 (22.1) 2 (10.0) 13 (27.1)
          Yes, hyperplastic 2 (2.9) 0 (0.0) 2 (4.2)
     Metaplasia
          No 52 (76.5) 17 (85.0) 35 (72.9)
          Yes, tubal 13 (19.1) 3 (15.0) 10 (20.8)
          Yes, clear cell 3 (4.4) 0 (0.0) 3 (6.2)
     Adenomyosis
          No 56 (82.4) 17 (85.0) 39 (81.2)
          Yes 12 (17.6) 3 (15.0) 9 (18.8)
     Leiomyomas
          No 52 (76.5) 16 (80.0) 36 (75.0)
          Yes 16 (23.5) 4 (20.0) 12 (25.0)
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(6/49). In addition, the presence of additional endometrial and myometrial pathology is 
shown in Table 2.
In a significant part of the women the endometrium was heterogeneous. In Table 3, an 
overview is given of what percentage of endometrial pathology covered the endometrial 
surface. In two women a focal area was identified with intramucosal endometrioid 
endometrial carcinoma. Both were located in a background of atypical hyperplasia and only 
Figure 2: Examples of the categories of the endometrium.
The nature of the endometrium in this 
prospective cohort of uterovaginal prolapsed 
cases was diagnosed in the following categories: 
A) Atrophic endometrium (level of 
magnification: 10x). B) Cystic atrophic (level 
of magnification: 10x). C) Proliferative 
endometrium (level of magnification: 
10x). D) Secretory endometrium (level of 
magnification: 10x). E) Disordered proliferative 
(DP) (level of magnification: 10x). F) Simple 
hyperplasia (SH) (level of magnification: 10x). 
G) Complex atypical hyperplasia (CAH) (level 
of magnification: 10x). H) Identical area with 
complex atypical hyperplasia (CH), as in picture 
G, but at a higher level of magnification (20x) 
to show the atypia. I) Focus of intramucosal 
carcinoma (level of magnification: 10x). J) 
Overview of endometrium with identical area 
with focus of intramucosal carcinoma as in I, but 
at lower level of magnification (2x). Adjacent 
to the focus of intramucosal carcinoma, areas 
with cystic atrophic endometrium to complex 
atypical hyperplasia. 
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a small area was diagnosed as atrophic in one case and disordered proliferative in the other 
(Table 3). 
Changes of endometrial diagnosis after review of the initial sections and the 
additional embedded endometrial sections
In 12% (8/68) of women the additional embedding of the entire endometrium resulted in 
the identification of more severe endometrial pathology. In five cases the primary sections 
revealed atrophic or disordered proliferative endometrium, whereas after viewing the extra 
embedded endometrium, sampled in accordance with the SEE-End protocol, the diagnosis 
was changed to simple hyperplasia in four cases and atypical hyperplasia in one case. In 
three cases, there was simple hyperplasia in the initial sections. However, after viewing 
the additional sections a diagnosis of complex atypical hyperplasia was made in one case, 
and a focus of intramucosal endometrioid endometrial carcinoma with adjacent atypical 
hyperplasia was identified in the two other cases. Both women with endometrial carcinoma 
were postmenopausal. 
Note that in one case with a focus of intramucosal carcinoma, the pre-operative ultrasound 
of the uterus showed an intra-cavitary abnormality. A biopsy was performed, and this 
abnormality was diagnosed as a benign polyp. When we reviewed this particular case we 
confirmed the presence of a benign polyp. The complex atypical hyperplasia and focus of 
carcinoma in this case were identified in the adjacent endometrium and not in the polyp. 
In other cases, including the second case with a focus of carcinoma, no abnormalities were 
reported on the pre-operative ultrasound. 
Comparison of patients without and with endometrial pathology
Women with and without endometrial pathology were compared with respect to clinical 
and pathologic characteristics (Table 4). Women with endometrial pathology revealed to 
be significantly older and more often postmenopausal compared to the cases without 
endometrial pathology. Furthermore, the mean number of deliveries was higher in patients 
with endometrial pathology. The mean body mass index of patients with endometrial 
pathology was not significantly higher compared to the patients without endometrial 
pathology (27.8 kg/m2 (range 23.1-39.8) vs. 25.3 kg/m2 (range 19.6-36.8); P=0.114). 
Preoperative ultrasound results showed no difference between women identified with 
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Table 4: Comparison of clinicopathologic characteristics between women without endometrial 
pathology and women with endometrial pathology (SH, CH, SAH, CAH and EEC).
No pathology 
(N=51)
Pathology 
(N=17)
Characteristic Mean/N (range/%) mean/N (range/%) P-value
Age          57.7 (33-89) 68.9 (51-85) 0.002 a
BMI 25.3 (19.6-36.8) 27.8 (23.1-39.8) 0.114 a
Parity 2.5 (1-8) 3.5 (1-7) 0.028 a
Menopausal status
     pre
     post
19 (37.3)
32 (62.7)
1 (5.9)
16 (94.1)
0.015 c
Diabetes Mellitus
     No
     Yes
45 (91.8)
4 (8.2)
13 (86.7)
2 (13.3)
0.618 c
Hypertension
     No
     Yes
38 (77.6)
11 (22.4)
11 (73.3)
4 (26.7)
0.737 c
Use Contraceptives
     No
     Yes
14 (70.0)
6 (30.0)
4 (100.0)
0 (0.0)
0.539 c
Use HRT
     No
     Yes
43 (87.7)
6 (12.3)
13 (86.7)
2 (13.3)
0.645 c
Additional identified lesions 
    Polyp
          No 41 (80.4) 10 (58.8) 0.075 b
          Yes 10 (19.6) 7 (41.2)
     Metaplasia
          No
          Yes
40 (78.4)
11 (21.6)
12 (70.6)
5 (29.4)
0.509 b
     Adenomyosis
          No
          Yes
46 (90.2)
5 (9.8)
10 (58.8)
7 (41.2)
0.003 b
     Leiomyomas
          No
          Yes
40 (78.4)
11 (21.6)
12 (70.6)
5 (29.4)
0.509 b
Thickness myometrium (mm) (N=46) 12.38 (8.0-19.0) 11.63 (8.0-14.0) 0.598 a
Thickness endometrium (mm) (N=67) 1.23 (0.2-4.0) 1.16 (0.7-2.5) 0.196 a
a Mann-Whitney U test, b Pearson Chi-Square, c Fisher’s exact test
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or without endometrial pathology. In only one case an endometrial thickness above the 
threshold level of 4 mm was measured on preoperative ultrasound and was diagnosed as 
proliferative after histologic assessment. Available results of preoperative ultrasound of 
women in whom endometrial pathology was identified are shown in Table 3. 
Further, no difference was found between endometrial thickness of pathologic and non-
pathologic endometrial lesions measured in histologic sections. The mean endometrial 
thickness of areas with (cystic) atrophic endometrium, (disordered) proliferative, simple 
(atypical) hyperplasia, complex (atypical) hyperplasia and carcinoma was 1.3 mm (range 
0.3-4.0 mm), 0.8 (range 0.5-1.3 mm), 1.2 (range 0.6-2.2 mm), 1.3 (range 0.7-2.2 mm) and 
1.2 (range 1.0-3.0 mm), respectively.
Discussion
In the current prospective study, we systematically sampled the entire endometrium 
of women who underwent a hysterectomy for uterovaginal prolapse. A surprisingly high 
prevalence of endometrial abnormalities was identified in these asymptomatic women. In 
25% of the women endometrial pathology was found: hyperplasia showed to be present in 
16%, atypical hyperplasia in 6%, and a small focus of intramucosal endometrioid endometrial 
carcinoma in 3%. The endometrial thickness measured in the endometrial sections was not 
increased when endometrial pathology was present, indicating that it is unlikely to find this 
pathology pre-operatively with ultrasound. 
Few studies analyzed the endometrium in asymptomatic women and reported a prevalence 
of endometrial abnormalities in only 5%. In studies examining curettage material in 
asymptomatic women, a prevalence of hyperplasia was found of 0.6-4.9%, hyperplasia 
with atypia of 0.5-0.6%, and adenocarcinoma of 0.5%.8,11,12 When analyzing the pathology 
reports of hysterectomy specimens removed for benign reasons, hyperplasia was found 
to be present in 1.2-5.5%, atypical hyperplasia in 0.5-1.1%, and adenocarcinoma in 0.3-
0.5%.9,10,13,16,17 Restricted endometrial sampling and not performing a review of the histologic 
assessment are both important limitations that can putatively explain the large difference 
in prevalence of endometrial lesions found in comparison to the current prospective study. 
The current study demonstrates the heterogeneity of the endometrium. Endometrial 
abnormalities can easily be missed when performing only standard sampling of the 
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endometrium of around two sections. In eight women (12%) the more extended embedding 
of the endometrium resulted in a more severe diagnosis, that was exclusively present in 
the additional embedded sections. In two women we found a small focus of intramucosal 
endometrioid carcinoma, which was not present in the standard embedded sections. 
Noteworthy is that in these two women, a diagnosis of hyperplasia was already made on the 
primary endometrial sections. This indicates that more extended review of the endometrium 
might be preferable in uteri of (asymptomatic) women in whom hyperplasia is found in the 
primary embedded slides. 
An important strength of this observational study is that it is prospective and multicentre. 
Limitations of the study are that the collection of the clinical data was retrospective, and 
therefore sometimes incomplete. Further, eight patients did use hormone replacement 
therapy. However, estrogen suppletion in these patients was opposed with progesterone, 
and the number of patients using hormone replacement therapy was equal in the group 
with and without endometrial pathology. All patients underwent a hysterectomy, so follow 
up of the endometrial lesions was not possible. The aim of the study was to analyze the 
appearance of the endometrium in hysterectomy tissue of a general population. However, it 
is not investigated if hysterectomy tissue of women with prolapse uteri is comparable with 
tissue from asymptomatic women in the general population. 
Moreover, the diagnosis of simple and complex hyperplasia with or without atypia is 
moderately reproducible. It has been proposed by several authors to use the hyperplasia-EIN 
(endometrial intraepithelial neoplasia) classification system for the diagnosis of pathologic 
endometrial proliferation.18 However, the reproducibility of the EIN system is a matter of 
debate as well.19 Therefore, we used the WHO classification system that is widespread, well 
understood and based on the classification system of Kurman and colleagues.4
The current study provides more insight into the appearance of the endometrium in 
hysterectomy tissue of asymptomatic women. The patients included in our study already 
underwent a hysterectomy, making the clinical importance of exactly identifying all types of 
endometrial lesions for these cases questionable. However, based on the results, we might 
conclude that endometrial lesions are more common in asymptomatic women than thought 
until now. These results are in line with a study on tubal epithelial lesions in normal women, 
reporting common presence of hyperplasia and minor atypia in the tubal epithelium 
as well.20 Moreover, Horwitz et al, in 1981 already observed a four times greater rate of 
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endometrial cancer at autopsy than during live, indicating that a proportion of endometrial 
cancers may exist without symptoms.21
The clinical significance of (focal) hyperplasia has not yet been determined.14 We considered 
the endometrium hyperplastic if at least ten percent of the endometrium met the criteria 
for hyperplasia, but the definition and impact of focal hyperplasia remains a grey area. 
Atypical hyperplasia diagnosed in endometrial curettings develops into carcinoma in about 
25%.4 However, if and in which percentage focal atypical hyperplasia needs to be present 
before it might progress to malignant disease is unclear. 
Furthermore, it is suggested in literature that a state of weak proliferation can be found 
in the endometrium in up to half of postmenopausal women.7 A plausible explanation for 
this phenomenon is the gradually declining estrogen stimulation without the opposition of 
ovulation in the first years after menopause. The results of our study confirm that a significant 
part of the postmenopausal patients have some form of weak proliferative endometrium. 
Disordered proliferation is stated to be a clinically benign process, since progression to 
hyperplasia may occur, but progression to carcinoma is extremely rare.14 In our study, we 
therefore did not consider disordered proliferative endometrium as a pathologic condition. 
Factors known to give an increased risk of endometrial hyperplasia are all linked to 
unopposed, increased or prolonged estrogen stimulation, like late menopause, obesity, 
nulliparity, anovulatory cycles, diabetes mellitus, use of hormonal replacement therapy, 
and treatment with tamoxifen.2,23 In the cohort of this study, except for a significant more 
advanced age and less premenopausal patients in the group with endometrial pathology, 
there were no differences in clinical characteristics between the group with and without 
endometrial pathology. An explanation for why a part of the postmenopausal patients 
developed hyperplasia and a part did not, cannot be given based on these results. 
In conclusion, in this descriptive study on histologic assessment of the entire endometrium 
of pre- and postmenopausal, asymptomatic women, we found a high number of women with 
endometrial pathology in especially the postmenopausal group. If hyperplasia is identified in 
primary endometrial sections, additional sampling of the endometrium is recommended to 
exclude presence of (pre)malignancy. Probably, there is a higher prevalence of endometrial 
pathology in asymptomatic women than we know of, based on the existing literature, and 
endometrial pathology may frequently exist without symptoms. 
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Abstract 
Objective: To determine the frequency of abnormal cervical cytology in preoperative 
cervical cytology of patients diagnosed with uterine papillary serous carcinoma (UPSC) and 
endometrioid endometrial carcinoma (EEC). In addition, associations between abnormal 
cervical cytology and clinicopathologic factors were evaluated.
Methods: In this multicentre study, EEC patients diagnosed at two hospitals from 1999 
to 2009 and UPSC patients diagnosed at five hospitals from 1992 to 2009, were included. 
Revision of the histologic slides was performed systematically and independently by three 
gynecopathologists. Cervical cytology within six months before histopathologic diagnosis of 
endometrial carcinoma was available for 267 EEC and 80 UPSC patients. Cervical cytology 
with atypical, malignant, or normal endometrial cells in postmenopausal women was 
considered as abnormal cytology, specific for endometrial pathology.
Results: Abnormal cervical cytology was found in 87.5% of UPSC patients, compared to 
37.8% in EEC patients. In UPSC, abnormal cytology was associated with extra-uterine spread 
of disease (P=0.043). In EEC, abnormal cytology was associated with cervical involvement 
(P=0.034). In both EEC and UPSC patients, abnormal cervical cytology was not associated 
with survival.
Conclusion: Abnormal cervical cytology was more frequently found in UPSC patients. It was 
associated with extra-uterine disease in UPSC patients, and with cervical involvement in EEC 
patients. More prospective research should be performed to assess the true clinical value of 
preoperative cervical cytology in endometrial cancer patients.
Cervical cytology in serous and endometrioid endometrial cancer
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Introduction
Endometrial cancer is the most frequent malignancy of the female genital tract in the 
western world.1 The majority of patients with endometrial cancer are diagnosed with 
endometrioid endometrial carcinoma (EEC), typically presenting at an early stage with 
an excellent prognosis; five-year overall survival rates of 70-80% have been reported.2,3 In 
contrast, uterine papillary serous carcinoma (UPSC) represents only 10% of endometrial 
cancers, but accounts for up to 39% of all endometrial cancer deaths. UPSC is therefore 
recognized as an aggressive tumor.4 Unlike its EEC counterpart, UPSC commonly presents 
with advanced stage of disease and poor prognosis, indicated by a five-year survival rate of 
only 18-45%.4,5
The treatment of endometrial cancer is primarily based on surgery, consisting of hysterectomy 
and bilateral salpingo-oophorectomy (BSO). There is no worldwide consensus whether 
pelvic and/or para-aortic lymphadenectomy should be performed as part of the staging 
procedure.6,7 For EEC patients the extensiveness  of surgery depends on the presence of risk 
factors for metastatic disease, like high tumor grade, deep myometrial invasion, and cervical 
involvement.7 However, preoperative assessment of these factors remains a challenge. After 
histopathologic examination, only 8-13% of the EEC patients have cervical involvement, and 
about 7% will have extra-uterine disease at the time of diagnosis.8,9 In contrast, in UPSC 
patients 55-87% have microscopic or macroscopic metastases outside the uterus at the time 
of diagnosis.10,11 For these patients, debulking surgery and comprehensive surgical staging 
(including hysterectomy, BSO, bilateral pelvic lymph node dissection with para-aortic lymph 
node sampling and omental biopsy or omentectomy) have been suggested to more reliably 
determine stage of disease, to guide adjuvant treatment, and to improve survival.12,14
In asymptomatic women, cervical cytology appeared to be a poor screening tool for 
endometrial carcinoma because of its low sensitivity.15,16 However, when normal or atypical 
endometrial cells are found in cervical cytology of postmenopausal women, it is predictive 
for endometrial pathology.15,17,18 Furthermore, cervical cytology has shown to be of additional 
value for the prediction of cervical stroma involvement and lymph node metastases.19-21 In 
addition, in patients with endometrial cancer, cervical cytology with atypical or malignant 
endometrial cells was associated with advanced stage of disease, high tumor grade and 
deep myometrial invasion.22-26
44
Chapter 3
In patients with endometrial cancer, the frequency of atypical or malignant endometrial 
cells in preoperative cervical cytology varies from 31-50%.22,24,25 It has been reported 
though, that in UPSC patients cervical cytology is more likely to contain atypical or malignant 
endometrial cells.27 However, cervical cytology has only been investigated in cohorts with 
limited number of UPSC patients, and evidence for associations with poor prognostic factors 
in UPSC patients is lacking.25,27-30 
The aim of this study was to evaluate the presence of shedded atypical endometrial cells in 
cervical cytology during the diagnostic and/or preoperative workup of patients with UPSC 
as compared to patients with EEC. Possible associations between abnormal cervical cytology 
and clinicopathologic variables were studied in both cohorts. Furthermore, we evaluated 
whether the presence of atypical endometrial cells in preoperative cervical cytology has 
prognostic significance for survival in UPSC and EEC patients.
Methods
Patient selection
The nationwide network and registry of histology and cytopathology in the Netherlands 
(Pathologisch Anatomisch Landelijk Geautomatiseerd Archief: PALGA)31 was used to search 
for all patients with primary EEC, diagnosed and treated at the Radboud University Nijmegen 
Medical Centre or the Canisius Wilhelmina Hospital in the period between January 1999 and 
December 2009. Furthermore, this network was used to search for all patients diagnosed 
with UPSC in the same two hospitals and three additional hospitals (Rijnstate Hospital 
Arnhem, Gelderse Vallei Hospital Ede, and Maas Hospital Boxmeer) from January 1992 till 
December 2009. Patients were excluded in case of a second primary malignancy. Pathologic, 
medical and operative records of all patients were retrieved from the hospitals involved. 
All histopathologic slides from surgery specimens were reviewed systematically by three 
expert pathologists (SZ, AW and JB). Review included tumor histology, tumor grade, 
depth of myometrial invasion, and the presence of lymphovascular space invasion (LVSI). 
As per definition, UPSC was considered to be grade 3 carcinoma.32,33 Patients with UPSC 
were included when the carcinoma comprised at least 10% serous histology according to 
previously published criteria.32,34 The included UPSC cases were defined as pure UPSC, with 
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the serous component comprising >75% of the total tumor, and mixed UPSC, with the serous 
component comprising 10-75% of the tumor. 
Revised UPSC and EEC patients were included when cervical cytology was taken for the 
diagnostic and/or preoperative workup because of clinical suspicion for malignancy, within 
a time frame of 6 months before histopathologic diagnosis. To note, all included patients 
had cervical cytology taken before endometrial biopsy or dilatation and curettage. In case 
multiple cervical smears were taken during this six months’ time interval, the smear with 
the most severe diagnosis was used for our analyses. 
Cervical Cytology
PALGA was used to retrieve the complete cervical cytology history of each EEC and UPSC 
patient. This database has nationwide coverage from 1991 onwards, showing all surgical 
specimens and cervical cytology ever taken from each patient, both by the general 
practitioner and medical specialist.31 Within our study period, cervical cytology was obtained 
using both conventional cytology and the more recently introduced liquid based cytology.35 
Liquid based cytology was introduced between 1996 and 2003 at the different pathology 
laboratories. Cervical cytology was screened and classified by cytotechnologists and 
approved by a pathologist according to the CISOE-A classification system, of which results are 
easily translatable to the various Bethesda 2001 subcategories.36 CISOE-A explicitly specifies 
the presence of normal and abnormal endometrial cells. Cervical cytology was classified as 
normal if there were no endometrial cells present. Atypical or malignant endometrial cells 
that were diagnosed in diagnostic or preoperative cervical cytology was considered as an 
abnormal cytological result, indicating endometrial pathology. Cervical cytology showing 
normal endometrial cells was considered abnormal only in postmenopausal women. To 
note, atypical squamous or atypical glandular/endocervical cells were not considered as 
abnormal cytology.
Because of the retrospective study design, patients were staged according to the 1988 FIGO 
surgical staging system.37 All patients underwent primary surgical treatment, except for 
four UPSC patients because of serious comorbidity (N=3) or because the patient refused 
treatment (N=1). These four patients remained to be included in our study to investigate 
the frequency of abnormal endometrial cells in preoperative cervical cytology and their 
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relationship with various clinicopathologic variables. However, these four UPSC patients did 
not receive optimal surgical and/or adjuvant treatment and were therefore excluded from 
further analyses on survival. Clinicopathologic data were collected regarding age, body mass 
index (BMI), FIGO stage, peritoneal cytology, lymph node metastases, cervical involvement, 
extra-uterine disease, histology, and tumor diameter. Extra-uterine spread of disease was 
defined as cervical involvement, nodal involvement, positive peritoneal cytology, and/or 
disease at any other site outside the uterus.
Statistical analysis
To analyze the correlation between different clinicopathologic variables with abnormal 
cervical cytology, univariable analyses were performed, with χ2 or Fisher’s exact test 
analyses for categorical variables, independent t test for continuous variables, and 
univariable logistic regression analyses when appropriate. Furthermore, to examine the 
effects of various clinicopathogic variables on progression free survival (PFS), univariable 
analyses were performed using the Cox proportional hazard method. PFS was defined as the 
time in months from initial surgery to the date of recurrence. In case of no recurrence, the 
date of last contact or death was used for censoring. All statistical analyses were performed 
using SPSS statistical software for windows, version 18.0 (SPSS, Inc, Chicago, IL). P<0.05 was 
considered statistically significant. 
Results
Records of 141 UPSC patients and 353 EEC patients were retrieved from the hospitals 
involved. In the UPSC group, 26 patients were excluded because the serous component 
within the tumor comprised less than 10%, whereas 19 EEC patients were excluded because 
of (partly) non-endometrioid histology. Furthermore, from 35 UPSC patients and 67 EEC 
patients cervical cytology was either not taken for diagnostic/preoperative workup within 6 
months prior to diagnosis, or unsatisfactory for diagnosis, and these patients were excluded. 
Thus, a total of 80 UPSC and 267 EEC patients comprised our study population.
Demographic and histopathologic characteristics of the UPSC and EEC patients are presented 
in Table 1. For UPSC patients, the median age at diagnosis was 72 years (range from 47 to 
86), whereas the median age at diagnosis for EEC was 63 years (range from 38 to 92). Forty-
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Table 1: Clinical and pathologic characteristics in patients with UPSC and EEC.
UPSC patients (N=80) EEC patients (N=267)
Variables  Median (range)/N (%) Median (range)/N (%)
Age at diagnosis (years) 72 (47-86) 63 (38-92)
BMI (kg/m2) 27.0 (18.0-41.0) 28.3 (18.4-53.6)
FIGO Stage
     I 28 (35.0) 215 (80.5)
     II 9 (11.3) 22 (8.2)
     III 21 (26.3) 18 (6.7)
     IV 22 (27.4) 12 (4.5)
Peritoneal Cytology
    Negative   42    (63.6) 189 (91.7)
    Positive 24 (36.4) 17 (8.3)
    Not sampled 14 61
Para-aortic and/or Pelvic Lymph nodes
    Negative 23 (63.9) 32 (91.4)
    Positive 13 (36.1) 3 (8.6)
    Not sampleda 44 232
Extra-uterine disease
    No 28 (35.0) 215  (80.5)
    Yes 52 (65.0) 52 (19.5)
Cervical involvement
    No 46 (59.7) 234  (87.6)
    Yes 31 (40.3) 33 (12.4)
    Unknown 3 0
LVSI
    No 41 (53.9) 202 (78.9)
    Yes 35 (46.1) 54 (21.1)
    Unknown 4 11
Histology
     Pure histology 62 (77.5) NA$
     Mixed histology 18 (22.5)     
Tumor Grade
    1 0 (0.0) 115 (43.0)
    2 0 (0.0) 110 (41.2)
    3 80 (100.0) 42 (15.7)
Myometrial invasion
     ≤1/2 myometrium 36 (48.0) 159 (59.6)
     >1/2 myometrium 39 (52.0) 108 (40.4)
     Unknown 5 0
Diameter of tumor (cm) 4.0 (0.5-10.0) 2.5  (0.2-8.0)
Median time of follow-up (months) 19 (1-163) 47 (0-126)
aLymph node status assigned only by inspection/palpation at laparotomy or from imaging; FIGO: International 
Federation of Obstetrics and Gynecologists; LVSI: lymphovascular space invasion; UPSC: uterine papillary serous 
carcinoma; EEC: endometrioid endometrial carcinoma. $Not available: the variable ‘histology’ is a constant in EEC 
patients.
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three (53.7%) UPSC patients were diagnosed with advanced stage (III-IV) disease, compared 
to 30 (11.2%) EEC patients. In 52 (65.0%) UPSC patients extra-uterine spread of disease 
was found, compared to 52 (19.5%) of the patients with EEC. UPSC patients, compared to 
EEC patients, more often had LVSI (46.1% and 21.1% respectively), cervical involvement 
(40.3% and 12.4% respectively) deep myometrial invasion (52.0% and 40.4% respectively), 
and a larger median tumor diameter (4.0 and 2.5 respectively). In 36 UPSC patients (45%) 
lymphadenectomy was performed of whom 36.1% had positive pelvic or para-aortic lymph 
nodes. To note, among UPSC patients without proper lymph node sampling, the majority 
had obvious disseminated disease based on macroscopic tumor deposits, bone or lung 
metastases or peritoneal disease. In EEC patients, lymph node sampling was omitted in 
cases without clinical suspicion of FIGO stage II or more, as recommended by the Dutch 
guidelines for endometrioid endometrial cancer treatment. Thirty-five EEC patients (13.1%) 
underwent lymphadenectomy of whom 8.6% had positive lymph nodes. The median follow-
up time for UPSC patients was 19 months (range 1-163 months) and 47 months (range 0-126 
months) for EEC patients. Thirty-seven UPSC patients (48.7%) and 34 EEC patients (14.8%) 
had recurrence of disease, resulting in a five-year PFS of 40.2% and 90.8% respectively. 
Preoperative cervical cytology
The cervical cytology findings in both UPSC and EEC patients are listed in Table 2. The 
median time interval between initial cervical cytology and final histopathologic diagnosis 
for endometrial carcinoma was 1 month (range 0-6 months) for UPSC patients and 1.5 
month (range 0-6 months) for EEC patients. In the group with 80 UPSC patients, 20 patients 
(25.0%) had atypical endometrial cells and 50 (62.5%) had malignant endometrial cells in 
their cervical cytology. Seven patients (8.8%) had normal cervical cytology preoperatively, 
and three patients (3.7%) had abnormal cervical cytology not specific for endometrial 
pathology: two cases with atypical glandular/endocervical epithelial cells and one case with 
atypical squamous epithelial cells. In total, 70 UPSC patients (87.5%) had abnormal cervical 
cytology, specific for endometrial pathology preoperatively (Table 2). 
Within the group of 267 EEC patients, in 48 patients (18.0%) atypical endometrial cells were 
found in cervical cytology. In four patients (1.5%) normal endometrial cells were found, 
these four patients were postmenopausal. Forty-nine patients (18.4%) had malignant 
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endometrial cells in their preoperative cervical cytology. In 163 EEC patients (61.0%) normal 
cervical cytology was found preoperatively, and three patients (1.1%) had abnormal cytology 
findings not specific for endometrial pathology: two with atypical squamous cells, and one 
with atypical glandular/endocervical cells. In total 101 EEC patients (37.8%) had abnormal 
cervical cytology, specific for endometrial pathology, prior to their diagnosis.
Associations of abnormal cervical cytology with clinicopathologic findings
In UPSC patients, only extra-uterine spread of disease (P=0.043) was significantly associated 
with an increased frequency of abnormal cervical cytology (Table 3). Using univariable 
logistic regression, extra-uterine disease remained the only factor associated with abnormal 
cervical cytology (OR 5.11, 95% CI 1.02–28.36; data not shown). Advanced stage of disease 
was not associated with abnormal cervical cytology; 23 of 28 UPSC patients (82.1%) with 
stage I disease already had abnormal cervical cytology. In addition, patients lacking poor 
prognostic factors, like negative peritoneal cytology, absence of lymph node metastases, 
or no cervical involvement, had abnormal cervical cytology in 37 of 40 (92.5%), 20 of 21 
(95.2%), and 41 of 46 (89.1%) cases, respectively. There was no significant difference in 
frequency of abnormal cervical cytology among pure UPSC and mixed UPSC patients. Other 
well-known prognostic factors such as myometrial invasion, LVSI, and tumor diameter, were 
also not associated with abnormal cervical cytology in UPSC patients. 
Table 2: Preoperative cervical cytology findings within six months prior to diagnosis of UPSC or EEC.
UPSC patients (N=80) EEC patients (N=267)
Pathology in cervical cytology N (%) N (%)
Normal endometrial cells in smear 0     (0) 4 (1.5)
Atypical endometrial cells in smear 20 (25.0) 48 (18.0)
Malignant endometrial cells in smear  50 (62.5) 49 (18.4)
Total abnormal cervical cytology 70 (87.5) 101 (37.8)
Cervical cytology without pathology 7 (8.8) 163 (61.0)
Other# pathology in smear 3 (3.7) 3 (1.1)
Total normal cervical cytology 10 (12.5) 166 (62.2)
UPSC: uterine papillary serous carcinoma; EEC: endometrioid endometrial carcinoma; #Atypical squamous epithelial 
cells, or atypical glandular/endocervical epithelial cells.
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Table 3: Associations preoperative cervical cytology findings with clinicopathologic variables in 
patients with UPSC and EEC.
Cervical cytology in UPSC patients‡ Cervical cytology in EEC patients‡
Variable Normal
(%)
Abnormal
(%)
P-value Normal 
(%)
Abnormal
(%)
P-value
Mean Age (years) 75.7 70.5 0.140# 64.6 63.4 0.270#
Mean BMI (kg/m2) 26.7 27.0 0.872# 28.9 30.5 0.092#
FIGO Stage
    I 5 (71.4) 23 (32.8) 0.151∞ 139 (83.7) 76 (75.3) 0.392
    II 0 (0.0) 7 (10.0) 12 (7.3) 10 (9.9)
    III 0 (0.0)  20 (28.6) 9 (5.4) 9 (8.9)
    IV 2 (28.6) 20 (28.6) 6 (3.6) 6 (5.9)
Peritoneal cytology
    Negative 3 (60.0) 37 (62.7) 0.904∞ 125 (92.6) 64 (90.1) 0.543
    Positive 2 (40.0) 22 (37.3) 10 (7.4) 7 (9.9)
Para-aortic and/or Pelvic 
Lymph nodes
    Negative 1 (50.0) 20 (62.5) 0.724∞ 20 (100.0) 12 (80.0) 0.070∞
    Positive 1 (50.0) 12 (37.5) 0 (0.0) 3 (20.0)
Extra-uterine spreading
    No 5 (71.4) 23 (32.9) 0.043∞ 139 (83.7) 76 (75.2) 0.089∞
    Yes 2 (28.6) 47 (67.1) 27 (16.3) 25 (24.8)
Cervical involvement
    No 5 (83.3) 41 (60.3) 0.265∞ 151 (91.0) 83 (82.2) 0.034
    Yes 1 (16.7) 27 (39.7) 15 (9.0) 18 (17.8)
LVSI
    No 3 (42.9) 36 (54.5) 0.556∞ 129 (81.6) 73 (74.5) 0.173
    Yes 4 (57.1) 30 (45.5) 29 (18.4) 25 (25.5)  
Histology
     Pure histology 5 (71.4) 56 (80.0) 0.594∞ 166 (100.0) 101 (100.0) NA$
     Mixed histology 2 (28.6) 14 (20.0) 0 (0.0) 0 (0.0)
Tumor grade
    1 0 (0.0) 0 (0.0) NA* 78 (47.0) 37 (36.6) 0.274
    2 0 (0.0) 0 (0.0) 65 (39.2) 45 (44.6)
    3 7 (100.0) 70 (100.0) 23 (13.8) 19 (18.8)
Myometrial invasion
     ≤1/2 myometrium 2 (33.3) 32 (48.5) 0.477∞ 98 (59.0) 61 (60.4) 0.826
     >1/2 myometrium  4 (66.7) 34 (51.5) 68 (41.0) 40 (39.6)
Mean Diameter 
of tumor (cm) 3.1 4.0 0.343# 2.9 2.6 0.236#
‡Adjusted for abnormal cytology specific for endometrial pathology; #Independent T-test was used for continues 
variables; ∞Fisher’s exact test; *Not available: the variable ‘tumor grade’ is a constant in UPSC patients. $Not 
available: the variable ‘histology’ is a constant in EEC patients. LVSI: lymphovascular space invasion; UPSC: uterine 
papillary serous carcinoma; EEC: endometrioid endometrial carcinoma.
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Table 4: Crude hazard ratios (HR) with 95% confidence interval (CI) of Progression Free Survival (PFS) 
by clinicopathological variable in UPSC and EEC patients, using univariable Cox regression.
PFS-UPSC PFS-EEC
Variable N HR (95% CI) N HR (95% CI)
Age at diagnosis (years) 76 1.00 (0.96-1.03) 283 1.03 (0.99-1.06)
BMI (kg/m2) 68 0.93 (0.86-1.01) 242 0.99 (0.93-1.05)
FIGO Stage
    I – II 37 1.00 (reference) 251 1.00 (reference)
    III – IV 39 6.87 (3.22-14.67) 32 9.66 (4.91-19.01) 
Histology
     Pure 58 1.00 (reference) NA$
     Mixed 18 0.79 (0.36-1.73)
Tumor grade
    Low (grade 1 - 2) NA* 242 1.00 (reference)
    High (grade 3) 41 5.82 (2.95-11.48)
Extra-uterine disease
     No 28 1.00 (reference) 212 1.00 (reference)
     Yes 48 6.67 (2.75-16.16) 51 6.75 (3.39-13.43)
Cervical involvement
     No 46 1.00 (reference) 230 1.00 (reference)
     Yes 29 1.84 (0.95-3.55) 33 3.29 (1.53-7.10)
Para-aortic and/or pelvic Lymph 
nodes
    Negative 21 1.00 (reference) 32 NA#
    Positive 12 3.96 (1.40-11.20) 3 NA#
LVSI
     No 41 1.00 (reference) 219 1.00 (reference)
     Yes 35 2.56 (1.34-4.92) 53 4.57 (2.27-9.18)
Myometrial invasion
     ≤1/2 myometrial 36 1.00 (reference) 172 1.00 (reference)
     >1/2 myometrial 39 1.76 (0.92-3.37) 111 2.42 (1.22-4.78)
Maximum diameter  tumor 63 1.13 (0.95-1.35) 103 1.05 (1.01-1.10)
Cervical cytology
    Normal 10 1.00 (reference) 180 1.00 (reference)
    Abnormal 66 1.73 (0.61-4.89) 103 1.41 (0.72-2.77)
*Not available: the variable ‘tumor grade’ is a constant in UPSC patients. $Not available: the variable ‘histology’ is 
a constant in EEC patients. LVSI: lymphovascular space invasion; UPSC: uterine papillary serous carcinoma; EEC: 
endometrioid endometrial carcinoma. #NA: Not available because the number of EEC patients with proper lymph 
node sampling was insufficient.
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In EEC patients abnormal cervical cytology was significantly associated with cervical 
involvement (P=0.034). All other clinicopathologic variables were not associated with 
abnormal cervical cytology in EEC patients (Table 3). Cervical involvement was the only 
variable associated with abnormal cervical cytology in EEC patients using univariable logistic 
regression (OR 1.61, 95% CI 1.14–4.88; data not shown). 
Survival analysis
In a Cox proportional hazard model clinicopathologic variables including preoperative 
cervical cytology were analyzed for their association with progression free survival (PFS). 
In univariable analyses in UPSC patients, FIGO stage, extra-uterine disease, lymph node 
metastases, and LVSI  were significantly associated with PFS (Table 4). Abnormal cervical 
cytology was not associated with PFS in UPSC patients. In addition, no associations were 
found between PFS and age, BMI, cervical involvement, myometrial invasion, tumor 
diameter, or the composition of the tumor (pure or mixed UPSC). In EEC patients, FIGO 
stage, tumor grade, extra-uterine disease, cervical involvement, LVSI, myometrial invasion, 
and tumor diameter were significantly associated with PFS (Table 4). However, also in EEC 
patients abnormal cervical cytology specific for endometrial pathology was not associated 
with PFS. 
Discussion
In this study a high frequency of abnormal cervical cytology was found in UPSC patients 
compared to EEC patients (87.5% and 37.8% respectively). In UPSC patients, abnormal 
cervical cytology was significantly associated with extra-uterine disease, whereas in EEC 
patients an association was found with cervical involvement. Abnormal cervical cytology 
specific for endometrial pathology was not associated with survival in either UPSC or EEC 
patients. 
The possible prognostic and diagnostic role of cervical cytology in patients with the suspicion 
of endometrial cancer has gained little attention so far. It was shown that cervical cytology 
may provide additional preoperative diagnostic information when normal, suspicious 
or malignant endometrial cells are detected. The presence of atypical endometrial cells 
has a significant correlation with the presence of endometrial cancer.15,17,18,39 In addition, 
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in endometrial cancer patients abnormal cervical cytology has been associated with 
unfavorable prognostic, clinical, and pathologic parameters.19,20,22,24,25,38,40 However, in none 
of these studies a difference was made between patients with EEC and UPSC.
The most striking finding in this study was the very high frequency of abnormal cervical 
cytology (87.5%) in UPSC patients relative to EEC patients. At present, there have only 
been a few studies with a limited number of patients on cervical cytology in UPSC patients, 
and frequencies of abnormal cervical cytology among UPSC patients have varied from 72-
88%.25,27-30 It has been suggested previously that cervical cytology of UPSC patients is more 
likely to contain suspicious or malignant endometrial cells, probably due to the papillary 
architecture of the tumor and the propensity to exfoliate.38,41 Although the molecular 
biology to account for this observation has not been thoroughly investigated, we and 
others propose there is a relation with change of expression of cell adhesion molecules 
such as CD44, integrin, E-cadherin, β-catenin and L1CAM.40-42 In addition, involvement of the 
endocervix by the serous uterine tumor is more prevalent when compared to EEC and hence 
could explain the high rate of positive cervical cytology.41,43
We showed that in UPSC patients extra-uterine disease was significantly associated with 
abnormal cervical cytology. Markedly, UPSC patients who lacked poor prognostic factors 
still had abnormal cervical cytology in most cases. This was illustrated by patients with 
negative peritoneal cytology or absence of lymph node metastases who had abnormal 
cervical cytology in 92.5% and 95.2% of the cases respectively. In EEC patients, we found an 
association of abnormal cervical cytology with cervical involvement. The prognostic impact 
of other clinicopathologic factors was in concordance with literature.1,17 We did not find a 
prognostic impact of BMI in our analyses, probably due to our separate analyses of the EEC 
and UPSC cohort. Furthermore, the number of EEC patients might not be sufficient to find a 
prognostic impact of BMI.
Investigators have studied whether preoperative cervical cytology is an independent 
prognostic factor for survival in endometrial cancer patients. Although in one study by 
Fukuda et al an association was found in univariable analyses,24 cervical cytology never 
was an independent prognosticator for survival. In concordance, we found no association 
between cervical cytology and progression free survival in both UPSC and EEC patients 
independently. The fact that abnormal cervical cytology was associated with extra-uterine 
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disease but not with PFS in UPSC patients may be explained by the very large number of 
UPSC patients with advanced stage of disease with a dismal prognosis.
It was shown by some investigators that preoperative cervical cytology with atypical 
glandular/ endocervical cells, especially in patients over 50 years of age, was associated 
with endometrial pathology in 5-25% of cases.44,45 In our UPSC cohort two patients had 
atypical glandular cells, and in the EEC cohort one patient had atypical glandular cells. 
When these smears were considered as abnormal cytology, results of the analyses were 
not different. In the UPSC group extra-uterine spread of disease remained the only variable 
significantly associated with an increased frequency of abnormal cervical cytology (OR 5.33, 
95% CI 1.12 – 29.54; data not shown), whereas cervical involvement remained the only 
variable significantly associated with abnormal cervical cytology in EEC patients (OR 5.67 
95% CI 1.07-30.09; data not shown). Furthermore, abnormal cervical cytology was still not 
associated with PFS in both cohorts (data not shown).
It is of great importance to identify UPSC already in the preoperative setting, because 
of UPSC’s aggressive behavior and different surgical and adjuvant treatment approach 
compared to its EEC counterpart, including radical debulking surgery, comprehensive staging 
and chemoradiation therapy.14,46 Biopsy of the endometrium using either outpatient biopsy 
techniques or dilatation and curettage has been the standard of care procedure to obtain a 
preoperative histopathologic diagnosis.6 However, diagnosis of the histologic type made on 
these biopsies or curettage specimen can be challenging, with up to 20% of the diagnoses of 
histologic type being changed after surgery.47 Preoperative cervical cytology might give an 
indication to suspect a more aggressive uterine tumor.
There are some limitations to this study, being retrospective as most important issue. In 
only a small portion of included EEC patients lymphadenectomy or lymph node sampling 
was performed, and not all UPSC patients were radically debulked and comprehensively 
staged for reasons like massive spread of disease, morbid obesity or medical co-morbidities. 
In addition, there was a change from conventional to liquid based cytology at different time 
points in the different laboratories involved. The sensitivity for the detection of endometrial 
cancer appears to be higher when liquid based cytology is used compared to conventional 
techniques.48 However, we cannot comment on the difference in detection rate in the 
current study, since data on the cytology method are not available for all individual patients. 
Furthermore, we found a difference in median time of follow up between the EEC and 
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UPSC cohort. However, this difference can be explained by the highly aggressive nature of 
UPSC, with its high mortality rate already soon after clinical presentation, and poor five-year 
overall survival rate compared to EEC patients. This multicentre study comprises patients 
of five different institutions, with UPSC and EEC histology confirmed by three dedicated 
gynecopathologists, and with a complete national coverage of cervical cytology history. 
Furthermore, in all included patients cervical cytology was taken before endometrial 
biopsy or dilatation & curettage, with a median time interval of 1-2 months prior to final 
histopathologic diagnosis. To our knowledge this is the first study analyzing endometrial 
pathology in cervical cytology in two large cohorts of UPSC and EEC patients specifically. 
In conclusion, abnormal cervical cytology was more frequently found in UPSC patients. It 
was associated with extra-uterine disease in UPSC patients and with cervical involvement 
in EEC patients. More prospective research should be performed to assess the true clinical 
value of preoperative cervical cytology in endometrial cancer patients.
56
Chapter 3
References
1. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491-505. 
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
3. Ronnett BM, Zaino RJ, Hedrick Ellenson L, Kurman RJ. Endometrial carcinoma. In: Kurman R.J, 
TeLinde R.W, editors. Blaustein’s Pathology of the Female Genital tract. 5 ed. Springer; 2000 p. 
501-46.
4. Hamilton CA, Kapp DS, Chan JK. Clinical aspects of uterine papillary serous carcinoma. Curr Opin 
Obstet Gynecol 2008;20:26-33.
5. Grice J, Ek M, Greer B et al. Uterine papillary serous carcinoma: evaluation of long-term survival 
in surgically staged patients. Gynecol Oncol 1998;69:69-73.
6. Mariani A, El-Nashar SA, Dowdy SC. Lymphadenectomy in endometrial cancer: which is the right 
question? Int J Gynecol Cancer 2010;20:S52-4.
7.  Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in 
endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-36.
8. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion 
specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-7.
9. Sturgeon SR, Sherman ME, Kurman RJ et al. Analysis of histopathological features of endometrioid 
uterine carcinomas and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev 1998;7:231-
5.
10. Gehrig PA, Groben PA, Fowler WC, Jr., et al. Noninvasive papillary serous carcinoma of the 
endometrium. Obstet Gynecol 2001;97:153-7.
11. Geisler JP, Geisler HE, Melton ME, et al. What staging surgery should be performed on patients 
with uterine papillary serous carcinoma? Gynecol Oncol 1999;74:465-7.
12. Bristow RE, Asrari F, Trimble EL, et al. Extended surgical staging for uterine papillary serous 
carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol 2001;81:279-86.
13. Chan JK, Loizzi V, Youssef M et al. Significance of comprehensive surgical staging in noninvasive 
papillary serous carcinoma of the endometrium. Gynecol Oncol 2003;90:181-5.
14. Schwartz PE. The management of serous papillary uterine cancer. Curr Opin Oncol 2006;18:494-9.
15. Zucker PK, Kasdon EJ, Feldstein ML. The validity of Pap smear parameters as predictors of 
endometrial pathology in menopausal women. Cancer 1985; 56:2256-63.
16. Mitchell H, Giles G, Medley G. Accuracy and survival benefit of cytological prediction of 
endometrial carcinoma on routine cervical smears. Int J Gynecol Pathol 1993;12:34-40.
17. Siebers AG, Verbeek AL, Massuger LF, et al. Normal appearing endometrial cells in cervical smears 
of asymptomatic postmenopausal women have predictive value for significant endometrial 
pathology. Int J Gynecol Cancer 2006;16:1069-74.
18. Yancey M, Magelssen D, Demaurez A, et al. Classification of endometrial cells on cervical cytology. 
Obstet Gynecol 1990;76:1000-5.
19. Dubeshter B, Deuel C, Gillis S, et al. Endometrial cancer: the potential role of cervical cytology in 
current surgical staging. Obstet Gynecol 2003;101:445-50.
Cervical cytology in serous and endometrioid endometrial cancer
57
3
20. Morimura Y, Nishiyama H, Hashimoto T et al. Diagnosing endometrial carcinoma with cervical 
involvement by cervical cytology. Acta Cytol 2002; 46(2):284-290.
21. Zuna RE, Erroll M. Utility of the cervical cytologic smear in assessing endocervical involvement by 
endometrial carcinoma. Acta Cytol 1996;40:878-84.
22. Dubeshter B, Warshal DP, Angel C, et al. Endometrial carcinoma: the relevance of cervical cytology. 
Obstet Gynecol 1991;77:458-62.
23. Dubeshter B. Endometrial cancer: predictive value of cervical cytology. Gynecol Oncol 1999;72:271-
2.
24. Fukuda K, Mori M, Uchiyama M et al. Preoperative cervical cytology in endometrial carcinoma 
and its clinicopathologic relevance. Gynecol Oncol 1999;72:273-7.
25. Larson DM, Johnson KK, Reyes CN, Jr., et al. Prognostic significance of malignant cervical cytology 
in patients with endometrial cancer. Obstet Gynecol 1994;84:399-403.
26. Brown AK, Gillis S, Deuel C, et al. Abnormal cervical cytology: a risk factor for endometrial cancer 
recurrence. Int J Gynecol Cancer 2005;15:517-22.
27. Kuebler DL, Nikrui N, Bell DA. Cytologic features of endometrial papillary serous carcinoma. Acta 
Cytol 1989;33:120-6.
28. Park JY, Kim HS, Hong SR, et al. Cytologic findings of cervicovaginal smears in women with uterine 
papillary serous carcinoma. J Korean Med Sci 2005;20:93-7.
29. Todo Y, Minobe S, Okamoto K et al. Cytological features of cervical smears in serous adenocarcinoma 
of the endometrium. Jpn J Clin Oncol 2003;33:636-41.
30. Skaznik-Wikiel ME, Ueda SM, Frasure HE et al. Abnormal cervical cytology in the diagnosis of 
uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype? Acta 
Cytol 2011;55:255-60.
31. Casparie M, Tiebosch AT, Burger G et al. Pathology databanking and biobanking in The Netherlands, 
a central role for PALGA, the nationwide histopathology and cytopathology data network and 
archive. Cell Oncol 2007;29:19-24.
32. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a 
highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
33. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. 
A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 
1992;16:600-10.
34. Fader AN, Starks D, Gehrig PA, et al. An updated clinicopathologic study of early-stage uterine 
papillary serous carcinoma (UPSC). Gynecol Oncol 2009;115:244-8.
35. Siebers AG, Klinkhamer PJ, Arbyn M, et al. Cytologic detection of cervical abnormalities using 
liquid-based compared with conventional cytology: a randomized controlled trial. Obstet Gynecol 
2008;112:1327-34.
36. Hanselaar AG. Criteria for organized cervical screening programs. Special emphasis on The 
Netherlands program. Acta Cytol 2002;46:619-29.
37. Creasman WT. New gynecologic cancer staging. Obstet Gynecol 1990;75:287-8.
38. Gu M, Shi W, Barakat RR, et al. Pap smears in women with endometrial carcinoma. Acta Cytol 
2001;45:555-60.
58
Chapter 3
39. Van den Bosch T, Vandendael A, Wranz PA, et al. Cervical cytology in menopausal women at high 
risk for endometrial disease. Eur J Cancer Prev 1998;7:149-52.
40. Brown AK, Gillis S, Deuel C, et al. Abnormal cervical cytology: a risk factor for endometrial cancer 
recurrence. Int J Gynecol Cancer 2005;15:517-22.
41. Lozowski MS, Mishriki Y, Solitare GB. Factors determining the degree of endometrial exfoliation 
and their diagnostic implications in endometrial adenocarcinoma. Acta Cytol 1986;30:623-7.
42. Huszar M, Pfeifer M, Schirmer U et al. Up-regulation of L1CAM is linked to loss of hormone receptors 
and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010;220:551-61.
43. Schneider ML, Wortmann M, Weigel A. Influence of the histologic and cytologic grade and 
the clinical and postsurgical stage on the rate of endometrial carcinoma detection by cervical 
cytology. Acta Cytol 1986;30:616-22.
44. Schnatz PF, Guile M, O’Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on 
cervical cytology. Obstet Gynecol 2006;107:701-8.
45. Lai CR, Hsu CY, Tsay SH, Li AF. Clinical significance of atypical glandular cells by the 2001 Bethesda 
System in cytohistologic correlation. Acta Cytol 2008;52:563-7.
46. Roelofsen T, van Ham MA, de Hullu JA, et al. Clinical management of uterine papillary serous 
carcinoma. Expert Rev Anticancer Ther 2011;11:71-81.
47. Huang GS, Gebb JS, Einstein MH, et al. Accuracy of preoperative endometrial sampling for the 
detection of high-grade endometrial tumors. Am J Obstet Gynecol 2007;196:243-5.
48. Sams SB, Currens HS, Raab SS. Liquid-based Papanicolaou tests in endometrial carcinoma 
diagnosis. Performance, error root cause analysis, and quality improvement. Am J Clin Pathol 
2012;137:248-54.
59
CHAPTER 4
ABSOLUTE DEPTH OF MYOMETRIAL INVASION IN 
ENDOMETRIAL CANCER IS SUPERIOR TO THE CURRENTLY USED 
CUT-OFF VALUE OF 50% 
Y.P. Geels1, J.M.A. Pijnenborg2, S.H.M. van den Berg-van Erp3, M.P.M.L. Snijders4, J. Bulten5, 
L.F.A.G. Massuger1
1.Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, The Netherlands 
2. Department of Obstetrics and Gynecology, TweeSteden Hospital, Tilburg, The Netherlands
3. Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands 
4. Department of Obstetrics and Gynecology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
5. Department of Pathology, Radboud University Nijmegen Medical Centre, The Netherlands
Gynecol Oncol. 2013 May;129(2):285-91
60
Chapter 4
Abstract
Objective: In endometrial carcinoma, myometrial invasion is a well-known predictor of 
recurrence, and important in the decision making for adjuvant treatment. According to 
the FIGO staging system, myometrial invasion is expressed as invasion of < 50% > of the 
myometrium (50%MI). It has been suggested to use the absolute depth of invasion (DOI), 
or the tumor free distance to the serosa (TFD). The aim of this study was to compare DOI, 
50%MI, and TFD.
Methods: All patients diagnosed with endometrioid endometrial carcinoma at the RUNMC, 
and the CWH from 1999-2009 were included. Histologic slides were reviewed for histologic 
type and grade, DOI, 50%MI, and TFD. After review, 335 patients were identified. DOI, 
50%MI, and TFD were evaluated for their prediction of clinicopathologic characteristics.
Results: The prediction of recurrence was best performed by DOI when compared to TFD, 
with an area under the ROC curve of 0.726, and 0.638 respectively. The optimal cut-off value 
for DOI was 4mm. DOI independently correlated with recurrence of disease, and death of 
disease. TFD was associated with advanced age and large tumor diameter. DOI was the best 
predictor of progression-free and disease-specific survival next to 50%MI and TFD (HR 3.15, 
95%CI 1.16-8.56) and (HR 10.35, 95%CI 1.23-86.93).
Conclusion: DOI showed better predictive performance than TFD, and was more strongly 
correlated with clinicopathologic parameters than TFD and 50%MI. Possibly, DOI should 
substitute 50%MI as measure to express myometrial invasion in daily clinical practice. 
External validation is mandatory to confirm the proposed cut-off value of 4mm.
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Introduction
Endometrial cancer is the most common gynecologic malignancy in western countries. 
The majority of patients have endometrioid endometrial carcinomas, which in general 
have a favorable prognosis and present in early stage disease. However, about 20% of the 
patients have a more aggressive type of carcinoma, and are more likely to develop recurrent 
disease.1,2 
From literature, several parameters are known to predict the chance of recurrence. 
Age, histologic subtype, tumor grade, FIGO stage, and myometrial invasion are the most 
important predictors of overall and recurrence free survival.3-6 The depth of myometrial 
invasion is routinely determined in patients surgically treated for endometrial carcinoma. 
In the FIGO staging system, the assessment whether myometrial invasion is less or more 
than 50% is important: it makes the difference between FIGO stage IA and IB.7 Moreover, 
the depth of myometrial invasion is, together with age and tumor grade, a key parameter 
in the decisional process around the adjuvant radiotherapeutic treatment of endometrial 
carcinoma patients.4
However, determination of myometrial invasion may be challenging due to an irregular 
endomyometrial junction, exophytic tumor growth, adenomyosis, extensive leiomyomas, 
and different patterns of myometrial invasion.8,9 In literature, the rate of discrepancy when 
myometrial invasion is reassessed is around 30%.9,10 Incorrect assessment of myometrial 
invasion can lead to suboptimal staging,  and hence, to suboptimal treatment. It has been 
suggested to use absolute depth of invasion and tumor free distance to the serosa as an 
alternative measurement of myometrial invasion. These measurements possibly better 
predict the chance of recurrent disease.11-15
The aim of the current study is to assess the predictive value of absolute depth of invasion 
and tumor free distance to the serosa, and to evaluate the relationship of these parameters 
with clinicopathologic factors and progression free survival. Absolute depth of myometrial 
invasion and tumor free distance were compared to the conventional rendering of 
myometrial invasion in more or less than 50% of the total myometrial thickness. 
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Methods
Patient selection
The Dutch nationwide network and registry of histology and cytopathology (Pathologisch 
Anatomisch Landelijk Geautomatiseerd Archief: PALGA) was used to search for all patients 
diagnosed, and surgically treated with at least hysterectomy and bilateral oophorectomy at 
the Radboud University Nijmegen Medical Center (RUNMC), and the Canisius-Wilhelmina 
Hospital, Nijmegen, The Netherlands, for primary endometrioid endometrial carcinoma 
between January 1999 and January 2010. A total of 354 endometrioid endometrial 
carcinoma patients were identified. Clinical data were retrospectively collected by studying 
the medical charts. Age, menopausal state, body mass index (BMI), parity, personal medical 
history, (adjuvant) treatment, stage of disease, date of recurrence, date of death, and the 
cause of death were registered. Stage of disease was based on the 2009 International 
Federation of Gynecology and Obstetrics (FIGO) staging system.7 Surgical treatment was 
performed according to the Dutch guidelines: In case of a pre-operative apparently stage 
I disease and grade 1 or 2 endometrioid endometrial carcinoma, pelvic and/or para-aortic 
lymphadenectomy is not recommended. In case of grade 3 endometrioid endometrial 
carcinoma, pelvic and para-aortic lymphadenectomy is considered.16 Adjuvant radiotherapy 
was recommended to patients according to the PORTEC criteria, i.e. the presence of two out 
of the following three criteria: age over 60, tumor grade 3, and more than 50% myometrial 
invasion.4 One patient was excluded because of a synchronous primary malignancy of the 
ovary. 
Review of pathologic specimens 
The slides of the primary endometrial carcinoma of all 353 patients were retrieved from 
the pathology archives and used for review. Review was done systematically including the 
following items: histologic type, tumor grade, myometrial thickness, depth of myometrial 
invasion (DOI), tumor free distance to the serosa (TFD), myometrial invasion more or less than 
50% (50%MI), and the presence of lymphovascular space invasion.17 Myometrial thickness 
was measured from the endomyometrial junction to the serosa in the section where the 
tumor demonstrated the deepest invasion. DOI was measured from the endomyometrial 
junction to the deepest point of myometrial invasion. The endomyometrial junction refers 
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to the transition from endometrium to myometrium. In case of an irregular endomyometrial 
junction, we determined the endomyometrial junction in the area where the tumor reached 
the deepest invasion. TFD was measured from the deepest point of myometrial invasion 
to the serosa. All measurements were performed in the same section where the tumor 
reached the deepest point of invasion. In case of a leiomyoma in the uterine wall in this 
section, the myometrial thickness in the area directly next to the leiomyoma was measured. 
Carcinoma involving adenomyosis was not measured as myometrial invasion. In case of 
carcinoma in adenomyosis, there are often some normal endometrial tubes present, and 
there is a sharp boundary between endometrium and myometrium.18 A median number of 
three slides (range 1-8) with tumor and adjacent myometrium with serosa were available 
for each patient to re-evaluate the depth of myometrial invasion. Figure 1 shows examples 
of how measurements were performed. Review was performed in both hospitals separately 
by an experienced pathologist (JB, SB), on the tissue of the patients of the concerning 
hospital,  who was unaware of the results of the original pathology reports, and the clinical 
outcome of the patients. A second pathologist of the concerning hospital was consulted 
in case of doubt about the myometrial invasion by the reviewer, or in case of discrepancy 
Figure 1: Depth Of myometrial Invasion DOI, Tumor Free Distance to the serosa (TFD), endomyometrial 
junction (EMJ), Deepest Invasion (DI).  
Figure 1A: Example of assessment of DOI and TFD
Figure 1B: Example of assessment of DOI and TFD in a patient with leiomyoma
Figure 1C: Example of assessment of DOI and TFD in a patient with exophytic tumor growth, there is no DOI in this 
case
Figure 1D: Example of assessment of DOI and TFD in a patient with deep myometrial invasion
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with the initial diagnosis, and consensus about the diagnosis was achieved. After review, 
18 patients were diagnosed with (partly) non-endometrioid histology and were excluded, 
335 endometrioid endometrial carcinoma patients remained for analysis. A tumor was 
diagnosed as (partly) non-endometrioid when 10% or more of the tumor consisted of non-
endometrioid histology like serous, or clear cell type.18 The assessment whether myometrial 
invasion was less or more than 50% changed in 75 of the 335 patients (22%) after review 
(data shown in Supplemental Material 1). To note, for the results and the analyses, the 
reviewed pathology results were used. 
Statistical analysis
Receiver operating characteristics (ROC) analyses were established to evaluate the diagnostic 
performance of DOI and TFD for the prediction of recurrent disease. The performance of the 
tests is summarized by the area under the ROC curve (AUC). By using the ROC analysis cut-
off values for the best sensitivity and specificity of DOI and TFD were established. These cut-
off values were used for further analysis to achieve an equal comparison with 50%MI. The 
correlations of DOI, TFD, and the conventional 50%MI with clinical and pathologic factors 
in all endometrioid endometrial carcinoma patients were made using univariable logistic 
regression. In addition, for the correlation with each clinicopathologic outcome measure 
separately, a multivariable logistic regression model was comprised entering only DOI, 
50%MI, and TFD using the forward stepwise method. Results of correlation analyses were 
expressed in Odds Ratios (OR) with 95% Confidence Intervals (95%CI). Survival techniques 
were used to study the progression free survival (PFS) and disease specific survival (DSS). 
PFS was calculated from the date of surgery until the date of recurrence. In case of no 
recurrence, the date of last contact or death was used for censoring. DSS was calculated from 
the date of surgery till the date of death as a consequence of the endometrial carcinoma. 
In case of death by other cause, data were censored. The prognostic impact of variables 
age, BMI, FIGO stage, 50%MI, DOI, TFD, lymph node involvement, cervical involvement, 
tumor grade, lymphovascular space invasion, and diameter of the tumor were analyzed by 
using univariable and multivariable Cox proportional hazards models. The forward stepwise 
method was used for selection procedures for multivariable Cox proportional hazards 
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models. These results were expressed as Hazard Ratio’s (HR) with 95%CI. Statistical analyses 
were performed using the software package SPSS 18.0 for Microsoft Windows (SPSS Inc).
Ethical committee approval
The Research Ethics Committee of the Radboud University Nijmegen Medical Centre 
declared that the study protocol is in accordance with the applicable rules concerning the 
review of research ethics committees and informed consent.
Results
Patient characteristics
Clinical and pathologic characteristics of all patients are shown in Table 1. A total of 335 
consecutive endometrioid endometrial carcinoma patients were included in the study. As 
expected, the majority was diagnosed with FIGO stage I. In 37.6% of the patients myometrial 
invasion was more than 50% of the myometrium. Median myometrial thickness was 13.0 
mm (range 3.0-30.0), median DOI was 4.0 mm (range 0-27.0), and median TFD was 7.0 
mm (range 0-28.0). One-hundred-and-twenty-seven patients (38.2%) received adjuvant 
therapy. Median time of follow up was 47 months (range 1-128). Forty-three patients 
(12.8%) developed recurrent disease, and 23 patients (6.9%) died as a consequence of the 
endometrial carcinoma. Lymph node dissection was omitted in 279 cases with tumor grade 
1 or 2 endometrioid endometrial carcinoma diagnosed on endometrial biopsy, without 
clinical suspicion of FIGO stage II or more, as recommended by the Dutch guidelines for 
endometrial cancer treatment.15 In the eight patients diagnosed as FIGO stage IIIC1 or IIIC2 
a median number of nine (range 1-29) lymph nodes were removed.  
ROC curves
DOI showed a larger area under the ROC curve (AUC) than TFD for prediction of recurrence 
of disease: 0.726, and 0.638 respectively (Figure 2). The optimal cut off value for DOI was 
3.75 mm, providing 85% sensitivity and 50% specificity. For TFD the optimal cut-off value 
was 7.25 mm with 74% sensitivity and 51% specificity. We further analyzed the accuracy 
of these cut-off values by dividing the population in patients with < 4 mm DOI and patients 
with ≥ 4 mm DOI. For the TFD we divided the population in patients with ≤ 7 mm TFD > and 7 
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Table 1: Clinical and pathologic characteristics of all patients (N=335).
Variable N /median       %/ range
Median age (years) 64
28.1
24-93
Median BMI* (kg/m2) 18.4-65.0
Diabetes Mellitus
     No
     Yes
     Unknown
281
48
6
83.9
14.3
1.8
FIGO stage (2009)
     IA
     IB
     II
     IIIA
     IIIB
     IIIC1
     IIIC2
     IVA
     IVB
195
92
13
6
6
4
4
3
12
58.2
27.4
3.9
1.8
1.8
1.2
1.2
0.9
3.6
Myometrial Invasion
     No
     <1/2
     ≥1/2
     Trough serosa
47
154
126
8
14.0
46.0
37.6
2.4
Myometrial Thickness (mm) 13.0
4.0
7.0
3.0-30.0
Depth Of myometrial Invasion (mm) 0.0-27.0
Tumor Free Distance to serosa (mm) 0.0-28.0
Nodal involvement
     No
     Yes
    Unknown
46
10
279
13.7
3.0
83.3
Cervical involvement
     No
     Endocervical
     Stromal
288
20
27
86.0
6.0
8.0
Tumor grade
     1
     2
     3
142
136
57
42.4
40.6
17.0
Lymphovascular space invasion
     No
     Yes 
267
68
79.7
20.3
Diameter of the tumor 25.0
47.0
1.0-80.0
Time of follow up in months 0-128
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Adjuvant therapy
     No adjuvant therapy     
     Radiotherapy
     Radiotherapy (+Chemotherapy/                      
Hormonal therapy)
     Unknown
206
118
10
1
61.5
35.2
3.0
0.3
Recurrence
     No
     Yes, local
     Yes, distance
     Unknown
286
19
25
6
85.3
5.6
7.4
1.7
Patient died
     No
     Yes, as a consequence of disease
     Yes, other cause
     Unknown
296
23
6
10
88.3
6.9
1.8
3.0
*Body Mass Index
Figure 2: ROC curve of Depth of myometrial Invasion and Tumor Free Distance to the serosa for 
predicting recurrence of disease.
―  DOI: AUC 0.726 (95%CI 0.647-0.804, P<0.001)
--- TFD: AUC 0.638 (95%CI 0.551-0.725, P=0.004)
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mm TFD. By using dichotomous values for DOI and TFD, the results could be compared with 
the conventional 50%MI in correlation analyses with clinicopathologic parameters.
Correlation of 50%MI, DOI, and TFD with clinical and pathologic parameters
The results of correlation analyses are shown in Table 2. In univariable analysis, DOI, 50%MI 
and TFD were all associated with the presence of several prognostic unfavorable parameters: 
advanced FIGO stage, cervical involvement, poor differentiation, and lymphovascular space 
Table 2: Correlation of DOI# using the cut-off value of <4 mm or ≥4mm, MI$ <50% or ≥50%, and TFD† 
of ≤7mm or >7mm with clinical and pathologic factors using univariable and multivariable logistic 
regression.
Univariable Multivariable 
Outcome   Predictor OR 95% CI OR 95% CI
FIGO stage (2009) II, III, IV   DOI ≥ 4mm
MI ≥ 50%
TFD ≤ 7mm
10.85
6.84
5.46
3.78-30.98
3.35-14.00
2.46-12.09
8.30
3.98
NS
2.86-24.05
1.75-9.02
Nodal involvement DOI ≥ 4mm
MI ≥ 50%
TFD ≤ 7mm
NA£
3.67
7.20
0.70-19.17
0.84-61.69
NA
NA
NA
Cervical involvement   DOI ≥ 4mm
MI ≥ 50%
TFD ≤7mm
4.54
3.11
2.85
2.05-10.07
1.63-5.90
1.42-5.74
3.61
NS
2.19
1.60-8.15
1.07-4.51
Tumor grade 3     DOI ≥ 4mm
MI ≥ 50%
TFD ≤7mm
2.94
4.17
4.55
1.51-5.72
2.27-7.69
2.25-9.17
NS
2.30
2.76
1.12-4.73
1.22-6.24
Lymphovascular space 
invasion
DOI ≥ 4mm
MI ≥ 50%
TFD ≤ 7mm
11.22
4.63
4.28
4.69-26.84
2.61-8.23
2.26-8.10
8.61
NS
3.03
3.55-20.88
1.55-5.92
Recurrence of disease DOI ≥ 4mm
MI ≥ 50%
TFD ≤ 7mm
5.79
4.29
2.97
2.37-14.14
2.14-8.60
1.44-6.14
3.35
NS
NS
1.17-9.62
Death as consequence  
of disease
DOI ≥ 4mm
MI ≥ 50%
TFD ≤ 7mm
19.54
6.10
2.61
2.60-146.81
2.20-16.86
1.00-6.841
19.18
NS
NS
2.55-144.17
Age >60 years DOI ≥ 4mm
MI ≥ 50%
TFD ≤7mm
1.33
2.58
2.93
0.85-2.08
1.60-4.17
1.83-4.67
NS
NS
2.86 1.79-4.58
Diameter of the tumor  
> 20 mm
DOI ≥ 4mm
MI ≥ 50%
TFD ≤ 7mm
1.43
2.92
2.84
0.39-2.97
1.35-6.33
1.36-5.96
NS
NS
2.69 1.28-5.67
#Depth Of myometrial Invasion, $Myometrial Invasion, †Tumor Free Distance to serosa, *Body Mass Index, £Not 
Applicable, &Not Selected
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invasion. Furthermore, all three methods of defining myometrial invasion were associated 
with recurrent disease, and death as a consequence of disease. Differences in correlation 
of DOI, 50%MI, and TFD with clinicopathologic parameters were found for age, and tumor 
diameter. Age ≥ 60 years and tumor diameter ≥ 20 mm were associated with TFD and 50%MI, 
but not with DOI. Note that Odd’s Ratios of DOI were higher when compared to 50%MI and 
TFD in almost all analyses, except for tumor grade, age, and tumor diameter. In multivariable 
analysis for each clinicopathologic outcome measure separately, recurrent disease, and 
death as a consequence of disease. Furthermore, DOI was most strongly associated with 
advanced FIGO stage, cervical involvement, and lymphovascular space invasion. TFD was 
independently associated with advanced age and large tumor diameter. TFD and 50%MI 
were equally correlated with high tumor grade.  
Survival analysis 
In univariable Cox proportional hazard’s models (Table 3) advanced FIGO stage, ≥ 50 %MI, 
≥ 4 mm DOI, ≤ 7 mm TFD, cervical involvement, high tumor grade, and the presence of 
lymphovascular space invasion were all significant predictors of progression free survival 
and disease specific survival. In addition, tumor diameter was a significant predictor of 
disease specific survival. In a multivariable Cox proportional hazard’s model (Table 4) only 
FIGO stage and tumor grade remained as predictors of poor progression free survival. In the 
multivariable model for disease specific survival FIGO stage, tumor grade, and DOI remained 
as significant predictors. Table 5 shows univariable Cox proportional hazard’s models in the 
group with only FIGO stage I patients (N=287). In this group DOI, 50%MI, tumor grade and 
the presence of lymphovascular space invasion were predictors of progression free survival 
and disease specific survival. In a multivariable Cox proportional hazard’s model in this 
group with FIGO stage I patients DOI and tumor grade remained as independent predictors 
of progression free survival and disease specific survival (Table 6). To be able to compare the 
three methods of defining myometrial invasion, we created a second multivariable model in 
which only DOI, 50%MI, and TFD were entered (Supplemental Material 2). DOI and 50%MI 
remained as predictors of progression free survival. DOI was found to be the strongest 
predictor of progression free survival with a higher hazard ratio than 50%MI. For disease 
specific survival DOI remained as independent predictor.
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Clinical implications of DOI instead of 50%MI
If the DOI cut-off value of ≥ 4 mm would be a criterion for adjuvant radiotherapy instead of 
≥ 50%MI, 22 additional patients would fulfill the criteria for adjuvant radiotherapy. Three 
of these 22 patients developed recurrent disease, one with distant and two with local 
recurrences. In addition, using the cut-off value of ≥ 4 mm DOI would implicate omission of 
Table 3: Crude hazard ratios (HR) of progression free survival (PFS) and Disease Specific Survival 
(DSS) by clinicopathologic variables using univariable Cox regression.
PFS DSS
Variable N HR 95%CI HR 95%CI
Age (years) 328 1.02 0.99-1.05 0.98 0.94-1.03
BMI (kg/m2) 282 0.98 0.92-1.03 1.01 0.95-1.07
FIGO stage (2009)
     I
     II, III, IV
281
48
1.00 
8.22 
reference
 4.54-14.89
1.00
8.90
reference
3.90-20.22
Depth Of myometrial Invasion 
     < 4mm
     ≥ 4mm
143
182
1.00 
5.26 
reference
2.22-12.47
1.00
18.41
reference
2.48-136.62
Myometrial Invasion
     <50%
     ≥50%
199
130
1.00 
3.98 
reference
 2.08-7.40
1.00
5.79
reference
2.15-15.58
Tumor Free Distance
     ≤ 7mm
     > 7mm
166
149
2.77 
1.00 
1.40-5.50 
reference
2.55
1.00
1.00-6.46
reference
Nodal involvement
     No
     Yes
46
8
1.00 
2.08 
reference 
0.59-7.40
1.00
0.87
reference
0.11-7.02
Cervical involvement
     No
     Yes (endocervical + stromal)
282
46
1.00 
3.67 
reference 
1.94-6.96
1.00
4.20
reference
1.76-10.02
Tumor grade
     1
     2
     3
139
133
57
1.00 
2.47 
8.93 
reference 
1.02-6.00 
3.79-21.03
1.00
1.71
14.92
reference
0.41-7.14
4.32-56.61
Lymphovascular space invasion
    No
    Yes 
262
66
1.00 
4.20 
reference 
2.30-7.66
1.00
7.24
reference
3.13-16.75
Diameter of the tumor 213 1.03 0.99-1.07 1.06 1.02-1.10
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radiotherapy in five patients who had received radiotherapy based on the reviewed 50%MI. 
Of these five patients, one patient developed distant recurrent disease. Within the group 
that did not receive radiotherapy (N=188), patients who would have received radiotherapy 
based on the newly proposed cut-off value of 4 mm had a hazard ratio of 1.67 (95%CI 
0.36-1.74) to develop recurrence of disease compared to the patients who would not have 
received radiotherapy based on the newly proposed cut-off value.
Table 4: Adjusted hazard ratios (HR) of progression free survival (PFS) and Disease Specific Survival 
(DSS) by clinicopathologic variables using multivariable Cox regression.
PFS DSS
Variable N HR 95%CI HR 95%CI
FIGO stage (2009)
     I
     II, III, IV
266
46
1.00
5.12
reference
2.65-9.89
1.00
2.93
reference
1.16-7.36
Depth Of myometrial Invasion 
     < 4mm
     ≥ 4mm
NS& 1.00
8.43
reference
1.07-66.46
Myometrial Invasion
     < 50%
     ≥ 50%
NS NS
Tumor Free Distance
     ≤ 7mm
     > 7mm
Cervical involvement
     No
     Yes (endocervical + stromal)
NS
NS
NS
NS
Tumor grade
     1
     2
     3
132
126
54
1.00
1.77
4.39
reference
0.71-4.40
1.74-11.08
1.00
0.80
5.74
reference
0.18-3.64
1.52-21.72
Lymphovascular space invasion
    No
    Yes 
NS
&Not Selected
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Table 5: Crude hazard ratios (HR) of progression free survival (PFS) and Disease Specific Survival 
(DSS) by clinicopathologic variables using univariable Cox regression in the group of patients with 
FIGO stage I disease (N=287).
PFS DSS
Variable N HR 95%CI HR 95%CI
Age (years) 274 1.00 0.96-1.05 0.96 0.90-1.02
BMI (kg/m2) 236 0.92 0.84-1.02 0.92 0.80-1.05
Depth Of myometrial Invasion 
     < 4 mm
     ≥ 4 mm
139
140
1.00
3.49
reference
1.83-9.45
1.00
10.13
reference
1.30-79.11
Myometrial Invasion
     <50%
     ≥ 50%
189
93
1.00
2.45
reference
1.06-5.68
1.00
3.51
reference
1.03-12.00
Tumor Free Distance
     ≤ 7 mm
     > 7 mm
128
141
1.95
1.00
0.82-4.64
reference 
1.87
1.00
0.55-6.40
reference
Tumor grade
     1
     2
     3
134
113
35
1.00
1.35
4.14
reference
0.49-3.72
1.45-11.80
1.00
0.74
8.45
reference
0.13-4.46
2.11-33.83
Lymphovascular space invasion
    No
    Yes 
242
40
1.00
2.71
reference
1.06-6.94
1.00
6.01
reference
1.83-19.73
Diameter of the tumor 107 1.04 0.99-1.09 1.06 1.00-1.11
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Table 6: Adjusted hazard ratios (HR) of progression free survival (PFS) and Disease Specific Survival 
(DSS) by clinicopathologic variables using multivariable Cox regression in the group of patients with 
FIGO stage I disease (N=287).
PFS DSS
Variable N HR 95%CI HR 95%CI
Depth Of myometrial Invasion 
     ≤ 4 mm
     > 4 mm
139
140
1.00
3.11
reference
1.12-8.60
1.00
9.05
reference
1.14-71.97
Myometrial Invasion
     < 50%
     ≥ 50%
188
91
NS& NS
Tumor grade
     1
     2
     3
134
112
33
1.00
1.08
3.34
reference
0.38-3.01
1.15-9.68
1.00
0.53
6.12
reference
0.87-3.17
1.51-24.76
Lymphovascular space invasion
    No
    Yes 
240
39
NS NS
&Not Selected
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Discussion
Myometrial invasion is an important predictor of recurrence and survival. In endometrioid 
endometrial carcinoma it is therefore a crucial parameter for the decision about adjuvant 
radiotherapy. In this study, the prognostic value and relationship with clinicopathologic 
parameters of DOI, TFD and 50%MI were analyzed and compared. DOI revealed a larger area 
under the ROC curve for prediction of recurrence than TFD, and the most discriminating cut-
off value for DOI was 4 mm. DOI had a stronger correlation with unfavorable clinicopathologic 
parameters, and was a better predictor of progression free survival than TFD and 50%MI. 
In endometrial carcinoma, the currently used cut-off value for adjuvant therapy is a 
percentage of invasion of the total myometrial thickness. In other gynecologic carcinomas 
absolute cut-off values are used for guidance in the choice of treatment. In vulvar carcinoma 
a cut-off value of 1 mm is used to decide on groin lymphadenectomy.19 In cervical carcinoma 
the extent of surgery and the choice for radiotherapy are based on invasion depths of 5 mm 
and 15 mm, respectively.20,21 Our results show that a cut-off value of 4mm DOI and 7 mm 
TFD led to the most effective balance between sensitivity and specificity. To our knowledge, 
for DOI no cut-off value has been suggested before. For TFD a cut-off value of 1 cm has been 
suggested in two reports. However, in these reports TFD was found to be only of modest 
predictive value.12,13 In addition, an optimal TFD cut-off value of 1.75 mm has been reported, 
which showed to be a good predictor of progression free and disease specific survival.15 
In the current study, DOI was a better predictor of recurrence than TFD, showing a larger 
area under the ROC curve. Therefore, DOI with this absolute cut-off value of 4 mm, may be 
preferable in endometrial carcinoma as well.
When compared to the conventional 50%MI, the newly proposed cut-off value of 4 mm 
has important clinical consequences: 22 additional patients would have received adjuvant 
radiotherapy. More importantly, three of these 22 patients developed recurrent disease, one 
distant and two local recurrences. The two local recurrences may have been prevented with 
adjuvant radiotherapy. In future research, the clinical implications of expressing myometrial 
invasion as DOI should be further explored. Moreover, the cut-off value of 4 mm should be 
externally validated, preferably in prospective research. 
Several authors have reported on optimizing the definition of myometrial invasion, with 
conflicting results. Lindauer et al reported that TFD is a better predictor of clinicopathologic 
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factors than DOI in a completely staged cohort of 153 patients.12 Kaku et al identified TFD 
as independent prognostic predictor in 88 stage I and II endometrial cancer patients.11 
Chattopadhyay et al reported that TFD is an independent predictor of survival and lymph 
node metastases in 288 endometrioid endometrial carcinoma patients.15 However, Schwab 
et al prospectively determined TFD, and did not find a difference in prediction of recurrence 
and death compared to DOI in 99 endometrial cancer patients.13 Moreover, in the study of 
Kondalsamy-Chennakesavan et al, DOI was found to be a better predictor for the presence 
of lymph node metastases than TFD and %MI in 338 endometrioid endometrial carcinoma 
patients.14 In three of the five above mentioned studies no review of the histologic slides 
was performed. Chattopadhyay et al reviewed slides to determine DOI and TFD.15 Only in 
the study of Kaku et al pathologic diagnosis was confirmed with independent histologic 
review.11 In the current study, DOI was a better predictor of recurrence than TFD, revealing 
a stronger correlation with clinicopathologic variables, and an independent correlation 
with recurrent disease and death as a consequence of disease when compared to TFD and 
50%MI. This superior correlation could be explained by the assumption that DOI better 
shows the potential of the tumor to invade the myometrium.
DOI, 50%MI, and TFD were all predictors of progression free survival in univariable 
analyses, although in a multivariable model FIGO stage and tumor grade remained as the 
strongest predictors. In the multivariable model of disease specific survival DOI remained as 
independent predictor next to FIGO stage and tumor grade. However, the 95%CI of DOI was 
large, due to few deaths as a consequence of disease, making the interpretation of these 
results difficult. When we compared the three ways of expressing myometrial invasion, DOI 
was a stronger predictor of progression free survival and disease specific survival. However 
in this model the influences of other prognostic parameters are ignored and these results 
may therefore be biased. In FIGO stage I patients the correct assessment of myometrial 
invasion is more important to provide prognostic information. In this particular group DOI 
independently predicted progression free survival and disease specific survival.    
Another reason for reconsidering 50%MI as a measure for myometrial invasion is the moderate 
reproducibility. The rate of discrepancy when 50%MI is reassessed is around 30%.9,10 We 
found a similar discrepancy rate between the initial pathology report and the reviewed data 
of 22%. Several studies have discussed the most important factors contributing to difficulties 
in the assessment of myometrial invasion. The most common reasons for underestimation of 
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myometrial invasion are leiomyomas, whereas the most common reasons for overestimation 
are exophytic tumor growth, and adenomyosis. In addition, an irregular endomyometrial 
junction may cause discrepancies in the measurement of myometrial invasion.9,10 For the 
pathologist, DOI is more practical to measure. The advantage of DOI above 50%MI is the fact 
that measuring myometrial thickness is not necessary. Hence, difficulties with assessing the 
myometrial thickness caused by leiomyomas are avoided. This is in contrast to the TFD, in 
which leiomyomas would cause difficulties as well. Furthermore, only one measurement is 
needed for DOI, for TFD and 50%MI two measurements are needed, enhancing the chance 
on disagreement. To our knowledge, no studies comparing the reproducibility of the three 
ways of assessing myometrial invasion exist yet. Currently, we are planning a study to 
compare the intra-observer variability of DOI, 50%MI, and TFD to confirm this hypothesis.
The shortcoming of this study is that it is a retrospective study. According to the endometrial 
carcinoma guidelines, a part of the study population received adjuvant radiotherapy, and 
a part did not. This means that the occurrence of recurrent disease is influenced by the 
adjuvant treatment strategy. Furthermore, in just a small portion of the study population 
lymphadenectomy was performed. Therefore, the prediction of the presence of lymph 
node metastases, and the predictive value of lymph node metastases have to be interpreted 
with caution. On the other hand, this study describes a large cohort, consisting only 
of endometrioid endometrial carcinoma patients. The exclusion of non-endometrioid 
histology prevents bias from results caused by significantly worse clinical behavior and 
prognosis of non-endometrioid tumors.18 Furthermore, diagnosis of endometrioid histology 
was confirmed by reviewing all histologic slides, and DOI and TFD have been measured by 
experienced pathologists.    
In conclusion, DOI shows superior predictive performance compared to TFD, and was more 
strongly correlated with clinicopathologic parameters than TFD and 50%MI. Possibly, DOI 
should substitute 50%MI as objective measure to express myometrial invasion in daily 
clinical practice. External validation is mandatory to confirm the proposed cut-off value of 4 
mm as most relevant clinical criterion for myometrial invasion.  
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Supplemental Material 1: Diagnosis of myometrial invasion in more or less than 50% according to 
the initial diagnosis and the diagnosis after review of the histologic slides.
Supplemental Material 2: Adjusted hazard ratios (HR) of progression free survival by Depth Of 
myometrial Invasion <4mm or ≥4mm, Myometrial Invasion <50% or ≥50%, and Tumor Free Distance 
≤7mm or >7mm using multivariable Cox regression.
Variable HR 95%CI HR 95%CI
Depth Of myometrial Invasion 
     < 4mm
     ≥ 4mm
136
177
1.00
3.15
reference
1.16-8.56
1.00
10.35
reference
1.23-86.93
Myometrial Invasion
     < 50%
     ≥ 50%
189
124
1.00
2.15
reference
1.01-4.58
NS
Tumor Free Distance
     ≤ 7mm 
     > 7mm
NS& NS
&Not Selected
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Abstract 
Objective: Type I endometrial carcinomas are characterized by endometrioid histology, 
develop from hyperplastic endometrium, and have a good prognosis. Type II, non-
endometrioid carcinomas, arise in atrophic endometrium, and have a poor prognosis. 
However, about 20% of cases do not fit within this dualistic model and include endometrioid 
carcinomas associated with recurrence, and possibly with atrophy. We aimed to evaluate 
grade 1 endometrioid endometrial carcinomas with atrophic endometrium, a putative third 
type endometrial carcinoma. 
Methods: Histologic slides of all grade 1 endometrioid endometrial cancers from the Radboud 
University Medical Centre and Canisius-Wilhelmina Hospital from 1999-2009, and from the 
Mayo Clinic from 2002-2008 were reviewed. Comparisons were made between patients with 
atrophic and hyperplastic endometrium. 
Results: After review, 527 patients were identified. In 88 patients (16.8%) background 
endometrium was atrophic, 387 patients (73.3%) had hyperplastic endometrium. Fifty-two 
patients (9.9%) had proliferative endometrium or no background endometrium and were 
excluded. Atrophy correlated with older age, low BMI, advanced FIGO-stage, malignant cells 
in peritoneal cytology, lymph node metastases, cervical involvement, lymphovascular space 
invasion, and deep myometrial invasion. Multivariable analysis showed that age (HR 1.06, 
95%CI 1.01-1.12), FIGO stage (HR 8.47, 95%CI 1.73-41.57), and background endometrium(HR 
3.11, 95%CI 1.11-8.70) were predictors of progression-free survival. 
Conclusion: Atrophic endometrium is an independent prognostic factor for patients with 
grade 1 endometrioid endometrial carcinoma. Endometrioid carcinoma with atrophy may 
not follow the hypothesized progression model for type I tumors and may arise through 
unique carcinogenic pathways. Future research should investigate the carcinogenic pathways 
in this interesting group of patients. 
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Introduction
Cancer of the uterine corpus is the most common gynecologic malignancy in industrialized 
nations with an incidence of 43,470 and an estimated death rate of 7,950 annually in 
the United States.1,2 A dualistic model for carcinogenesis in endometrial cancer has been 
accepted worldwide.3-5 The majority of endometrial carcinomas are classified as type 
I carcinomas, and are related to unopposed estrogenic stimulation due to obesity, or 
exogenous hormone use. Type I endometrioid endometrial carcinomas occur in women at a 
median of sixty years of age, originate from hyperplastic endometrium, and generally have 
a good prognosis. In contrast, type II carcinomas include serous and clear cell histology, 
are unrelated to estrogenic stimulation, and occur in relatively older women. The majority 
of type II endometrial carcinomas arise in a background of atrophic endometrium, and 
generally have a poor prognosis.6,7 
Distinct carcinogenic pathways underlie the observed clinical differences between type I and 
II endometrial cancer. Type I carcinomas are characterized by diploid tumors, expression of 
estrogen and progesterone receptors, PTEN alterations, microsatellite instability (MSI), and 
mutations of KRAS and CTNNB1. Type II carcinomas on the contrary, are often aneuploid, 
and show over expression of p53 and Her2/neu.5-8,10 
Approximately 20% of cases do not fit within the dualistic model described above, and 
include patients with endometrioid endometrial carcinoma associated with recurrence 
and poor clinical outcome.9,11 It has been suggested that a third endometrial cancer entity 
exists: endometrioid carcinomas arising in atrophic endometrium. This purported “type III 
endometrial cancer” is hypothesized to be associated with clinical outcomes intermediate 
between type I and type II lesions.12 Furthermore, carcinogenesis in this group may occur 
through distinct mechanisms. 
The aim of the current study was to estimate the clinical relevance of this hypothesized 
third type endometrial carcinoma. Therefore, we compared clinical and pathologic features 
in patients with hyperplastic and atrophic background endometrium in a large series of 
grade 1 endometrioid endometrial carcinoma patients. Second, we analyzed the prognostic 
impact of the background endometrium. 
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Materials and Methods
Patient selection
The Dutch nationwide network and registry of histology and cytopathology (Pathologisch 
Anatomisch Landelijk Geautomatiseerd Archief: PALGA) was used to search for all patients 
diagnosed, and surgically treated with at least hysterectomy and bilateral oophorectomy at 
the Radboud University Nijmegen, Medical Centre (RUNMC), and the Canisius-Wilhelmina 
Hospital, Nijmegen, The Netherlands for primary grade 1 endometrioid endometrial 
carcinoma between January 1999 and January 2010. Subsequently, all patients diagnosed 
with primary grade 1 endometrioid endometrial carcinoma, and surgically treated with at 
least hysterectomy and bilateral oophorectomy in the Mayo Clinic, Rochester, Minnesota, 
USA, from January 2002 till January 2009 were included in the study. A total of 572 grade 
1 endometrioid endometrial carcinoma patients were identified. This number included 
143 patients from Nijmegen, and 429 patients from the Mayo Clinic. Clinical data were 
abstracted from patient records. Age, menopausal state, body mass index (BMI), parity, 
personal medical history, treatment, stage of disease, date of recurrence of disease, date 
of death, and the cause of death were registered. Stage of disease was based on the 2009 
International Federation of Gynecology and Obstetrics (FIGO) staging system.13 Patients 
with a personal history of any malignancy, or any synchronous primary malignancy were 
excluded from further analyses. Follow up data were extracted from the medical charts. In 
case of incomplete follow-up data, the patient or the physician was contacted. The median 
time of follow up was 50 months (range 0-128).  
Review of the histologic slides 
The slides of the primary carcinoma and the surrounding background endometrium of 
all patients were retrieved from the pathology archives and reviewed. Review was done 
systematically including the following items: the histologic type, tumor grade, depth of 
myometrial invasion (MI), the presence of lymphovascular space invasion (LVSI), and 
the nature of the background endometrium.14 Review was performed in every hospital 
separately by an independent experienced pathologist (JB, SB, DV), who was unaware of 
the results of the original pathology reports or the clinical outcome of the patients. There 
was no systematic review between the centers. In case of doubt about the diagnosis, or in 
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case of discrepancy with the original pathology report a second review was performed by 
another experienced pathologist from the concerning hospital, and consensus about the 
diagnosis was made. 
Background endometrium was grouped in eight categories: simple hyperplasia (SH), 
simple atypical hyperplasia (SAH), complex hyperplasia (CH), complex atypical hyperplasia 
(CAH), disordered proliferative endometrium, atrophic endometrium, normal proliferative 
endometrium, and determination of the background endometrium not possible.
Hyperplasia was defined as a proliferation of glands with an increase in gland:stroma ratio 
of 3:1 and a variety of abnormal architectural patterns.15 Cytological atypia was defined as 
enlarged, rounded, polymorphic nuclei with loss of polarity, prominent nucleoli, chromatin 
clumbing, and an increased nuclear to cytoplasmic ratio.6 Hyperplasia was categorized 
according to the World Health Organization (WHO) classification system for hyperplasia, 
which is based on the study of Kurman and colleagues.16 
The endometrium was considered disordered proliferative when some of the present glands 
in postmenopausal women showed proliferative activity, and the gland:stroma ratio was 
slightly increased, but did not meet the hyperplasia criterion of 3:1.6,15     
Atrophic endometrium was defined as shallow endometrium with a thin basalis, and with 
a few tubular glands lined by inactive epithelium.17 In case of focal hyperplasia or focal 
disordered proliferative endometrium, the background endometrium was diagnosed as 
atrophic when more than 50% of the background endometrium was atrophic. In these cases 
the sub classification “mixed atrophy” was used, whereas cases without any proliferative 
glands were classified as “pure atrophy”. 
In premenopausal women, proliferative endometrium was defined as widely spread, 
sometimes tortuous, tubular glands that showed mitotic activity, and abundant stroma.17 
In some cases the tumor covered the entire endometrial cavity, so the nature of the 
background endometrium could not be determined.  
The median number of slides available per patient in the cases with hyperplasia was four 
(range 1-23). For the patients with atrophic endometrium the median number of available 
slides was four as well (range 2-10). 
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Statistical analysis
Comparison was made between the group with atrophic and the group with hyperplastic 
background endometrium. The atrophy group consisted of patients with mixed and 
pure atrophy. The hyperplasia group consisted of patients with SH, SAH, CH, CAH, and 
disordered proliferative endometrium. When normal proliferative endometrium was found 
in premenopausal patients, or when no background endometrium could be found in the 
endometrial cavity, patients were excluded from analyses. Sub analyses were performed 
comparing pure atrophic background endometrium with mixed atrophic background 
endometrium. Differences in clinical and pathologic parameters between the group of 
patients with atrophic and hyperplastic endometrium were tested for statistical significance 
using the Pearson’s chi-Square (χ2) test, or the Fisher’s exact test, and the Mann-Whitney 
test. The P-values presented are two-sided, and associations were considered significant 
if the P-value was less than 0.05. Survival techniques were used to study the progression 
free survival (PFS). PFS was calculated from the date of surgery until the date of recurrence. 
In case of no recurrence, the date of last contact or death was used for censoring. The 
prognostic impact of patient and tumor characteristics age, BMI, FIGO stage, peritoneal 
cytology, lymph node involvement, cervical involvement, lymphovascular space invasion, 
myometrial invasion, diameter of the tumor, and background endometrium were analyzed by 
using univariable and multivariable Cox proportional hazards models. The forward stepwise 
method was used for selection procedures for multivariable Cox proportional hazards 
models. These results were expressed as hazard ratio’s (HR) with their 95% confidence 
intervals (95% CI). Statistical analyses were performed using the software package SPSS 18.0 
for Microsoft Windows (SPSS Inc).
Ethical committee approval
For the cohort from the Mayo Clinic the study protocol was approved by the Institutional 
Review Board of Mayo Foundation; in accordance with the Minnesota Statute for Use 
of Medical Information in Research, only those patients who consented to the use of 
their medical records were included. For the cohort from the RUNMC and the Canisius-
Wilhelmina Hospital, the Research Ethics Committee of the Radboud University Nijmegen 
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Medical Centre declared that the study protocol is in accordance with the applicable rules 
concerning the review of research ethics committees and informed consent.
Results
Patient characteristics
In total 572 grade 1 endometrioid endometrial carcinoma patients were identified. 
Thirty-two patients were excluded because of personal history of other malignancy. After 
review, thirteen cases were diagnosed with tumor grade 2 and were excluded. A total of 
527 patients with grade 1 endometrioid endometrial carcinoma remained for analyses. 
Demographic and histopathologic characteristics of the 527 patients are shown in Table 1. 
As expected, the majority of patients were stage I and demonstrated favorable histologic 
characteristics. Fifty-nine patients received adjuvant therapy. In 21 patients recurrence of 
disease occurred, and only 7 patients died as a consequence of the disease. This results in 
a five year progression free survival rate of 96% and a five year overall survival rate of 99%. 
Note that lymph node dissection was omitted in a large proportion of the cohort. For the 
429 patients from Mayo clinic, omission of lymph node dissection in 185 patients occurred 
as per protocol for patients with less than 50% myometrial invasion and tumor diameter 
less than 2cm as previously described.18 For the 143 patients from Nijmegen, lymph node 
dissection was omitted in 137 cases without clinical suspicion of FIGO stage II or more, as 
recommended by the Dutch guidelines for endometrioid endometrial cancer treatment.19 
Nature of the background endometrium
The type of background endometrium diagnosed in the total cohort is shown in Table 2. Some 
derivation of hyperplasia was present in 387 patients (73%) while atrophic endometrium 
was diagnosed in 88 patients (17%). In 25 patients (5%) there was extensive growth of 
the tumor in the endometrial cavity causing the entire endometrium to be substituted 
by the carcinoma. In these patients no background endometrium could be identified 
and were therefore excluded from analyses. Furthermore, in 27 patients (5%) normal 
premenopausal, proliferative endometrium was found. Since the hormonal regulated status 
of the premenopausal endometrium is not comparable to the non-stimulated status of the 
postmenopausal endometrium, these patients were also excluded from further analyses. An 
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Table 1: Clinical and pathologic characteristics of all grade 1 endometrioid endometrial carcinoma 
patients (N=527).
Variables  median / N range/ %
Age at diagnosis (years) (N=527) 62 25-92
BMI (kg/m2) (N=507) 32 16-76
FIGO Stage (2009)
     I A 
B
459
54
87.0
10.2
     II 3 0.6
     III 10 2.0
     IV 1 0.2
Hypertension
     No 243 46.1
     Yes 282 53.5
     Unknown 2 0.4
Diabetes Mellitus
     No 426 80.8
     Yes 99 18.8
     Unknown 2 0.4
Peritoneal Cytology
    Negative 370 70.2 
    Positive 32 6.1
    Not sampled 125 23.7
Para-aortic and/or Pelvic Lymph nodes
    Negative 221 41.9
    Positive Pelvic
Pelvic and para-aortal
4
1
0.8
0.2
    Not sampled 301 57.1
Cervical involvement
    No 517 98.1
    Yes Endocervical glands
Cervical stroma
7
3
1.3
0.6
Lymphovascular space invasion
    No 510 96.8
    Yes 17 3.2
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Myometrial invasion
     No invasion of myometrium 141 26.7
     ≤1/2 myometrium 324 61.5
     >1/2 myometrium 62 11.8
Diameter of tumor (mm) (N=409)  25 1-145
Adjuvant therapy
     No
     Radiotherapy
     Chemotherapy
     Chemotherapy + radiotherapy
     Unknown 
467
48
5
6
1
88.6
9.1
1.0
1.1
0.2
Recurrence of disease
     No
     Yes
     Unknown
502
21
4
95.3
4.0
0.7
Patient died
     No 
     Yes, as a consequence of disease
     Yes, different cause
     Yes, unknown cause
494
7
20
6
93.7
1.4
3.8
1.1
Table 2: Background endometrium in all endometrioid endometrial carcinoma patients (N=527).
N Per cent
Simple hyperplasia 36 6.8
Simple hyperplasia with atypia 10 1.9
Complex hyperplasia 7 1.3
Complex hyperplasia with atypia 308 5.4
Disordered proliferative endometrium 26 4.9
Total hyperplasia 387 73.3
Pure atrophy
Mixed atrophy
44
44
8.4
8.4
Total atrophy 88 16.8
Normal proliferative endometrium 27 5.1
No background endometrium 25 4.8
Total excluded from analyses 52 9.9
Total 527 100
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example of endometrioid endometrial carcinoma with atrophic background endometrium, 
and endometrioid endometrial carcinoma with hyperplastic background endometrium is 
shown in Figure 1.
Results of analyses of atrophic background endometrium (N=88) and hyperplastic 
background endometrium (N=387) with clinical and pathologic characteristics are shown in 
Table 3. There were significant associations between atrophic endometrium and older age 
(P<0.01), and lower BMI (P<0.01). Furthermore, patients with atrophic endometrium were 
more likely to have advanced stage disease (P<0.01), malignant cells in peritoneal cytology 
(P=0.01), lymph node metastases (P=0.01), cervical involvement (P=0.03), lymphovascular 
space invasion (P<0.01), and deep myometrial invasion (P<0.01). Note that atrophic 
endometrium was present in all patients with metastatic lymph nodes. No differences were 
found between the atrophic and hyperplastic group with respect to hypertension, diabetes 
mellitus, and tumor diameter.  When analyses were limited to patients with pure atrophic 
endometrium versus patients with mixed atrophic endometrium, a significant association 
was found only with pure atrophic endometrium and deep myometrial invasion (data shown 
in Supplemental Digital Content 1). 
Figure 1: Atrophic and hyperplastic background endometrium.
Figure 1A: Endometrioid endometrial carcinoma with atrophic endometrium
Figure 1B: Endometrioid endometrial carcinoma with hyperplastic endometrium
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Table 3: Clinical and pathologic characteristics in patients with atrophic background endometrium 
compared with patients with hyperplastic background endometrium.
Atrophy (N=88) Hyperplasia (N=387)
mean/N range/% mean/N range/% P-value
Median age (years) 69 40-89 62 25-89 <0.01 
Median BMI (kg/m2) 30.9 20.0-66.0 33.5 16.0-76.0 <0.01
FIGO (2009)
     Stage I 82 93.2 383 99.0 <0.01
     Stage II,III, IV 6 6.8 4 1.0
Hypertension
     No 37 42.5 176 45.6 0.60
     Yes 50 57.5 210 54.4
Diabetes Mellitus
     No 74 85.1 308 79.8 0.26
     Yes 13 14.9 78 20.2
Peritoneal Cytology
    Negative 59 84.3 272 91.9 0.01
    Positive 11 15.7 18 8.1
Para-aortic and/or Pelvic lymph nodes
    Negative 41 93.2 154 100 0.01
    Positive 3 6.8 0 0.0
Cervical involvement (glands and/or stroma)
    No 84 95.5 384 99.2 0.03
    Yes 4 4.5 3 0.8
Lymphovascular space invasion 
     Negative 81 92.0 380 98.2 <0.01
     Positive 7 8.0 7 1.8
Myometrial invasion
     <50% 68 77.3 359 92.5 <0.01
     >50% 20 22.7 28 7.5
Median diameter of tumor (mm) 28.0 1.0-90.0 24.0 1.0-110.0 0.06
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Survival analysis
In a Cox proportional hazard model clinicopathologic variables including pre-existing 
endometrium were analyzed for their association with progression free survival. In 
univariable analyses age, BMI, FIGO stage, malignant cells in peritoneal cytology, lymph 
node metastases, lymphovascular space invasion, myometrial invasion, and atrophic 
endometrium were significantly associated with PFS (Table 4). No associations were found 
between PFS and cervical involvement, and diameter of the tumor. In multivariable analyses 
Table 4: Crude hazard ratios (HR) of progression free survival (PFS) by clinicopathologic variables 
using univariable Cox regression.
Variable N HR 95%CI
Age at diagnosis in years 508 1.07 (1.03-1.11)
BMI* in kg/m2 489 0.94 (0.88-0.99)
FIGO (2009)
     Stage I 508 1.00 reference
     Stage II,III, IV 14 10.98 (3.19-37.77)
Peritoneal Cytology
    Negative 369 1.00 reference
    Positive 31 5.14 (1.95-13.55)
Para-aortic and/or Pelvic lymph nodes
    Negative 220 1.00 reference
    Positive 5 21.38 (4.51-101.43)
Cervical involvement (glands and/or stroma)
    No 513 1.00 reference
    Yes 10 3.00 (0.40-22.54)
Lymphovascular space invasion
     Negative 507 1.00 reference
     Positive 16 5.39 (1.24-23.46)
Myometrial invasion
     <50% 459 1.00 reference
     >50% 63 5.13 (2.12-12.41)
Diameter of tumor (mm) 394 1.01 0.98-1.03
Background endometrium
     Atrophic 86 5.37 (2.07-13.91)
     Hyperplastic 385 1.00 reference
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only older age, advanced FIGO stage, and the presence of atrophic endometrium were 
independent predictors of PFS (Table 5). Furthermore, when comparing pure atrophic 
endometrium with mixed atrophic endometrium no significant difference in PFS was found 
(data shown in Supplemental Digital Content 2).
Table 5: Adjusted hazard ratios (HR) of progression free survival (PFS) by clinicopathologic variables 
using multivariable Cox regression.
Variable N HR 95%CI
Age at diagnosis in years 471 1.06 (1.01-1.12)
FIGO (2009)
     Stage I 461 1.00 Reference
     Stage II,III, IV 10 8.47 (1.73-41.57)
Lymphovascular space invasion
     Negative NS
     Positive
Myometrial invasion
     <50% NS
     >50%
Background endometrium
     Atrophic 86 3.11 (1.11-8.70)
     Hyperplastic 385 1.00 Reference
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Discussion
In this study, the presence of atrophic endometrium in patients with grade 1 endometrioid 
endometrial carcinoma was associated with predictors of poor clinical outcome including high 
FIGO stage, lymphovascular space invasion, and deep myometrial invasion. Furthermore, 
atrophic endometrium was significantly associated with poor progression free survival in 
multivariable analyses. 
The association with deep myometrial invasion and lymphovascular space invasion indicates 
more aggressive behavior of the tumors with atrophic background endometrium. The 
expression of this aggressive behavior can be found in the correlation with high FIGO stage, 
malignant cells in peritoneal cytology, and a poor progression free survival.
Atrophy has been associated with poor survival previously.12 However, in the study by Sivridis 
and colleagues endometrioid endometrial carcinomas with tumor grades 1, 2, and 3 were 
included. The tumor grade is one of the most important predictors of recurrent disease 
in endometrioid endometrial carcinoma patients.20,21 Grade 3 endometrioid endometrial 
carcinomas are a distinct, biologically more aggressive subtype, showing p53 expression 
in 17-57% of the cases.22,23 It has been suggested that grade 3 endometrioid endometrial 
carcinoma is a type II endometrial cancer; furthermore, the diagnosis of serous carcinoma 
versus grade 3 endometrioid endometrial carcinoma is subject to a great deal of variability 
among pathologists. In addition, grade 3 endometrioid endometrial carcinomas are more 
often seen in a background of atrophic endometrium, whereas grade 1 endometrioid 
endometrial carcinomas more often have a background of hyperplastic endometrium.7,24 
Therefore, the difference in survival found by Sivridis and colleagues could be partly 
confounded by the inclusion of grade 3 tumors. In the current study, atrophic endometrium 
remained a significant predictor of poor PFS with multivariable analyses in a group limited 
to grade 1 endometrioid endometrial carcinoma patients. 
The dualistic model for oncogenesis in endometrial cancer patients is not applicable for 
about 20% of individual cases who present with advanced disease, or recur despite 
the absence of risk factors. These cases with less favorable clinical outcomes may be 
represented by the cohort we describe here, namely patients with grade 1 endometrioid 
endometrial carcinoma and an atrophic background endometrium. In our study 17% of the 
patients had atrophic endometrium, a similar proportion of patients who do not fit into the 
A new type endometrial carcinoma: endometrioid histology with atrophic endometrium and poor prognosis
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dualistic model.9,11,12 These grade 1 endometrioid endometrial carcinomas may not follow 
the progression model for type I tumors with unopposed estrogenic stimulation resulting 
in hyperplasia followed by transition to endometrioid carcinoma.6,15,25 The fact that we find 
grade 1 endometrioid endometrial carcinomas in atrophic endometrium, the correlation 
of atrophic endometrium with predictors of poor clinical outcome, and the correlation of 
atrophy with poor PFS indicate that carcinogenesis in these cases may occur through distinct 
mechanisms. 
Many molecular markers have been identified to emphasize the difference between type I and 
type II endometrial cancer. Type I tumors are characterized by estrogen- and progesterone 
receptor expression, Micro Satellite Instability (MSI), PTEN alterations, and mutations of 
KRAS and CTNNB1, whereas the majority of type II carcinomas have p53 mutations and 
her-2/neu amplifications.8,10 The considerable number of molecular changes identified in 
type I endometrial carcinomas make it less likely that one pathway will fit all individual 
cases. Future endometrial cancer research should compare the immunohistochemical 
and molecular appearance of endometrial cancer patients with atrophic and hyperplastic 
background endometrium.  
The majority of postmenopausal women have atrophic endometrium.26 However, while 
hyperplastic endometrium is generally a result of diffuse estrogenic stimulation of the entire 
endometrium, focal proliferation and hyperplasia have been described.15 Furthermore, 
weakly proliferative endometrium has been reported in disease free postmenopausal 
women in half of the cases in one study.27 These results are comparable with the results found 
in our study; 50% of the carcinoma patients with atrophic endometrium show proliferation 
to some extent in the endometrium. The arbitrarily chosen cut off point of more than 50% 
atrophic endometrium was used to categorize the background endometrium showing these 
ambiguous features of atrophy with focal proliferation. When comparing patients with 
mixed atrophic background endometrium versus patients with pure atrophic background 
endometrium, few differences in clinical and pathologic characteristics were found, and no 
difference in PFS was found, indicating that both groups are comparable. 
Proliferative endometrium is present in premenopausal women in the proliferative 
phase of the menstrual cycle. Proliferative endometrium is stimulated by estrogens, but 
it is not caused by unopposed estrogen excess.17 This condition is comparable neither to 
the non-stimulated atrophic endometrium, nor to unopposed stimulated, hyperplastic 
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endometrium.6 Therefore, patients with proliferative premenopausal endometrium were 
excluded from analyses. 
This is a multicentre study including a large number of patients. Although it is retrospective 
with the inherent limitations of selection-bias and missing data, we were able to collect 
complete clinical data in the vast majority of the patients. All histologic slides were reviewed 
by three pathologists separately in the relating hospitals where the patients were treated. 
Criteria for the diagnosis of atrophy, hyperplasia, or disordered proliferative endometrium 
were set clearly before the start of the study, and were followed systematically by all 
pathologists. 
In conclusion, we found atrophic background endometrium to be an independent prognostic 
factor in this large series of grade 1 endometrioid endometrial carcinoma patients. 
Endometrioid endometrial carcinoma with a background of atrophic endometrium may not 
follow the progression model for type I tumors, which normally arise in a background of 
hyperplasia. The nature of the background endometrium should be mentioned in every 
pathology report since it provides important prognostic information. Future research should 
investigate possible differences in carcinogenic pathways in these patients with atrophy and 
endometrioid endometrial carcinoma. 
Figure 2: Kaplan-Meier survival analysis showing differences in progression-free survival in patients 
with atrophic and hyperplastic background endometrium.
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Supplemental Digital Content 1: Clinical and pathologic characteristics in patients with pure atrophic 
background endometrium compared with patients with mixed atrophic background endometrium.
Pure atrophy 
(N=44)
Mixed atrophy 
(N=44)
P-value 
N (%) N (%)
Median age in years (range) 69 (40-85) 70 (48-89) 0.37
Median BMI in kg/m2 (range) 30.9 (20.0-55.0) 31.0 (20.0-66.0) 0.87
Hypertension
     No 20 46.5 17 38.6 0.46
     Yes 23 53.5 27 61.4
Diabetes Mellitus
     No 34 79.1 40 90.9 0.14
     Yes 9 20.9 4 9.1
FIGO (2009)
     Stage I 41 93.2 41 93.2 1.00
     Stage II,III, IV 3 6.8 3 6.8
Peritoneal Cytology
    Negative 32 88.9 27 45.8 0.34
    Positive 4 11.1 7 63.6
Para-aortic and/or Pelvic lymph nodes
    Negative 19 95.0 22 53.7 1.00
    Positive 1 5.0 2 66.7
Cervical involvement (glands and/or stroma)
    No 40 90.9 44 52.4 0.17
    Yes 4 9.1 0 0.0
LVSI 
     Negative 43 93.2 40 90.9 1.00
     Positive 1 6.8 4 9.1
Myometrial invasion
     <50% 30 68.2 38 86.4 0.04
     >50% 14 31.8 6 13.6
Diameter of tumor (mm) 34.5 (11.0-85.0)  25.0 (1.0-90.0) 0.15
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Supplemental Digital Content 2: Crude hazard ratios (HR) of progression free survival (PFS) by mixed 
atrophy vs. pure atrophy using univariable Cox regression.
Variable N HR 95%CI
Background  endometrium
     Mixed atrophy 43 1.00 reference
     Pure atrophy 43 0.88 0.24-3.30
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Abstract
Objective: Endometrial carcinoma is divided into type I endometrioid endometrial 
carcinoma (EEC), the majority of which arises from hyperplastic endometrium, and type II 
nonendometrioid endometrial carcinoma (mainly serous histology), the majority of which 
arises from atrophic endometrium. However, a minority (20%) of EECs are found to have an 
atrophic background endometrium, which was found to be a marker of a worse prognosis. 
The aim of the present study was to compare the immunohistochemical and genetic profile 
of this possible third type to that of the known two types.
Methods: 43 patients with grade 1 EEC and hyperplastic background endometrium (type 
I), 43 patients with grade 1 EEC and atrophic background endometrium (type III) and 21 
patients with serous carcinoma (type II) were included (N=107). Tissue microarrays of tumor 
samples were immunohistochemically stained for PTEN, L1CAM, ER, PR, p53, MLH1, PMS2, 
β-catenin, E-cadherin, and MIB1. The BRAF, KRAS, and PIK3CA genes were analyzed for 
mutations.
Results: A significantly higher expression of ER and PR, and lower expression of L1CAM, 
p53, and MLH1 in type I and III compared to type II carcinomas was seen. Expression of 
E-cadherin was significantly lower in type III compared to type I carcinomas. Mutation 
analysis showed significantly less mutations of the KRAS gene in type III compared to type I 
and II carcinomas (P<0.01).
Conclusion: There appears to be only slight immunohistochemical and genetic differences 
between EEC with hyperplastic and with atrophic background endometrium. Carcinogenesis 
of EEC in atrophic endometrium is to be characterized by loss of E-cadherin and a lack of KRAS 
mutations. As expected, there were many significant differences in immunohistoschemical 
expression profiles between endometrioid and serous carcinomas.
Immunohistochemical and genetic profile of endometrioid endometrial carcinoma arising from atrophic endometrium
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Introduction
Cancer of the uterine corpus is the most common gynecologic malignancy among women 
in the developed world. In 2012, it affected 47,130 women and caused the death of 8,010 
women in the US.1 
It is generally accepted that endometrial carcinoma (EC) can be divided into two subtypes.2 
Type I endometrial carcinoma is the most common subtype. It affects women at a median 
age of 60 years, and has a good prognosis. These tumors usually are related to unopposed 
estrogen stimulation, and show endometrioid histology, arising from hyperplastic 
endometrium. In contrast, the less common type II carcinomas affect older women, and 
have a poor prognosis. These tumors are not related to unopposed estrogen stimulation, 
and are characterized by clear cell or serous histology, arising from atrophic endometrium.3-5 
Distinct carcinogenic pathways have been described in each subtype. Type I carcinomas are 
characterized by microsatellite instability and alterations of the PTEN, KRAS, PIK3CA, and 
CTNNB1 genes, whereas type II carcinomas are often aneuploid and show over expression 
of p53 and Her2/neu.6-9 
However, some tumors do not fit within this dualistic model. In a recent study we reviewed 
slides from 527 patients with grade 1 endometrioid endometrial carcinomas, and found 
that 17% of these carcinomas had atrophic background endometrium.10 Furthermore, the 
presence of atrophic background endometrium adjacent to EEC was associated with several 
predictors of poor survival, and an independent predictor of reduced progression free 
survival in endometrioid endometrial carcinomas.
The aim of the present study was to analyze the hypothesis that endometrioid endometrial 
carcinoma with a background of atrophic endometrium arises through different carcinogenic 
pathways than type I and II endometrial carcinomas. Therefore, the expression patterns 
of several immunohistochemical markers and the presence of distinct genetic mutations 
in endometrioid endometrial carcinoma with a background of atrophic endometrium was 
compared to that of type I and II carcinomas. 
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Materials and methods
Patients
For this study, patients with endometrial carcinoma from two cohorts, at least treated with a 
hysterectomy and bilateral salpingo-oophorectomy and who did not have a personal history 
of malignancy, were evaluated for inclusion. The first cohort is comprised of patients treated 
for grade 1 endometrioid endometrial carcinoma at the Radboud University Nijmegen, 
Medical Center  and the Canisius-Wilhelmina Hospital in Nijmegen, The Netherlands, 
between January 1999 and December 2009, and at the Mayo Clinic in Rochester, Minnesota, 
USA, between January 2002 and December 2008.10 The second cohort is comprised of 
patients with uterine serous carcinoma treated at the Radboud University Nijmegen, 
Medical Center and the Canisius-Wilhelmina Hospital, Nijmegen between January 1999 and 
December 2009.11,12
Slides of the primary carcinoma and background endometrium from the cohort of patients 
with grade 1 endometrioid endometrial carcinoma were reviewed with special attention to 
the nature of the background endometrium by experienced pathologists (JB, SB, DV), who 
were unaware of the original pathology results and clinical outcome. In case of doubt or 
discrepancy with the original pathology report, a second review was performed by another 
pathologist and consensus was reached. Background endometrium was categorized as 
simple hyperplasia, simple atypical hyperplasia, complex hyperplasia, complex atypical 
hyperplasia, disordered proliferative, atrophic, and normal proliferative. These definitions 
are well described in literature and are summarized in Table 1.5,10,13-15 Some cases had to 
be excluded because the tumor covered the entire cavity of the uterus and there was no 
background endometrium to be evaluated.
All patients with grade I endometrioid endometrial carcinoma and a background of pure 
(100%) atrophic endometrium (abbreviated as type III) as well as a similar amount of 
patients with grade I endometrioid endometrial carcinoma and a background of hyperplastic 
endometrium (type I) were included. Subsequently, all patients from the uterine serous 
carcinoma (type II) cohort of whom there was uterine tissue available were included. This 
cohort consisted of both pure and mixed serous histology. It has been described previously 
that about half of the serous carcinomas have pure serous histology.16 
Immunohistochemical and genetic profile of endometrioid endometrial carcinoma arising from atrophic endometrium
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Tissue microarray and immunohistochemistry
Tissue microarrays were created from the primary carcinoma.17 Two representative areas 
of the carcinoma were selected on hematoxylin and eosin-stained slides. For the type II 
cases, areas with pure serous histology were selected. Two cylinders with a diameter of 2 
mm were punched out of every donor block from the selected areas and mounted into a 
recipient paraffin block using a manual tissue microarrayer (Tissue-Tek, Quick-Ray, Sakura 
Finetek, USA). 
The tissue microarrays were cut in 4 μm slides and immunohistochemically stained. Several 
markers were selected to be stained, based on the difference in their expression in type I 
and type II endometrial carcinoma [6-9, 18, 19]. An overview of the antibodies used in this 
study is shown in Table 2.
Immunohistochemical analysis of PTEN, L1CAM, ER, PR, p53, MLH1, PMS2, β-catenin, 
E-cadherin, and MIB1 expression was performed according to local protocols. These markers 
were chosen because previous literature has shown that their expression is different in 
type I and II EC [8, 9, 19]. In short, formalin fixed paraffin sections were stained with the 
primary antibody following EDTA antigen retrieval, blocking of endogenous background 
with Peroxidase Blocking Reagent and protein blocking using horse serum. Subsequently, 
Table 1. Definitions used in characterizing the background endometrium.
Definition Criteria
Hyperplasia
Gland proliferation, increased gland:stroma ratio of 3:1, a variety of 
abnormal architectural changes
Simple or complex As defined by the WHO and Kurman et al 14
Atypical
Enlarged, rounded, polymorphic nuclei with loss of polarity, prominent 
nucleoli, chromatin clumping, increased nuclear:cytoplasmatic ratio
Atrophic
Shallow endometrium with thin basalis, few tubular glands lined by 
inactive endometrium
Mixed >50% atrophy
Pure 100% atrophy
Disordered proliferative
Some gland proliferation, but no hyperplasia. In postmenopausal 
women
Normal proliferative
Widely spread, sometimes tortuous, tubular glands showing mitotic 
activity and abundant stroma. In premenopausal women
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a secondary antibody was added and visualization was performed with Vectastain and 
3,3’-Diaminobenzidine (Zymed lab. California, USA) as substrate. Staining was enhanced 
in CuSO
4
 and slides were counterstained with Mayer’s haematoxylin. Finally, slides were 
dehydrated and mounted. 
Tumor samples were given a score ranging from 0-9 by two independent evaluators (YG, AT), 
which was the product of the percentage of cells stained (0%=0; 1-10%=1; 11-50%=2; 51-
100%=3) and intensity of staining (none=0; weak=1; moderate=2; strong=3).20 The evaluators 
were unaware whether the tissue cylinders were from type I, type II or type III carcinomas. 
Samples with too little tissue to assess or samples not containing any malignant tissue were 
not included in the calculations. In case of a large discrepancy between the score of the 
two evaluators (i.e. a difference in percentage or intensity score >2 or disagreement on the 
presence of malignant tissue) a third independent reviewer (JB), who was unaware of the 
score given by the first evaluators, scored the sample as well. 
The final score per case (range 0-9) was calculated by adding all scores given to the two tissue 
samples and dividing them by the number of scores in the sum (which varied depending on 
the presence of tumor tissue in the sample and the need for a third review). 
Table 2: Antibodies used in this study.
 Antibody Company
PTEN inactivation 6H2.1 Dako*
L1CAM UJ127 Thermo Scientific†
ER expression SP1 Thermo Scientific
PR expression PgR 636 Dako
P53 mutations DO-7 Thermo Scientific
Loss of MLH1 G168-15 BD‡
Loss of PMS2 A16-4 BD
β-catenin alteration 14/Beta-Catenin BD
E-cadherin alteration SPM471 Thermo Scientific
High proliferation rate MIB1 Thermo Scientific
*Dako , Glostrup, Denmark; † Thermo Fisher Scientific Inc., Waltham, Massachusetts, US; ‡ Becton, Dickinson and 
Company, Franklin Lakes, New Jersey, US
Immunohistochemical and genetic profile of endometrioid endometrial carcinoma arising from atrophic endometrium
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Mutation analysis
Slides with at least 10% representative tumor tissue were selected for DNA isolation. For the 
cases from the Mayo Clinic, the two TMA tumor biopsies were used instead. DNA was isolated 
with TET-lysis buffer (10 mmol/L Tris-HCl, pH 8.5; 1 mmol/L EDTA, pH 8; 0.1% Tween-20) 
containing 5% Chelex-100 (Bio-Rad, Hercules, CA). Protein digestion was performed by 
adding proteinase K to each sample and incubation at 56°C for 48 hours. Next, Protein K 
was inactivated at 95°C for ten minutes. The samples were centrifuged for ten minutes at 
14.000 rpm (RT) and the DNA concentration of the supernatant was measured using the 
Quant-it picogreen dsDNA assay kit (Invitrogen, Carlsbad, California, U.S.) before storage 
at 4°C. For the detection of mutations, DNA was amplified for exons of the KRAS, BRAF and 
PIK3CA genes using earlier published PCR primers.21 The amplified exons were assessed for 
mutations at 22 nucleotide positions by single nucleotide probe extension assays using a 
SNaPshot Multiplex kit (Applied Biosystems, Foster City, CA) as described previously.21,22
Statistical analysis
Differences between the three subtypes of endometrial carcinoma in marker scores were 
calculated using the Mann-Whitney-U test. The differences between the subtypes of 
endometrial carcinoma in the amount of cases with genetic mutations were calculated using 
the Chi square test and the Fisher‘s exact test. P-values <0.05 were considered significant. 
IBM SPSS 20.0 statistical software was used for analysis of the data.
Results
Patients
Of the 527 patients with grade 1 endometrioid endometrial carcinoma, background 
endometrium was hyperplastic in 387 (73%) and atrophic in 88 (17%). The background 
endometrium was normal premenopausal, proliferative in 27 (5%) patients and could not 
be assessed due to the size of the tumor in 25 (5%) patients. Pure atrophy was found in 43 
(48.9%) of the 88 patients with atrophic background endometrium. Out of the 387 patients 
with hyperplastic background endometrium, 43 (11.1%) were randomly selected as controls. 
From the cohort of patients with uterine serous carcinoma, all patient data as well as tissue 
was present in 21 cases (out of 47 meeting the inclusion criteria), 14 (66.7%) of which had 
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pure serous histology, which is slightly higher than in the general population of patients with 
uterine serous carcinoma.16 In total, 107 cases were included for immunohistochemical and 
mutation analysis. Patient and tumor characteristics per type are shown in Table 3.
Immunohistochemistry
After initial evaluation of 2140 tissue samples, additional review because of discrepancy 
between the evaluator’s scores was necessary for 107 samples (44 type I, 19 type II and 
44 type III). This was not significantly more or less for one of the markers. Three type III 
cases were excluded from calculations because both tumor samples contained too little 
representative tissue or because they did not contain malignant tissue (one ER case, one 
MLH1 case, and one MIB1 case). The final marker scores per type of endometrial carcinoma 
and the differences between the scores are shown in Figure 1.
When looking at the differences between the subtypes it can be seen that in both type I and 
III EC expression of ER and PR was significantly higher than in type II EC, while expression 
of L1CAM, p53 and MLH1 was significantly lower in type I and III EC than in type II EC. 
Expression of E-cadherin was significantly lower in type III EC compared to type I and II EC. 
An overview of the markers with significant differences in expression is shown in Figure 2.
Mutation analysis
A representative part of the tumor could be retrieved for every case and DNA yield was 
adequate for every sample when assessed by spectral photometry. Mutation analysis of 
the PIK3CA gene was successful in all cases, of the BRAF gene in all but one type I case, and 
the KRAS gene in all but two type I, one type II, and two type III cases. The distribution of 
wild type and mutated genes per type as well as the differences between types is shown in 
Table 4. The only significant difference was found with the KRAS gene, which was mutated in 
37.2% of the type I and 23.8% of the type II carcinomas, compared to only 2.3% of the type 
III carcinomas. The BRAF gene was not mutated in any of the cases, while the PIK3CA was 
mutated more often in type II EC (23.8%) than in type I (14%) and III (11.6%) EC, but these 
differences were not significant.
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Table 3: Patient and tumor characteristics.
 
Type I
N (SD/%)
Type II
N (SD/%)
Type III 
N (SD/%)
Age (years) 62 (SD10.3) 70 (SD9.6) 68 (SD10.1)
BMI (kg/m2) 33 (SD8.1) 31 (SD7.4) 31 (SD7.4)
Hypertension    
Yes 20 (46.5) 7 (33.3) 23 (53.5)
No 22 (51.2) 13 (61.9) 19 (44.2)
Unknown 1 (2.3) 1 (4.8) 1 (2.3)
Diabetes    
Yes 10 (23.3) 3 (14.3) 9 (20.9)
No 32 (74.4) 17 (81) 33 (76.7)
Unknown 1 (2.3) 1 (4.8) 1 (2.3)
Surgical approach    
Minimally invasive 6 (14) - 6 (14)
Laparotomy 16 (37.2) 21 (100) 16 (37.2)
Unknown 21 (48.8) - 21 (48.8)
Lymphadenectomy    
Negative 10 (23.3) 10 (47.6) 19 (44.2)
Positive - 5 (23.8) 1 (2.3)
Not sampled 33 (76.7) 6 (28.6) 23 (53.5)
Cervical involvement    
Endocervical 2 (4.7) 2 (9.5) 2 (4.7)
Stromal - 9 (42.9) 2 (4.7)
No 41 (95.3) 10 (47.6) 39 (90.7)
LVSI*    
Yes 2 (4.7) 12 (57.1) 3 (7)
No 41 (95.3) 9 (42.9) 40 (93)
Myometrial invasion    
<50% 41 (95.3) 8 (38.1) 30 (69.8)
≥50% 2 (4.7) 13 (61.9) 13 (30.2)
FIGO stage    
IA 38 (88.4) 4 (19) 28 (65.1)
IB 4 (9.3) 2 (9.5) 9 (20.9)
II - 3 (14.3) 2 (4.7)
III 1 (2.3) 5 (23.8) 4 (9.3)
IV - 7 (33.3) -
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Figure 1: Boxplots showing the different marker scores per type of endometrial carcinoma. 
P-values were calculated using the Mann-Whitney Test.
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Figure 2: Overview of markers with a significant difference in expression between the subtypes of 
endometrial carcinoma. 
Shown are examples of L1CAM (A), ER (B), PR (C), p53 (D) and MLH1 (E) expression in type I (left) and type II 
(right) endometrial carcinoma as well as examples of E-cadherin (F) expression in type I (left) and type III (right) 
endometrial carcinoma.
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Discussion
In this study we have analyzed the immunohistochemical and genetic profiles of 
endometrioid endometrial carcinoma with a background of hyperplastic (type I) or atrophic 
(type III) endometrium, which were quite comparable. However, endometrioid carcinomas 
with atrophic background endometrium showed less expression of E-cadherin and fewer 
mutations in KRAS compared to endometrioid carcinomas with hyperplastic background 
endometrium. As expected, when comparing carcinomas with endometrioid histology to 
those with serous histology (type II), they had a different immunohistochemical profile.
The immunohistochemical differences between type I and II endometrial carcinoma in 
this study are in line with previous literature.8,9,19 As expected, ER and PR expression were 
significantly higher in type I carcinomas, while L1CAM, p53 and MLH1 were significantly 
higher in type II carcinomas. Moreover, while the differences in PMS2, E-cadherin, β-catenin 
and MIB1 expression were not significant, the observed trends were according to the 
findings in previous literature on these markers. Interestingly, only the results of PTEN 
Table 4: Results of the mutation analysis per type of endometrial carcinoma.
 
Type I
N (%)
Type II
N (%)
Type III
N (%)
P (I-II)* P (I-III)* P (II-III)*
BRAF    
 
- 
 
 
 -
 
 
 -
 
Wild type 42 (97.7) 21 (100) 43 (100)
Mutated - - -
Unknown 1 (2.3) - -
KRAS    
 
0.58 
 
 
 <0.01
 
 
<0.01 
 
Wild type 26 (60.5) 14 (66.7) 40 (93)
Mutated 15 (34.9) 6 (28.6) 1 (2.3)
Unknown 2 (4.7) 1 (4.8) 2 (4.7)
PIK3CA    
0.48 1.00
 
 0.28
 
Wild type 37 (86) 16 (76.2) 38 (88.4)
Mutated 6 (14) 5 (23.8) 5 (11.6)
Unknown - - -
*P-value for the Fisher’s exact test
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expression were not in line with previous literature, as it was surprisingly found to be lowest 
in serous carcinomas, while a loss of PTEN is expected in endometrioid carcinomas.
There were no BRAF gene mutations, regardless of the subtype, which is in line with the 
low BRAF mutation rate previously described in endometrial carcinoma.23 PIK3CA mutations 
have been extensively shown to be present in both endometrioid and non-endometrioid 
endometrial carcinomas and have been associated with invasive growth and poor 
prognosis.24-27 Indeed, in our study we found the PIK3CA mutation rate to be highest in type 
II carcinomas.
Mutations of the KRAS proto-oncogene have been described in up to 30% of endometrioid 
endometrial carcinomas, but in only up to 10% in type II carcinomas.9 These mutations 
have been found to be an early event in the carcinogenesis of endometrioid endometrial 
carcinomas, present in an equal amount of endometrial hyperplasias and carcinomas.28 We 
found a slightly higher amount of mutations in type I carcinomas than previously reported, 
but the discrepancy between previously published results and the amount of mutations 
we observed in type II carcinomas was much larger. As a representative sample of type II 
cases was included in this study, several of them had a minor component with non-serous 
histology.16 Three of the six type II cases with mutations in the KRAS gene had a minor 
endometrioid component and the KRAS mutations might not have been present in the areas 
with serous histology, but in those with endometrioid histology.28
It was hypothesized that type III carcinomas would have a distinct immunohistochemical 
and genetic pattern when compared to type II carcinomas, and most interestingly, when 
compared to type I carcinomas. However, for most immunohistochemical markers, there 
was no difference in expression between type I and III carcinomas. Only the expression of 
E-cadherin was significantly lower in type III compared to type I carcinomas. Furthermore, 
the amount of mutations in the KRAS gene was significantly lower in type III compared to 
type I and II carcinomas.
In epithelial cells, E-cadherin is the major molecule of the cadherin family, which is essential 
for tight cell-cell connections.29 Loss of E-cadherin by methylation of the E-cadherin gene has 
been described in grade 3 endometrioid as well as in non-endometrioid carcinomas, but not 
in hyperplastic endometrium. Loss of E-cadherin was correlated with depth of myometrial 
invasion and advanced stage of disease.30,31 Type III carcinomas had a significantly reduced 
expression of E-cadherin compared to type I carcinomas and the expression even tended to 
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be lower than in type II carcinomas. This might explain a more aggressive behavior of type 
III carcinomas when compared to type I carcinomas.
KRAS mutations are described to be an early event in the carcinogenesis of endometrioid 
endometrial carcinoma and they were shown to be present in all endometrial hyperplasia 
or in atypical hyperplasia only.28,32 These findings support the lack of KRAS mutations in 
endometrioid carcinomas arising from atrophic endometrium. In addition, Guerrero et al. 
have described up regulation of E-cadherin expression by KRAS mutations.33 Subsequently, 
Singh et al. described that Zeb1, a transcription factor repressing E-cadherin expression, is 
expressed specifically in tumor cell lines that grow independent of KRAS.34 These studies 
support our findings of a combination of few KRAS mutations and loss of E-cadherin in type 
III carcinomas. It is unclear whether loss of E-cadherin is an early event of carcinogenesis 
of type III carcinomas, or secondary to the fact that carcinogenesis of these carcinomas is 
less characterized by KRAS mutations. However, it is likely that loss of E-cadherin is (partly) 
responsible for previous findings that type III carcinomas are associated with adverse 
pathologic findings and an adverse outcome.10 
This study is the first to analyze the immunohistochemical and genetic profile of 
endometrioid endometrial carcinomas with atrophic background endometrium. A large 
set of immunohistochemical markers and genes was analyzed to give a clear view of the 
similarities and differences between the different endometrial tumor types. A weakness 
may be the fact that DNA was extracted for mutation analysis from whole slides instead of 
selected tumor tissue. However, while this might be responsible for the high mutation rate 
we found in type II carcinomas, it does not interfere with answering the question whether 
there is a difference between type I and III carcinomas. If anything, it highlights more clearly 
that very few KRAS mutations are found in type III carcinomas as well as in the surrounding 
tissue.
In conclusion, on an immunohistochemical and genetic level, endometrioid carcinomas 
arising from atrophic background endometrium were shown to be quite comparable to 
endometrioid carcinomas arising from hyperplastic background endometrium. However, 
while KRAS mutations are an early event in carcinogenesis of endometrioid endometrial 
carcinoma in hyperplastic endometrium, such mutations were rare in endometrioid 
carcinomas with atrophic background endometrium. Carcinogenesis of these carcinomas 
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seems to be characterized by early loss of E-cadherin, which was previously associated with 
a worse prognosis.
116
Chapter 6
References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecologic oncology. 
1983;15(1):10-7.
3. Liu FS. Molecular carcinogenesis of endometrial cancer. Taiwanese journal of obstetrics & 
gynecology. 2007;46(1):26-32.
4. Ellenson HL, Ronnett BM, Kurman RJ. Precursor lesions of endometrial carcinoma. In: Kurman RJ, 
Ellenson HL, Ronnett BM, editors. Blaustein’s Pathology of the Female Genital Tract. Sixth ed. New 
York: Springer; 2011. p. 359-91.
5. Ellenson HL, Ronnett BM, Soslow RA, Zaino RJ, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, 
Ronnett BM, Ellenson HL, editors. Blaustein’s Pathology of the Female Genital Tract. Sixth ed. New 
York: Springer; 2011. p. 393-452.
6. Ellis PE, Ghaem-Maghami S. Molecular characteristics and risk factors in endometrial cancer: 
what are the treatment and preventative strategies? International journal of gynecological cancer 
: official journal of the International Gynecological Cancer Society. 2010;20(7):1207-16.
7. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS. 
2009;117(10):693-707.
8. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 
2013;62(1):111-23.
9. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a 
phenotypical to a molecular-based classification. Virchows Archiv : an international journal of 
pathology. 2004;444(3):213-23.
10. Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Bulten J, Visscher DW, Dowdy SC, et al. 
Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis. Obstetrics 
and gynecology. 2012;120(5):1124-31.
11. Roelofsen T, Geels YP, Pijnenborg JM, van Ham MA, Zomer SF, van Tilburg JM, et al. Cervical 
Cytology in Serous and Endometrioid Endometrial Cancer. International journal of gynecological 
pathology : official journal of the International Society of Gynecological Pathologists. 2013.
12. Roelofsen T, van Ham MA, Wiersma van Tilburg JM, Zomer SF, Bol M, Massuger LF, et al. Pure 
compared with mixed serous endometrial carcinoma: two different entities? Obstetrics and 
gynecology. 2012;120(6):1371-81.
13. Mills AM, Lonacre TA. Endometrial hyperplasia. Seminars in Diagnostic Pathology. 2010;27:199-
214.
14. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 
“untreated” hyperplasia in 170 patients. Cancer. 1985;56(2):403-12.
15. McCluggage WG. Benign Diseases of the Endometrium. In: Kurman RJ, Ellenson LH, Ronnett BM, 
editors. Blaustein’s Pathology of the Female Genital Tract. 6th ed: Springer; 2011. p. 305-58.
16. Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O’Malley DM, et al. An updated 
clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecologic 
oncology. 2009;115(2):244-8.
Immunohistochemical and genetic profile of endometrioid endometrial carcinoma arising from atrophic endometrium
117
6
17. Arafa M, Boniver J, Delvenne P. Progression model tissue microarray (TMA) for the study of 
uterine carcinomas. Disease markers. 2010;28(5):267-72.
18. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and 
related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and 
malignant endometrium. Human pathology. 1998;29(10):1150-9.
19. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, et al. Up-regulation of L1CAM 
is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial 
carcinomas. The Journal of pathology. 2010;220(5):551-61.
20. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, et al. Immunohistochemical detection 
of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The 
Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the 
EORTC. Journal of clinical pathology. 2000;53(8):634-5.
21. Lurkin I, Stoehr R, Hurst CD, van Tilborg AA, Knowles MA, Hartmann A, et al. Two multiplex assays 
that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA 
genes. PloS one. 2010;5(1):e8802.
22. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, 
HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for 
surveillance and therapy. PloS one. 2010;5(11):e13821.
23. Moreno-Bueno G, Sanchez-Estevez C, Palacios J, Hardisson D, Shiozawa T. Low frequency of BRAF 
mutations in endometrial and in cervical carcinomas. Clin Cancer Res. 2006;12(12):3865; author 
reply -6.
24. Catasus L, D’Angelo E, Pons C, Espinosa I, Prat J. Expression profiling of 22 genes involved in the 
PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different 
molecular alterations. Modern pathology : an official journal of the United States and Canadian 
Academy of Pathology, Inc. 2010;23(5):694-702.
25. Catasus L, Gallardo A, Cuatrecasas M, Prat J. PIK3CA mutations in the kinase domain (exon 20) 
of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. 
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, 
Inc. 2008;21(2):131-9.
26. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, et al. PIK3CA and PTEN 
mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res. 
2006;12(20 Pt 1):5932-5.
27. Kuhn E, Wu R-C, Guan B, Wu G, Zhang J, Wang Y, et al. Identification of molecular pathway 
aberrations in uterine serous carcinoma by genome-wide analyses. Journal of the National Cancer 
Institute. 2012;104(19):1503-13.
28. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, et al. Mutation of the Ki-ras 
protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 1993;53(8):1906-
10.
29. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 
1991;251(5000):1451-5.
118
Chapter 6
30. Saito T, Nishimura M, Yamasaki H, Kudo R. Hypermethylation in promoter region of E-cadherin 
gene is associated with tumor dedifferention and myometrial invasion in endometrial carcinoma. 
Cancer. 2003;97(4):1002-9.
31. Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J, et al. Abnormalities of E- and 
P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer 
and endometrial atypical hyperplasia. The Journal of pathology. 2003;199(4):471-8.
32. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, et al. K-ras activation in 
premalignant and malignant epithelial lesions of the human uterus. Cancer Res. 1991;51(19):5308-
14.
33. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces 
higher level of resistance to apoptosis and predisposition to anchorage-independent growth than 
codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60(23):6750-6.
34. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression 
signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. 
Cancer cell. 2009;15(6):489-500.
119
CHAPTER 7
COMPARISON OF A PANEL OF IMMUNOHISTOCHEMICAL 
MARKERS IN ENDOMETRIOID ENDOMETRIAL CARCINOMA 
WITH AND WITHOUT METASTATIC DISEASE
Y.P. Geels1, A.A.G. van Tilborg1,2, B.E.C. Nienhaus1, S.H. van den Berg- van Erp3, 
M.P.L.M. Snijders4, L.F.A.G. Massuger1, A. van der Wurff5, J. Bulten2, J.M.A. Pijnenborg6
1 Department of Obstetrics and Gynecology, Radboud University Nijmegen, Medical Centre 
2 Department of Pathology, Radboud University Nijmegen, Medical Centre 
3 Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen 
4 Department of Obstetrics and Gynecology, Canisius-Wilhelmina Hospital, Nijmegen
5 Department of Pathology, St. Elisabeth Hospital, Tilburg
6 Department of Obstetrics and Gynecology, TweeSteden Hospital, Tilburg
The Netherlands 
Submitted
120
Chapter 7
Abstract
Introduction: The aim of this study was to analyze differences in immunohistochemical 
expression patterns in endometrioid endometrial carcinomas (EECs) with and without 
metastases. Second, the aim was to look for potential differences in immunohistochemical 
profile between the primary and the metastatic tumor. 
Methods: All patients with FIGO stage III or IV EEC treated in four hospitals in the south of 
the Netherlands between 1999 and 2010 were selected as cases. A control group treated 
for FIGO stage I disease in two of these four hospitals was matched on tumor grade. Tissue 
Micro Arrays (TMAs) were prepared, and slides of the TMAs were stained with p53, p16, 
p21, MIB1, β-catenin, E-cadherin, MLH1, PMS2, ER, PR, L1CAM, and PTEN.
Results: Significant lower ER expression was found in the primary tumor of patients with 
metastases compared to patients without metastases (P=0.04). Significant stronger p16 and 
p21 expression was found when tumor tissue from the metastatic site was compared to the 
primary tumor (P=0.01 and P=0.02 respectively). In addition, when comparing the primary 
tumor tissue of patients with locoregional and distant metastases, the distant metastasizing 
tumors showed significant lower ER and PR expression, and increased MIB1 expression 
(P=0.04, P=0.04, and P<0.01 respectively).
Conclusion: In conclusion, this study gives more insight into the expression patterns of 
immunohistochemical markers related to the metastatic potential of EECs. ER, PR, p16, p21, 
and MIB1 may be involved in the metastatic process of EECs.  
Comparison of a panel of immunohistochemical markers in endometrioid endometrial carcinoma with and without metastatic disease
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Introduction
Endometrial carcinoma has become the most common gynecologic cancer in the western 
world today, counting for 1900 newly diagnosed patients annually in the Netherlands.1,2 This 
increasing  incidence can be partly attributed to increasing obesity and life expectancy.3,4 
Endometrial carcinoma can be divided into two subtypes with different clinical and pathologic 
characteristics.5 Type I carcinomas occur around the age of 60, have a good prognosis, and 
are directly related to unopposed estrogen stimulation. The majority of these carcinomas 
arise in a background of hyperplastic endometrium and show endometrioid histology. Type 
II, non-endometrioid carcinomas occur in women around the age of 70, are unrelated to 
estrogen stimulation, arise in atrophic endometrium, and have a relatively poor prognosis.6 
Several molecular pathways are known to be involved in the carcinogenesis of endometrial 
carcinoma. Type I carcinomas show microsatellite instability, and mutations in PTEN, PIK3CA, 
KRAS and CTNNB1 (β-catenin), whereas type II carcinomas reveal alterations in TP53, and 
molecular alterations of STK15, CDKN2A (p16), CDH1 (E-cadherin) and ERBB2 (Her2/neu).7,8
Although the prognosis of endometrioid endometrial carcinoma (EEC) in general is favorable, 
a minority of these carcinomas do metastasize. Little is known about the molecular 
pathways responsible for the process of metastasizing in endometrioid endometrial cancer. 
The role of epithelial to mesenchymal transition and the loss of E-cadherin expression in 
endometrioid endometrial carcinoma have been described recently.9 Furthermore, changed 
expression of ER, PR, Stathmin, and p-mTOR was found in recurrent endometrial carcinoma 
when compared to the primary tumor.10 In addition, differential expression patterns of p21, 
p53, and MIB were associated with poor prognosis in endometrial carcinoma. Changes 
in the MLH1 gene were also found to play a role in the carcinogenesis of non-hereditary 
EECs.8,11,12 L1CAM has been recently reported as an important immunohistochemical marker 
with superior prognostic properties in EEC.13 
The cornerstone of the treatment of endometrial carcinoma is surgery. In the Netherlands, 
adjuvant radiotherapy is advised when two out of three risk factors, age > 60, myometrial 
invasion > 50%, and tumor grade 3, are present.14 The treatment strategy of type I carcinomas 
differs from that of type II carcinomas. To date, in The Netherlands, for type II carcinomas a 
complete surgical staging procedure is advised. In addition, adjuvant chemotherapy may be 
considered. For type I, low grade EEC hysterectomy and bilateral salpingo-oophorectomy is 
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advised. For high grade endometrioid carcinoma a consensus about the optimal treatment 
has not yet been conceived in the Dutch guidelines.2 A more thorough understanding of the 
mechanisms underlying the metastatic potential of EEC may provide routes to individualize 
treatment.
The aim of the present study was, primarily, to analyze potential differences in 
immunohistochemical expression patterns in endometrioid endometrial carcinomas with 
metastases compared to endometrioid endometrial carcinomas limited to the uterus. 
Secondary, the aim was to look for potential changes in immunohistochemical profile of the 
primary tumor and the metastatic site. To this end, a panel of markers known to be altered 
in aggressive endometrial carcinoma was composed. 
Methods
Patient selection and histopathologic review
For this case-control study the Dutch nationwide network and registry of histology and 
cytopathology (Pathologisch Anatomisch Landelijk Geautomatiseerd Archief: PALGA) was 
used to search for all patients diagnosed and surgically treated for FIGO stage III or IV 
endometrioid endometrial carcinoma (EEC) at the Radboud University Nijmegen Medical 
Centre (RUNMC), the Canisius-Wilhelmina Hospital Nijmegen, the TweeSteden Hospital 
Tilburg, and the St. Elisabeth Hospital Tilburg, between January 1999 and January 2010. A 
total of 53 EEC patients with FIGO stage III or IV were identified. 
All histologic slides of the primary carcinoma and the metastatic site were retrieved from the 
pathology archives and reviewed. Review was done systematically including the following 
items: the histologic type and tumor grade of both the primary tumor and the metastasis 
or metastases. Of the primary tumor site, depth of myometrial invasion, presence of 
lymphovascular space invasion, and the nature of the background endometrium were 
reviewed as well.15 Review was performed in every hospital separately by an independent 
experienced pathologist (JB, SB, AW), who was unaware of the results of the original 
pathology reports or the clinical outcome of the patients. There was no systematic review 
between the centers. In case of doubt about the diagnosis, or in case of discrepancy with 
the original pathology report consensus between the three reviewing pathologists was 
achieved. 
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After review, in total 15 cases were excluded for several reasons. Ten patients were 
excluded because of a diagnosis of non-endometrioid histology like serous, clear cell, or 
undifferentiated endometrial carcinoma after review. One patient was excluded because 
the metastatic site was diagnosed as a second primary malignancy after review, and from 
four patients insufficient material was available. Thus, a total of 38 patients comprised our 
EEC case group; tumor grade 1 (N=3), tumor grade 2 (N=16), and  tumor grade 3 (N=19).
Control group selection
Subsequently, a matched control group was collected from a well defined, reviewed database 
with endometrial cancer patients diagnosed in the RUNMC and the Canisius-Wilhelmina 
Hospital from January 1999 until January 2010.16 The control group consisted of clinical FIGO 
stage I EEC patients and was matched on tumor grade. A total of 37 EEC patients comprised 
the control group: tumor grade 1 (N=4), tumor grade 2 (N=17), and tumor grade 3 (N=16).   
Patient characteristics
Clinical data were abstracted from patient records. Age, menopausal state, body mass index 
(BMI), parity, medical history, treatment, stage of disease, date of recurrence of disease, 
date of death, and the cause of death were registered. Stage of disease was based on the 
2009 International Federation of Gynecology and Obstetrics (FIGO) staging system.17 Follow 
up data were extracted from the medical charts. The median time of follow up was 36 
months (range 1-105).  
Tissue microarray and immunohistochemistry (IHC)
Tissue microarrays were created from the primary carcinoma, the corresponding metastatic 
site, and from the carcinomas in the control group. A representative area of the carcinoma 
was selected on hematoxylin and eosin-stained slides. One cylinder with a diameter of 3 
mm was punched out the donor block from the selected area, and mounted into a recipient 
paraffin block using a manual tissue microarray (Tissue-Tek, Quick-Ray, Sakura Finetek, USA). 
The tissue microarrays were cut in 4 μm slides and immunohistochemically stained. Briefly, 
immunohistochemical analysis for p53, p16, p21, MIB1, β-catenin, E-cadherin, MLH1, PMS2, 
ER and PR expression was performed as follows: after EDTA antigen retrieval, sections were 
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stained with the primary antibody using the automated I6000 immunostainer (Biogenics, 
San Ramos, California, USA).  Staining of tissue was visualized using 3,3’-Diaminobenzidine 
(Zymed lab, California, USA) as substrate and counterstained with Mayer’s haematoxylin. 
For PTEN and L1CAM staining formalin fixed paraffin sections were deparaffinized and 
rehydrated. EDTA antigen retrieval was performed and staining was done on a Manual 
Staining Box lined with moist toweling. Endogenous background was blocked using 
Peroxidase Blocking Reagent (3%H2O2 in PBS). A protein blocking step was added using 
horse serum. The slides were incubated with PTEN or L1CAM overnight at 4°C. Subsequently 
a secondary horse anti-mouse antibody was added. Visualization was performed with 
the Vectastain ABC Method (Vector Laboratories, CA, USA) and 3,3’-Diaminobenzidine 
(Zymed lab, California, USA) as substrate. Staining was enhanced in CuSO
4
 and slides were 
counterstained with Mayer’s haematoxylin. Finally, slides were dehydrated and mounted. 
An overview of all antibodies used in this study is shown in Table 1.
Evaluation of staining
Two authors independently evaluated the stained slides semi quantitatively by standard light 
microscopy (YG, HB). They were unaware if the tissue cylinders were primary, metastatic, 
or from the control group. Categories were made for the percentage of stained nuclei: 0 
Table 1: Antibodies used for staining.
Antibody Clone Vendor Retrieval Dilution Staining
β-catenin 14/Beta-
catenin
BD EDTA 10’ 1:100 Membranous, 
cytoplasm
E-cadherin SPM471 Thermo Scientific EDTA 10’ 1:300 Membranous
ER SP1 Thermo Scientific EDTA 10’ 1:80 Nuclear
PR PgR636 DAKO citrate 10’ 1:250 Nuclear
MLH1 G168-15 BD EDTA 10’ 1:50 Nuclear
PMS2 A16-4 BD EDTA 10’ 1:100 Nuclear
L1CAM UJ127 Thermo Scientific EDTA 10’ 1:100 Membranous
MIB MIB-1 DAKO citrate 10’ 1:100 Nuclear
PTEN 6H2.1  DAKO EDTA 10’ 1:100 Nuclear, cytoplasm
P53 DO-7 Thermo Scientific citrate 10’ 1:400 Nuclear
P16 G175-405 BD citrate 10’ 1:20 Nuclear, cytoplasm
P21 CDS-60.2 Neomarkers citrate 10’ 1:75 Nuclear
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(0% of the tumor cells positive), 1 (0-10% of the tumor cells positive), 2 (10-50% of the 
tumor cells positive), and 3 (>50% of the tumor cells positive). The intensity of the staining 
was subdivided in 0 (none), 1 (weak), 2 (moderate), and 3 (strong). A staining index was 
calculated as the product of nuclear staining intensity and staining area (range 0-9).10   
Statistical analysis
Comparison was made between the primary carcinoma of the case group and the primary 
carcinoma of the control group. Differences in clinical and pathologic parameters were 
tested for statistical significance using the Pearson’s Chi-square (χ2) test or the Fisher’s exact 
test, and the Mann-Whitney test. Comparison of the IHC expression was made between the 
primary carcinoma of the case-group and the primary carcinoma of the control group, and 
between the primary carcinoma of the case group and the metastatic site of the case group. 
In addition, a comparison of IHC expression was made between patients with loco-regional 
metastases (direct local invasion and spread through the abdominal cavity) and distant 
metastases (lymphogenous and hematogenous spread). Boxplots were generated to depict 
the differences in IHC expression, and statistical significance was tested using the Mann-
Whitney test. The P-values presented are two-sided, and associations were considered 
significant if the P-value was less than 0.05. Statistical analyses were performed using the 
software package SPSS 20.0 for Microsoft Windows (SPSS Inc).
Results
Clinical and pathologic characteristics
The clinical and pathologic characteristics of all patients are shown in Table 2. A comparison 
of the distribution and presence of clinicopathologic characteristics was made between the 
group with and the group without metastatic disease. Median age, BMI and menopausal 
status were similar between the two groups. Since the group with metastases had advanced 
FIGO stage and the control group had clinical FIGO stage I disease, more patients were 
treated with adjuvant radiotherapy and/or chemotherapy in the group with metastases. 
Also, more patients had deep myometrial invasion, cervical involvement and lymphovascular 
space invasion. In addition, in the metastatic group, more patients died as a consequence 
of the carcinoma. Median follow-up was longer in the group without metastatic disease.
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Table 2: Clinical and pathologic characteristics of all patients (N=75).
Patient group (N=38) Control group (N=37) P-value
Variable N / median % / range N / median % / range
Median age (years) 65.5 49-82 66.0 45-82 0.84
Median Body Mass Index (kg/m2) 28.7 19.4-50.8 28.3 18.7-41.4 0.87
Menopausal state
     Premenopausal
     Postmenopausal
5
33
13.0
87.0
5
32
13.5
86.5
0.96
FIGO stage (2009)
     IA
     IB
     II
     III
     IV
0
0
0
19
19
0
0
0
50.0
50.0
26
11
0
0
0
70.3
29.7
0
0
0
Adjuvant radiotherapy
     No
     Yes, external beam therapy
     Yes, vaginal brachy therapy
     Yes, combination
     Unknown
11
10
0
11
6
28.9
26.3
0
28.9
15.8
22
9
6
0
0
59.5
24.3
16.2
0
0
0.04
Adjuvant chemotherapy
     No
     Yes
     Unknown
31
5
2
81.6
13.2
5.3
37
0
0
100
0
0
0.02
Grade
     1
     2
     3
3
16
19
7.9
42.1
50.0
4
17
16
10.8
45.9
43.2
1.00
Myometrial invasion
     <1/2
     ≥1/2
7
31
18.4
81.6
22
14
61.1
38.9
<0.01
Cervical involvement
     No
     Endocervical
     Stromal
28
7
10
55.3
18.4
26.3
35
2
0
94.6
5.4
0.0
<0.01
Lymphovascular space invasion
     No
     Yes
15
23
39.5
60.5
34
3
91.9
8.1
<0.01
Recurrence
     No
     Yes, local
     Yes, regional
     Yes, distance
     Unknown
14
2
4
14
4
36.8
5.3
10.5
36.8
10.5
37
0
0
0
0
100
0
0
0
0
<0.01
Patient died
     No
     Yes, consequence of disease
     Yes, other cause
26
12
0
68.4
31.6
0
36
0
1
97.3
0
2.7
<0.01
Time of follow up (months) 27 1-105 44 1-79 0.01
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All cases with metastatic disease were FIGO stage III or IV. The localization of the most distant 
metastatic sites of these cases are shown in Table 3. Of the 38 patients with metastatic 
disease, the most distant metastatic site was local in 17 patients (44.7%), the abdominal 
cavity in seven patients (18.4%), lymphogenous in ten patients (26.3%), and hematogenous 
(liver/lung) metastases in four patients (10.6%). One of the four patients with hematogenous 
metastases had proven lymphatic spread of disease as well.
Immunohistochemical expression
Examples of immunohistochemical expression patterns of all antibodies are presented in 
Figure 1. An overview of the numbers of patients with negative or positive staining is given 
in Table 4. The tumor was considered negative with a staining index of 0-1, and the tumor 
was considered positive with a staining index of 2-9.
Differences in immunohistochemical expression between the primary tumor of patients 
with metastatic disease and the primary tumor of patients in the control group are depicted 
in Figure 2. When comparing the group with metastatic disease with the control group, 
apart from a significant loss of ER expression in the group with metastatic disease (P=0.04), 
Table 3: Sites of metastases in the cases with metastatic disease.
Site N Total
Locoregional Ovaries and/or tubes 4
Parametrium 2
Vagina 4
Peritoneum bladder 1
Sigmoid, descendent colon, distal ileum, cecum, appendix 5
Sacro-uterine ligament 1 17 (44.7%) 
Abdominal Omentum 3
Peritoneum of the abdominal cavity 3
Diaphragm 1 7 (18.4%)
Lymphogenous Pelvic 6
Para-aortal lymph nodes 3
Inguinal lymph node 1 10 (26.3%)
 Hematogenous Liver 2
Lung 2 4 (10.5%)
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Figure 1: Examples of positive IHC staining.
β-catenine (A), E-cadherin (B), ER (C), PR (D), MLH1 (E), PMS2 (F), L1CAM (G), MIB1 (H), PTEN (I), p53 (J), p16 (K), 
and p21 (L).
Comparison of a panel of immunohistochemical markers in endometrioid endometrial carcinoma with and without metastatic disease
129
7
Table 4: Comparison between primary tumor of patients with and without metastases, the primary 
tumor and the metastatic site, and locoregional and distant metastases.
Cases 
N (%)
Control 
N (%)
Primary 
N (%)
Metastasis
N (%)
Locoregional
N (%)
Distant
N (%)
Bcat
     Neg*
     Pos
1 (2.6)
37 (97.4)
0 (0.0)
37 (100.0)
1 (2.6)
37 (97.4)
2 (6.3)
30 (93.8)
1 (4.2)
23 (95.8)
0 (0.0)
14 (100.0)
Ecad
     Neg
     Pos
3 (7.9)
35 (92.1)
1 (2.7)
36 (97.3)
3 (7.9)
35 (92.1)
6 (18.8)
26 (81.3)
1 (4.2)
23 (95.8)
2 (14.3)
12 (85.7)
ER
     Neg
     Pos
10 (26.3)
28 (73.7)
2 (5.4)
35 (94.6)
10 (26.3)
28 (73.3)
6 (20.0)
24 (80.0)
3 (12.5)
21 (87.5)
7 (50.0)
7 (50.0)
PR
     Neg
     Pos
13 (34.2)
25 (65.8)
9 (24.3)
28 (75.7)
13 (34.2)
25 (65.8)
18 (54.5)
15 (45.5)
5 (20.8)
19 (79.2)
8 (57.1)
6 (42.9)
MLH1
     Neg
     Pos
11 (28.9)
27 (71.1)
11 (29.7)
26 (70.3)
11 (28.9)
27 (71.1)
6 (18.8)
26 (81.3)
9 (37.5)
15 (62.5)
2 (14.3)
12 (85.7)
PMS2
     Neg
     Pos
11 (28.9)
27 (71.1)
8 (21.6)
29 (78.4)
11 (28.9)
27 (71.1)
8 (25.0)
24 (75.0)
8 (33.3)
16 (67.7)
3 (21.4)
11 (78.6)
L1CAM
     Neg
     Pos  
26 (68.4)
10 (26.3)
29 (78.4)
7 (18.9)
27 (71.1)
11 (28.9)
20 (66.7)
10 (33.3)
17 (70.8)
7 (29.2)
10 (71.4)
4 (28.6)
MIB
     Neg
     Pos
6 (15.8)
32 (84.2)
6 (16.2)
31 (83.8)
6 (15.8)
32 (84.2)
5 (16.1)
26 (83.9)
6 (25)
18 (75)
0 (0.0)
14 (100.0)
PTEN
     Neg
     Pos
21 (55.3)
16 (42.1)
20 (54.1)
17 (45.9)
21 (55.3)
16 (42.1)
10 (33.3)
20 (66.7)
12 (50.0)
12 (50.0)
9 (69.2)
4 (30.8)
P53
     Neg
     Pos
5 (13.2)
33 (86.8)
10 (27.0)
27 (73.0)
5 (13.2)
33 (86.3)
0 (0.0)
32 (100.0)
4 (16.7)
20 (83.3)
1 (7.1)
13 (92.9)
P16
     Neg
     Pos 
10 (26.3)
28 (73.7)
4 (10.8)
33 (89.2)
10 (26.3)
28 (73.3)
3 (9.1)
30 (90.9)
7 (29.2)
17 (70.7)
3 (21.4)
11 (78.6)
P21
     Neg
     Pos
21 (55.3)
17 (44.7)
19 (51.4)
18 (48.6)
21 (55.3)
17 (44.7)
7 (22.6)
24 (77.4)
13 (54.2)
11 (45.8)
8 (57.1)
6 (42.9)
* A staining index of 0-1 was considered negative, and a staining index of 2-9 was considered positive.
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no significant differences in staining patterns in the primary tumor were observed. Figure 3 
shows the difference in expression among the patients with metastatic disease between the 
primary and the metastatic tumor. In this immunohistochemical comparison, the metastatic 
sites showed significant more p16 and p21 expression compared to the primary tumor 
(P=0.01 and P=0.02 respectively). 
Figure 2: IHC staining score of the primary tumor of patient with metastases, compared to the 
primary tumor of patients without metastases depicted with boxplots. 
P-values were calculated using the Mann-Whitney Test.
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Differences in staining pattern between different sites of metastases
In Figure 4, the patients with locoregional and/or abdominal spread (N=24) were grouped 
and compared with respect to the immunohistochemical expression pattern of the primary 
tumor with the primary tumor of patients with lymphogenous and/or hematogenous 
spread of disease (n=14). In the group with lymphogenous and hematogenous spread 
Figure 3: IHC staining score of the primary tumor site, compared to the metastatic site within the 
same patient depicted with boxplots. 
 P-values were calculated using the Mann-Whitney Test.
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there was more expression of MIB, and less expression of ER and PR (P=<0.01, 0.04, and 
0.04 respectively). When we compared the primary tumor of patients with lymphogenous 
metastases (N=10) with the primary tumor of patients with hematogenous metastases (N=4) 
no significant differences in expression of the immunohistochemical panel were found (data 
not shown).
  
Figure 4: IHC staining score of the primary tumor of patients with loco-regional metastases compared 
to the primary tumor of patients with distant metastases  depicted with boxplots. 
P-values were calculated using the Mann-Whitney Test.
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Discussion
In this study, immunohistochemical profiles in EEC patients with and without metastatic 
disease were compared. Low or absent ER expression was found significantly more 
frequently in the primary tumor of patients with metastatic EEC. In addition, we compared 
the primary and the metastatic tumor, and found an increase of p21 and p16 expression 
in the metastatic site. Furthermore, the immunohistochemical profile of local and distant 
metastases demonstrated differences in the expression of ER, PR, and MIB.
Loss of ER expression in EEC related with a more aggressive clinical course is already known 
for many years. ER and PR are independent prognostic factors for survival and recurrence.7,8 
Loss of ER expression has also been reported in recurrent tumors of endometrial carcinoma 
patients.10 As mentioned before, type I carcinomas are directly related to estrogen. Estrogen 
and progesterone, binding to estrogen receptors (ER) and progesterone receptors (PR) 
respectively, lead to specific phenotypic effects.4 Estrogen promotes cell proliferation and 
inhibits apoptosis, including modulation of tumor suppressor function.18 In tumor grade 2 
and 3 EECs, it has been demonstrated that increased expression of ER and PR is associated 
with a better prognosis.19,20
The results of this study show a significant decrease in ER expression in the primary tumor 
of EEC patients with metastatic disease when compared to patients with the carcinoma 
confined to the uterus, thus more or less predicting the presence of metastases. Possibly, the 
carcinogenesis of these metastatic EECs differs from the estrogen stimulated carcinogenesis 
of type I carcinomas. We previously suggested the existence of an estrogen independent 
carcinogenetic pathway in EEC patients.21 Furthermore, ER and PR expression were 
significantly more decreased in patients with distant hematogenous and lymphogenous 
spread of disease. This emphasizes the predictive value of ER and PR in EEC. It furthermore 
underlines that loss of ER and PR has an important role in tumor progression in EEC. ER and 
PR would be a useful help in the preoperative setting for therapy decision making.  
MIB-1 is a cell-cycle regulator with increased expression in about half of endometrial 
carcinomas, associated with poor clinical outcome, vascular invasion, and hormone 
receptor loss.8,22 In the current study, the expression of MIB-1 was found more frequently 
in the primary tumor of patients with lymphogenous and hematogenous metastases when 
compared to the primary tumor of patients with abdominal and loco-regional metastases. 
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This indicates that activation of this proliferation marker may be one of the steps in the 
process of distant metastasizing. High MIB1 expression could therefore be a useful marker 
for the identification of EEC with potential aggressive behavior. 
Low expression-patterns of p16 have been associated with poor prognosis in endometrial 
carcinoma.23-26 However, increased p16 expression was associated with high FIGO stage in 
tumor grade 3 EECs.27 Over-expression of p16 has been observed at the invasive front of 
endometrial carcinomas.28 In the current study, the metastatic site shows an increase of p16 
expression when compared to the primary tumor. In literature, a possible explanation for 
these conflicting data can be found. There are three mechanisms known that alter the P16 
gene, i.e. homozygous deletion, promoter hypermethylation, and point mutations, all giving 
different degrees of aberrant protein staining.23,29,30 A substantial part of the underlying 
mechanism of P16 inactivation in endometrial carcinoma is not known. Loss of expression 
has been reported in 14-74% of endometrial carcinomas, whereas mutations, deletions and 
promoter methylation only occur in 2-6% of the endometrial carcinomas.8
In addition, conflicting data were found for p21 expression, a critical downstream effector 
in the P53 pathway, inducing cell cycle growth arrest.31 The inactivation of P21 could lead to 
tumor progression.11 In literature, a loss of expression was associated with poor prognosis 
in endometrial carcinoma.11,26,32 However, a gradual increase of expression of MIB-1, p16, 
and p21, from inactive endometrium to hyperplasia to EEC has also been reported.33 In the 
current study, a gain of p21 expression was found in the metastatic tumor when compared to 
the primary tumor. It is known from literature that a mutation of the P53 tumor-suppressor 
gene leads to accumulation of the mutant protein, showing increased expression of nuclear 
p53.18,19,34 This means that immunohistochemical expression of the protein is not equivalent 
to a functional protein status. Possibly, the same mechanism applies for mutation of the P21 
gene, resulting in over expression of the mutant protein in the metastatic site. 
The abovementioned studies reported on p16 and p21 expression in the primary tumor,11,23-26-32 
whereas in the current study we analyzed both primary and metastatic tumors. It may be 
possible that alterations in the P16 and P21 gene mark a next step in tumor progression 
of EECs. As mentioned before, a gradual increase of p16 and p21 expression was found 
comparing hyperplasia to inactive endometrium, and EEC to hyperplasia.28 The current 
study follows this line by finding an increase of p16 and p21 expression when comparing the 
metastatic tumor to the primary tumor in EEC patients.  
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In the current study, some immunohistochemical markers known to be predictors of poor 
survival, such as p53, L1CAM and E-cadherin did not reveal a significantly different expression 
pattern between the metastatic and control group, neither in the metastatic group between 
the primary and the metastatic tumor.8,12,13 P53 did show a trend of increased expression 
in 1) the primary tumor of patients with metastasis in comparison to the control group, 2) 
the metastatic site when compared to the primary tumor, and 3) the distant metastases 
when compared to loco-regional metastases. Also E-cadherin showed a trend of decrease 
in expression in the metastatic site when compared to the primary tumor. L1CAM did not 
show any difference in all comparisons. This observation may be partially explained by the 
low prevalence of L1CAM expression in EEC patients, but also by the low staining intensity 
and percentage of positive cells in L1CAM positive patients. In literature, 18% of patients in a 
large EEC cohort were L1CAM positive [13]. In the current study, containing a selected group 
of metastatic EECs, 18 of the 75 patients (24%) showed L1CAM expression.
This is a unique study, analyzing a large set of immunohistochemical markers in EEC patients. 
The cohort of EEC patients with histologically proven metastatic disease is relatively large 
and the tissue of the metastatic site was available for immunohistochemical analysis. 
Besides, the control group was matched on tumor grade, avoiding this possible bias in the 
IHC comparison between patients with and without metastatic disease. The shortcoming of 
this study is that it is a retrospective study harboring potential selection bias. Furthermore, 
all patients were treated according to the standardized Dutch guidelines of endometrial 
carcinoma treatment.2 This implicates that for the majority of the patients no routine 
lymphadenectomy i.e. formal staging was performed. Metastatic disease was surgically 
removed when there was a clear suspicion of metastatic disease during either pre-operative 
workup or during the operation. It further means that in only a minority of the patients in the 
control group the absence of lymphogeneous metastatic disease was histologically proven 
by a lymphadenectomy. However, no patient in the control group did develop recurrent 
disease during a median follow-up period of 44 months, which emphasizes the absence of 
metastatic disease at primary treatment.
In conclusion, this study gives more insight into the expression patterns of IHC markers 
potentially involved in the metastatic process of endometrioid endometrial carcinomas. 
Knowledge about these expression patterns may be useful in the pre-operative risk 
assessment of EEC patients and thus the individualization of treatment. More research 
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needs to be performed to gain more insight into the processes responsible for progression 
of disease in endometrioid endometrial carcinomas.  
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Abstract
Objective: Endometrial carcinomas are classified in two subtypes. Type I tumors are 
endometrioid endometrial carcinomas (EECs), associated with estrogen stimulation and 
generally with good prognosis. Type II tumors represent non-endometrioid endometrial 
carcinomas (NEECs) with poor prognosis. However, 20% of the EECs are associated with 
poor clinical outcome despite a favorable histology. The aim of this study was to determine 
if L1CAM expression, a recently reported biomarker for aggressive tumor behavior in 
endometrial carcinoma, was associated with clinicopathologic features of EECs. 
Methods: The immunohistochemical expression of L1CAM was determined in 103 EEC 
patients diagnosed from 1993-2009 in the Radboud University Medical Centre Nijmegen. 
Results: Eighteen L1CAM positive EECs were identified. Surprisingly, review of the diagnostic 
slides revealed that 11 of the 18 L1CAM positive tumors contained a serous- or mixed 
carcinoma component that was previously not reported. L1CAM expression was associated 
with older age of the patient, poor tumor grade, and lymphovascular space invasion. A 
worse five year progression-free survival rate was observed for patients with L1CAM positive 
tumors (55.6% for the L1CAM positive group, compared to 83.3% for the L1CAM negative 
group P=0.01), but L1CAM expression was not an independent determinant of survival. 
Significant predictors of survival were high FIGO stage (III-IV) (HR 4.68, 95% CI 1.88-11.66), 
lymphovascular space invasion (HR 3.91, 95% CI 1.56-9.75), and NEEC (HR 4.12, 95% CI 1.38-
12.31). 
Conclusion: We conclude that L1CAM expression analysis supports correct classification of 
endometrial carcinomas and that it carries prognostic value for histologically confirmed EEC. 
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Introduction
Endometrial carcinoma is the most common gynecologic malignancy in industrialized 
nations.1 Worldwide it is the third most common malignancy of the female genital tract 
with an incidence of 198,783, and a mortality rate of 50,327 annually.2 The majority of 
endometrial carcinomas is classified as type I endometrioid endometrial carcinoma (EEC), 
and is related to unopposed estrogenic stimulation due to obesity, or exogenous hormone 
use. EEC originates from hyperplastic endometrium, and generally has a good prognosis. 
Type II carcinoma represents non-endometrioid endometrial carcinoma (NEEC), like uterine 
papillary serous carcinoma (UPSC) and clear cell carcinoma, and carries a high risk of disease 
progression.3
There are differences with respect to the molecular pathways that are important in the 
development of these different types of endometrial carcinomas. Type I carcinomas are 
characterized as diploid tumors, with the presence of estrogen-, and progesterone receptors, 
PTEN alterations, microsatellite instability (MSI), mutations of KRAS, and CTNNB1. Type 
II carcinomas on the contrary, are often aneuploid, and show over expression of p53 and 
Her2/neu.4-6 Yet, about 20% of the individual cases does not fit within this dualistic model: 
EECs associated with poor clinical outcome and atrophic endometrium.5,7,8 This group of 
endometrial carcinomas are either misclassified based on their histologic appearance, or 
are inherently different despite truly morphological and clinical characteristics of EEC. 
Recently, expression of L1 cell adhesion molecule (L1CAM) has been associated with 
aggressive subtypes of endometrial carcinoma.9,10 Moreover, L1CAM has shown to be 
of great importance for the prediction of clinical outcome of FIGO stage I, histologically 
confirmed EECs.11 L1CAM is a neural cell recognition molecule, implicated in embryonic 
brain development.12 It is a member of the immunoglobulin super family, with a structure 
of six immunoglobulin like domains, five fibronectin type III like domains, a transmembrane 
stratch, and a highly conserved cytoplasmic component.13 L1CAM has an important role 
in the regulation of cell-cell interactions in neurohistogenesis, including axon outgrowth, 
neuronal migration, and regeneration after trauma.12,14 In carcinoma cell lines, L1CAM over 
expression augments cell motility and tumor growth. In addition to endometrial carcinoma, 
L1CAM expression is associated with poor prognosis in melanoma, ovarian-, breast-, and 
colon carcinoma.15-21 
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The current study was conducted in order to identify the clinicopathologic features of 
L1CAM positive EECs, and to assess the prognostic value of L1CAM in EEC patients.
Materials & methods
Patients and tissue specimen
The nationwide network and registry of histology and cytopathology in the Netherlands 
(Pathologisch Anatomisch Landelijk Geautomatiseerd Archief: PALGA) was used to search for 
patients diagnosed, and surgically treated with hysterectomy and bilateral oophorectomy 
at the Radboud University Nijmegen Medical Centre (RUNMC) for EEC between January 
1993 and January 2009. The terms “uterus” and “endometrioid carcinoma” were used to 
search through the PALGA database. Clinical data were collected by studying the medical 
charts. Age, menopausal state, body mass index (BMI), parity, use of estrogen, treatment, 
stage of disease, date of recurrence of disease, date of death, and the cause of death 
were registered. Stage of disease was based on the 1988 International Federation of 
Gynecology and Obstetrics (FIGO) staging system .22 Four to eight representative slides of all 
patients were retrieved from the pathology archive and used for review. Review was done 
systematically including the following items: tumor grade, depth of myometrial invasion 
(MI), the presence of vascular space invasion either in lymphatic or blood vessels (LVSI), and 
the histologic type.23 Review was performed independently by an experienced pathologist 
(RM) and an expert gyneco-pathologist (JB), who were unaware of the original pathology 
report, and the clinical outcome of the patient. Initial diagnosis was compared with the 
diagnosis after review. In case of discrepancy, the final diagnosis was obtained by consensus 
between the two pathologists. The EECs were also included in the study of Zeimet et al.11 
Immunohistochemical analysis of L1CAM was performed on sections of all endometrial 
carcinomas. The stained sections were analyzed by an independent pathologist who was 
not aware of the clinical outcome of the patients. Positive staining was defined as >10% 
immunoreactivity in any section derived from the tumor. 
Antibodies and Immunohistochemistry
A monoclonal antibody to L1CAM (L1-40.10) was obtained after immunization of mice 
with human L1-Fc protein comprising the ectodomain of L1.24 Staining was performed as 
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described previously.11 Briefly, following EDTA antigen retrieval, sections were stained using 
the automated I6000 immunostainer (Biogenics, San Ramos, California, USA), staining of 
tissue was visualized using 3,3’-Diaminobenzidine (Zymed lab. California, USA) as substrate, 
and counterstained with Mayer’s haematoxylin.
Statistical analysis
Differences in age, body mass index (BMI), FIGO stage, tumor histology, tumor grade, and 
LVSI between the group of patients with L1CAM positive and L1CAM negative tumors were 
tested for statistical significance using the Pearson’s Chi-Square (χ2) test or the Fisher’s exact 
test, and Mann-Whitney test. Survival analyses were performed to study the progression 
free survival (PFS), and the disease specific survival (DSS). PFS was calculated from the date 
of surgery until the last date of progression free follow-up. DSS was calculated from the 
date of surgery until the date of death. Standard Kaplan-Meier curves were used to plot 
the survival estimates. Differences between curves were statistically tested using the log 
rank test. All P-values presented are two-sided, and associations were considered significant 
if the P-value was less than 0.05. The prognostic impact of the variables age, FIGO stage, 
tumor grade, MI, LVSI, histologic type, and L1CAM status were analyzed by using univariable 
and multivariable Cox proportional hazards models. The forward stepwise method was 
used for selection procedures for multivariable Cox proportional hazards models. These 
results were expressed as hazard ratio’s (HR) with their 95% confidence intervals (95% CI). 
All statistical analyses were performed using the software package SPSS 18.0 for Microsoft 
Windows (SPSS Inc).
Ethical committee approval
The Research Ethics Committee of the Radboud University Nijmegen Medical Centre 
declared that the study protocol is in accordance with the applicable rules concerning the 
review of research ethics committees and informed consent.
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Results
Patient characteristics and treatment
Between January 1993 and January 2009, 103 patients with EEC were retrieved, and 
included for analysis. Patient characteristics are presented in Table 1. The median age was 
63 years, the majority of the patients was postmenopausal, and diagnosed at an early 
FIGO stage. Information for BMI calculation at diagnosis was available for 81 patients. 
The median BMI of these 81 patients was 28.9 kg/m2. All patients underwent abdominal 
hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection was omitted in 
80 cases that were without clinical suspicion of FIGO stage II or more, as recommended by 
the Dutch guidelines for endometrioid endometrial cancer treatment.25 In only one patient 
lymph node metastases were identified. Forty patients received additional treatment; 39 
patients received radiotherapy, one patient diagnosed as FIGO stage IV received adjuvant 
chemotherapy. Radiotherapy was either vaginal brachytherapy (N=11), external beam 
radiotherapy (N=21), or a combination of both (N=7). The five year DSS rate was 88.8%, the 
five year PFS rate was 77.7%. The median time of follow up was 57 months (range 0-148).
Review of the histologic slides
After review, the initial diagnosis was adjusted in 31 patients. In 25 cases tumor grade 
changed: upgrading from grade 1 to 2 (N=8), from grade 2 to 3 (N=10), from grade 1 to 
3 (N=1), downgrading from grade 3 to 2 (N=3), and 2 to 1 (N=3). In 11 cases the histology 
was classified different than the initial diagnosis of EEC. Five tumors were finally diagnosed 
as uterine papillary serous carcinoma (UPSC), three tumors were diagnosed as mixed 
carcinoma, and three as undifferentiated carcinomas. The diagnosis of mixed carcinoma 
was defined when at least 10% of a second component was present. The differences in 
initial diagnosis, and diagnosis after review of patients with changed histology are shown 
in Table 2. 
Immunohistochemistry
In the total study population of 103 carcinomas, 18 patients showed L1CAM positive 
staining in the tumor. All 11 NEECs, and seven confirmed EECs were L1CAM positive. L1CAM 
staining showed variable intensity. Staining had a tendency to more intensity at the invasive 
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Table 1: Clinical and pathologic characteristics (after review) in the total population (N=103).
Clinico-pathologic characteristics Total (N=103)
Median/N (range/%)
Median age (years) 63 (24-86 )
Postmenopausal
     No
     Yes
     Unknown
22 (21.3)
73 (70.9)
8   (7.8)
Median BMI* (kg/m2) 28.9 (18.7-53.6)
Lymph nodes
     Positive
     Negative
     Unknown
Adjuvant radiotherapy
     Yes
     No
Adjuvant chemotherapy
     Yes
     No
FIGO stage** 
     Low  (I-II)
     High (III-IV)
1 (1.0)
22 (21.3)
80 (77.7)
39 (37.9)
64 (62.1)
1     (1.0)
102 (99.0)
84 (81.6)
19 (18.4)
Tumor grade
     Low (1-2)
     High (3) 
78 (75.7)
25 (24.3)
Myometrial Invasion
     <50%
     >50%
61 (59.2)
42 (40.8)
Lymphovascular Space Invasion
     Not present
     Present
80 (77.7)
23 (22.3)
Histology
     Endometrioid
     Non- endometrioid
92 (82.3)
11 (10.7)
Adjuvant radiotherapy
     No
     Yes
64 (62.1)
39 (37.9)
Adjuvant chemotherapy
     No
     Yes
100 (99.0)
1   (1.0)
Five year disease specific survival rate 88.8%
Five year progression free survival rate 77.7%
Median follow up (months) 57 (0-148)
*Body Mass Index **1988 International Federation of Gynecology and Obstetrics staging system
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front (Figure 1A). The five tumors, diagnosed as pure UPSC after review of the histological 
slides, showed positive L1CAM staining throughout a major part of the tumor specimens. 
A representative example is shown in Figure 1B. Figure 1C shows an example of L1CAM 
positive staining in EEC. In the two mixed carcinomas with 50% serous component, and 
50% endometrioid component, the serous component was strongly positive, while the 
endometrioid component was weakly positive, or L1CAM negative (Figure 1D and 1E). 
Figure 1F shows L1CAM positive staining in an undifferentiated carcinoma, which is diffuse 
positive trough the tumour specimen. 
L1CAM expression and clinicopathologic characteristics 
The clinical and pathological characteristics of L1CAM negative and L1CAM positive patients 
after review are summarized in Table 3. Adjuvant treatment and mean time of follow up 
were equal in both groups. Patients with L1CAM negative tumors were significantly younger 
compared to patients with L1CAM positive tumors. There was no significant difference 
between L1CAM negative and L1CAM positive tumors with respect to menopausal state, 
BMI, and FIGO stage. 
Table 2: Initial diagnosis and diagnosis after review of cases with a changed diagnosis of EEC into 
NEEC.
Before revision After revision
Case Histology Grade Histology Grade 
6 Endometrioid 3 Serous 3
12 Endometrioid 3 Serous 3
14 Endometrioid 2 Undifferentiated 3
18 Endometrioid 2 Serous 3
21 Endometrioid 2 50% endometrioid / 50% serous 3
32 Endometrioid 3 Serous 3
45 Endometrioid 2 50% endometrioid / 50% serous 3
47 Endometrioid 3 Undifferentiated 3
48 Endometrioid 3 Serous 3
50 Endometrioid 2 50% serous/ 50% clear cell 3
53 Endometrioid 3 Undifferentiated 3
L1CAM expression in endometrial carcinomas is of prognostic value and supports correct histopathologic classification
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In addition, comparison of L1CAM negative and positive tumors revealed significant 
differences in distribution of tumor grade and frequency of lymphovascular invasion. No 
significant difference was found concerning myometrial invasion in both groups. The five 
year PFS rate was 82.3% in patients with EEC compared to 44.4% in patients with NEEC 
(Figure 2A, P<0.01). The five year DSS rate was 89.8%, and 50.0% respectively (Figure 2B, 
P<0.01). Comparing survival in L1CAM negative and L1CAM positive patients resulted in a 
five year PFS rate of 83.3% and 55.6% respectively (Figure 2C, P<0.01), and a five year DSS 
rate of 91.3% and 76.0% respectively (Figure 2D, P=0.04). 
Importantly, seven of 92 histopathologically confirmed EECs (7.6%) showed L1CAM 
expression. Comparing patients with L1CAM negative status and L1CAM positive status in 
Figure 1: L1CAM expression in endometrial carcinoma.
L1CAM expression at the invasive front of endometrioid endometrial carcinoma (A), papillary serous carcinoma (B), 
and endometrioid endometrial carcinoma with L1CAM positive staining (C). A mixed carcinoma (50% endometrioid 
: 50% serous) with no L1CAM expression in the endometrioid component (D) but with L1CAM expression in the 
serous component (E). L1CAM expression in an undifferentiated carcinoma (F).
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Table 3: Clinical and pathologic characteristics (after review) in the total population, the L1CAM 
negative and the L1CAM positive tumors.
Clinico-pathologic characteristics L1CAM negative L1CAM positive P-value
N=85
(range/%)
N=85
(range/ %)
Mean age (years) 59.7 (24-86)  68.2  (47-81) <0.01
Postmenopausal
     No
     Yes
21 (26.3)
59 (73.7)
1   (6.7)
14 (93.3) 0.18
Median BMI in kg/m2 (range) 29.3 (18.7-53.6) 27.1 (19.8-47.1) 0.12
Lymph nodes
     Positive
     Negative
FIGO stage* 
     Low  (I-II)
     High (III-IV)
1 (5.6)
17 (94.4)
71 (83.5)
14 (16.5)
0 (27.8)
5 (100.0)
13 (72.2)
5 (27.8)
1.00
0.32
Tumor grade
     Low (1-2)
     High (3) 
75 (88.2)
10 (11.8)
3 (16.7)
15 (83.3) <0.01
Myometrial Invasion
     <50%
     >50%
54 (63.5)
31 (36.5)
7 (38.9)
11 (61.1) 0.06
Lymphovascular Space Invasion
     Not present
     Present
73 (85.9)
12 (14.1)
7 (38.9)
11 (61.1) <0.01
Histology
     Endometrioid
     Non- endometrioid
85 (100)
0  (0.0)
 7 (38.9)
11 (61.1) <0.01
Radiotherapy
    No
    Yes
49 (57.6)
36 (42.4)
13 (81.3)
3 (18.8) 0.10
Mean follow-up (months) 60.4 (0.4-148.0) 51.1 (0-147.0) 0.40
*1988 International Federation of Gynecology and Obstetrics staging system
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the group with only EEC patients did not result in significant differences in survival due to 
this limited number of L1CAM positive EEC cases (data not shown). 
The results of the univariable- and multivariable analyses of the risk of recurrence or 
progression of disease and death as a consequence of disease are shown in Table 4 and 5. 
High FIGO stage (FIGO III-IV), poor tumor grade (grade 3), the presence of lymphovascular 
space invasion, NEEC, and L1CAM positivity were significant predictors of PFS. Significant 
predictors of DSS were high FIGO stage (III-IV), tumor grade (grade 3), myometrial invasion 
>50%, the presence of lymphovascular space invasion, NEEC, and L1CAM positive staining. 
When entering these significant factors in a multivariable model, only high FIGO stage (III-
IV), the presence of LVSI, and NEEC remained significant predictors of both poor PFS and 
DSS. Furthermore, there was a strong correlation between L1CAM status and histological 
type after multivariable analyses of prognostic variables related with PFS and DSS. 
Figure 2: Survival characteristics of endometrial carcinoma patients.
Progression free survival (A) and disease specific survival (B) of EEC patients compared to NEEC patients in months. 
Progression free survival (C) and disease specific survival (D) of patients with L1CAM positive or negative tumors 
in months.
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Table 4: Hazard Ratio’s (HR) with 95% Confidence Interval (95% CI) of the prognostic variables 
for recurrence and death as a consequence of disease after univariable Cox proportional hazards 
models .
Prognostic variable Recurrence Death of disease
N HR (95% CI) N HR (95% CI)
Age 
     < 60
     > 60
48
54
1.00 (reference)
1.41 (0.59- 3.37)
47
51
1.00 (reference)
1.57 (0.54- 4.54)
FIGO stage* 
     low: I-II
     high: III-IV
83
19
1.00 (reference)
4.02 (1.66- 9.75)
81
17
1.00 (reference)
3.99 (1.33- 12.00)
Tumor grade
     Low: 1-2
     High: 3
78
24
1.00 (reference)
3.80 (1.61- 9.00)
75
23
1.00 (reference)
4.04 (1.39- 11.74)
Myometrial Invasion
     <50%
     >50% 
60
42
1.00 (reference)
2.28 (0.96- 5.42)
60
38
1.00 (reference)
3.42 (1.14- 10.25) 
Lymphovascular space Invasion
     Not present
     Present
79
23
1.00 (reference)
4.13 (1.73- 9.86)
76
22
1.00 (reference)
4.20 (1.45-12.11)
Histology
     Endometrioid
     Non-endometrioid
92
10
1.00 (reference)
4.67 (1.70- 12.81)
89
9
1.00 (reference)
6.86 (2.09- 22.54)
L1CAM 
     Negative
     Positive
85
17
1.00 (reference)
3.69 (1.53- 8.93)
82
16
1.00 (reference)
3.09 (1.03- 9.23)
* 1988 International Federation of Gynecology and Obstetrics staging system
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Table 5: Adjusted Hazard Ratio’s (HR) of the prognostic variables for recurrence and death as a 
consequence of disease after multivariable Cox proportional hazards models with forward selection 
procedures.
Prognostic variable Recurrence Death of disease
N HR (95% CI) N HR (95% CI)
FIGO stage* 
     Low: I-II
     High: III-IV
83
19
1.00 (reference)
4.68 (1.88-11.66)
81
17
1.00 (reference)
4.17 (1.30-13.39)
Tumor grade
     Low: 1-2
     High: 3
NS** NS
Myometrial Invasion
     < 50%
     > 50%
NS NS
Lymphovascular Space Invasion 
     Not present
     Present
79
23
1.00 (reference)
3.91 (1.56-  9.75)
76
22
1.00 (reference)
3.79 (1.20-12.00)
Histology 
     Endometrioid
     Non-endometrioid
92
10
1.00 (reference)
4.12 (1.38-12.31)
89
9
1.00 (reference)
5.15 (1.34-19.78)
L1CAM 
     Negative
     Positive
NS NS
* 1988 International Federation of Gynecology and Obstetrics staging system **Not Selected
154
Chapter 8
Discussion
This study was conducted to determine whether L1CAM expression in EECs is related to 
pathologic features and clinical outcome. Our study revealed L1CAM expression in 18/103 
(17%) of the tumors originally diagnosed as EEC. Eleven of these cases were reclassified after 
expert review of the original diagnostic slides. Seven L1CAM positive EECs were identified. 
The study group of 103 endometrial carcinoma patients is representative for the population 
diagnosed with endometrial cancer, with a median age at diagnosis of 63 years, a median 
BMI of 28.9 kg/m2, a majority of early stage disease, and a minority of poorly differentiated 
tumors.3,26 However, the number of patients with EEC during the selected period of time 
was less than expected. This is probably due to the fact that the search terms “uterus” 
and “endometrioid carcinoma” in the PALGA database do not cover all EEC patients. Since 
selection of patients was accomplished using a search question we believe the studied 
group can be considered as a representative sampling. 
Furthermore, due to the retrospective character of the study over a long period of time, 
and the fact that UPSC has been recognized since the turn of the century, it is likely that 
UPSC has been misdiagnosed in the period till 2001.3 This is supported by our findings that 
all missed diagnosis of UPSC were diagnosed between 1993 and 2001. Improved awareness 
of the pathologist of the existence of UPSC nowadays, decreases the number of UPSCs 
mistaken for EECs. 
A recent multicentre study of L1CAM expression in 1021 histologically confirmed EECs 
demonstrated that L1CAM expression in EEC is an independent predictor of clinical outcome. 
A small percentage of these cases showed areas of non-endometrioid differentiation in 
less than 10% of the tumor, and this was associated with L1CAM positive staining.11 The 
molecular mechanism that drives L1CAM expression and how this contributes to poor 
prognosis remains largely elusive. 
Several studies have shown that L1CAM expression is associated with aggressive carcinoma 
subtypes and tumor progression.10,15-21 In serous ovarian and endometrial carcinomas, 
L1CAM expression is frequently present.10 If L1CAM expression is present in EECs, it is 
associated with poor tumor differentiation, absence of estrogen and progesterone receptors, 
and loss of E-cadherin expression.9 In our study, L1CAM expression was a predictor of poor 
progression free survival in univariable analysis. In multivariable analysis L1CAM was not 
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a significant predictor of survival, but was strongly correlated with NEEC, which was an 
independent predictor of poor clinical outcome. 
Consensus on the treatment of endometrial cancer patients is lacking and molecular 
markers for risk stratification are needed. Ideally, patients who would benefit from a 
more aggressive treatment strategy such as lymphadenectomy, should be identified pre-
operatively. Therefore, prognostic immunohistochemical markers should be used on 
endometrial specimens obtained with dilatation and curettage or pipelle. A set of markers 
including survivin, p21, and p53 has been suggested to predict prognosis in early stage 
endometrial carcinoma.27 Moreover, p53 and bcl-2 expression on pre-operative biopsies of 
the endometrium were found to be predictive for lymph node metastases.28 In this pre-
operative setting L1CAM could be a useful additional tool. It not only helps to identify 
NEECs, but it also identifies those EEC patients who are at high risk of disease progression. 
The prognostic value of a multiplexed biomarker analysis needs to be determined for risk 
stratification of endometrial cancer patients. 
Similarly, the predictive value of  L1CAM expression in the adjuvant setting needs to 
be determined. The use of adjuvant chemotherapy for the treatment of endometrial 
carcinoma is subject of debate. In two randomized trials no difference was found between 
adjuvant chemotherapy and adjuvant radiotherapy in high-risk patients.29,30 Combination 
of chemotherapy and radiotherapy is reported to improve progression free survival 
compared to radiotherapy only, yet, no differences were found in overall survival.31 Adjuvant 
chemotherapy is advised in NEEC patients with myometrial invasion and/or lymph node 
involvement.32 Our findings that L1CAM positive ECC is associated with poor PFS and DSS 
warrants further investigation into the predictive value of L1CAM expression for adjuvant 
chemotherapy for EEC patients. 
Determination of histology in poorly differentiated tumors can be challenging. Yet, accurate 
diagnosis of endometrial carcinomas is of great clinical importance, given the prognostic 
and therapeutic implications.33,34 In our study group of 103 EECs, 11 patients were diagnosed 
incorrectly, and were found to be NEEC patients. None of these 11 patients were properly 
staged, or received adjuvant chemotherapy. Three patients were diagnosed with FIGO stage 
IV and were never free of disease after primary treatment. Three other patients had distant 
recurrence of disease within two years. These six patients could have benefit from adjuvant 
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chemotherapy. Equally for radiotherapy, an incorrect histologic diagnosis resulted in under 
treatment in three cases. 
Taken this together, it is of great importance that in poorly differentiated tumors differentiation 
between NEEC and EEC is appropriate. In this study, the mixed endometrial carcinomas 
showed positive L1CAM staining in the serous component, whereas the endometrioid 
component was L1CAM negative. These observations have been described previously.9 In 
literature, several immunohistochemical markers are used to support the diagnosis of UPSC, 
i.e. over expression of p53, and p16, as well as loss of hormone receptors. Additionally, loss 
of PTEN expression supports the diagnosis of tumor grade 3 EEC.35,36 L1CAM might be a 
useful marker to add to a panel of markers to distinguish EEC from NEEC.  In addition, L1CAM 
staining was observed to be strongest at the invasive front, which confirms the suggestion 
that L1CAM is important for tumor invasion. However in the to date largest reported study 
on L1CAM expression in EEC, this  particular pattern of L1CAM staining was not observed.11
In conclusion, L1CAM is significantly associated with non-endometrioid histology and other 
clinicopathologic factors predicting poor survival. This makes L1CAM a potential marker 
for pre-operative identification of patients needing aggressive surgical and/or adjuvant 
treatment. Furthermore, distinction between NEEC and poorly differentiated EEC is 
challenging, but of great clinical importance. L1CAM could be a useful marker in the detection 
of non-endometrioid histology and of EEC with poor prognosis. A large prospective study is 
required to determine the clinical implications of L1CAM in endometrial carcinomas.
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General Discussion
This thesis describes the histopathologic appearance of the endometrium of asymptomatic 
women and endometrioid endometrial carcinoma (EEC) patients in detail, and discusses 
the pathogenesis of EEC. Furthermore, it describes the role of several pathologic, and 
immunohistochemical (IHC) markers in the prediction of the clinical course of endometrial 
carcinoma patients. The relevance and possible clinical consequences of the findings of this 
thesis are discussed in this chapter. 
The endometrium in postmenopausal women 
It is expected that, in its natural course, the endometrium of premenopausal women shows 
a cyclic pattern, whereas in postmenopausal women the endometrium is atrophic.1 In order 
to investigate endometrial carcinogenesis, the physiological conditions of the endometrium 
should be clear. In Chapter 2, it is shown that the endometrium of postmenopausal, 
asymptomatic women demonstrates focal proliferation or hyperplasia in 16 out of 48 
patients (33%). Weak proliferation in the endometrium of asymptomatic postmenopausal 
women has been reported before.2 Whether this proliferation is pathologic, and of clinical 
importance has yet to be determined. It is assumed that the transition of proliferative 
endometrium into atrophic endometrium after menopause is a gradual process,1 marked 
by varying serum estradiol levels, decreased serum progesterone levels, and a potentially 
disturbed ovarian-pituitary-hypothalamic feedback relationship.3,4 This gradual process 
could explain why years after menopause features of proliferative endometrium can still be 
found in the remaining inactive endometrium.
The focal presence of proliferative endometrium might indicate that the endometrium is 
only partially sensitive for the influence of circulating estrogens and progesterone. Possibly, 
within the same patient, the presence of Estrogen Receptors (ER) and Progesterone 
Receptors (PR) is heterogeneous in the endometrial surface. Yet, Sivridis et al performed 
immunohistochemical staining of postmenopausal endometrium and found positive ER and 
PR staining independent of whether the endometrium was active or inactive. However, they 
did find more evident staining patterns of epidermal growth factor receptor, proliferation by 
MIB1, and increased angiogenic activity in the stroma of weakly proliferative endometrium 
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when compared to inactive endometrium.5 Future research of asymptomatic endometrium 
should give more insight into the mechanism of focal proliferation. 
Carcinogenesis of endometrioid endometrial carcinoma 
It is generally believed that endometrioid endometrial carcinomas are a consequence of 
unopposed estrogen stimulation. Their carcinogenesis follows a stepwise process, gradually 
originating from hyperplastic endometrium.6-8 In Chapter 5, it is demonstrated that in 17% of 
patients with a grade 1 EEC tumor no, or only focal, hyperplasia was found in the background 
endometrium, indicating that this carcinogenic model does not explain fully the emergence 
of all EECs. However, it may be that these EECs in atrophic background endometrium 
developed in focal proliferative or hyperplastic areas. This hypothesis is supported by the 
finding of focal proliferation in further atrophic endometrium in Chapter 2. In addition, the 
expression pattern of IHC markers and mutations in BRAF and PIK3CA were comparable 
between EEC patients with hyperplastic and with atrophic endometrium. These findings 
suggest that part of the carcinogenesis is directed through the same pathways. 
Nevertheless, in Chapter 6, KRAS mutation was found in only 2% of patients with 
atrophic background endometrium, and in 37% of patients with hyperplastic background 
endometrium. KRAS mutations are known to be an early event in endometrioid endometrial 
carcinogenesis and are found in a large percentage of patients with hyperplastic 
endometrium.9,10 This means that the EECs with atrophic background endometrium might 
lack a crucial step in the current model of EEC carcinogenesis. In addition, KRAS mutation 
results in an upregulation of E-cadherin expression, and repressors of E-cadherin are found 
in endometrial carcinoma cell lines without KRAS mutation.11,12 We found loss of E-cadherin 
expression in the carcinomas with atrophic background endometrium when compared to 
the carcinomas with background endometrial hyperplasia. Loss of E-cadherin expression, 
which is the most important cell-cell adhesion molecule in epithelial cells, is known to be a 
predictor of poor clinical outcome.13-15 The carcinomas with atrophic endometrium showed 
a worse prognosis compared to the carcinomas with hyperplastic endometrium, which has 
been reported by other authors before.16 These findings support the hypothesis that EECs 
with atrophic background endometrium partly develop through different pathways than 
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EECs with hyperplastic background endometrium. Possibly, this may be the so-called third 
type endometrial carcinoma.16,17 
Prognostic value of pathologic markers
As pointed out in the introduction, prediction of the clinical course is extremely important 
in order to prevent under and overtreatment. Whereas prediction will be more and more 
supported by immunohistochemistry and molecular analyses, currently, most predictive 
models of endometrial carcinoma are still based on clinical and pathologic features,18 of 
which some are analyzed in this thesis. 
For the pre-operative setting, in Chapter 3 it is shown that the vast majority of patients 
with uterine papillary serous carcinoma have malignant endometrial cells in the cervical 
cytology, in contrast to only one third of the patients with endometrioid carcinomas. These 
results confirm the findings of other studies.19,20 Cervical cytology could be a predictive 
tool for patients with endometrial carcinoma, since it may give a warning sign of a non-
endometrioid type tumor. Furthermore, like in our study, the presence of malignant or 
atypical endometrial cells in cervical cytology has been associated with other predictors of 
poor survival such as stromal invasion of the cervix and advanced FIGO stage.21 It has been 
demonstrated recently that mutations found in the hysterectomy specimens of endometrial 
carcinoma patients were also found in the liquid based Papanicolaou smears of the same 
patients.22 Whether DNA analyses of PAP smears may be of clinical use in the detection of 
endometrial carcinoma or in the prediction of clinical behavior needs to be sorted out in 
future research.
For the post-operative setting, in Chapter 5 it is shown that atrophic background 
endometrium is an important predictor of clinical outcome. In current clinical practice, one 
or two slides of the endometrium adjacent to the carcinoma are evaluated. Unfortunately, it 
is not incorporated in the guidelines of pathologists to mention the nature of the background 
endometrium. Given the results of Chapter 6, the nature of the background endometrium 
should be mentioned in every pathology report. 
Additionally, in the post-operative setting, myometrial invasion is known to be one of 
the most important predictors of recurrence of disease.18,23,24 Therefore, to our opinion 
this parameter should be as reliable as possible. Currently, in the FIGO staging system, 
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myometrial invasion is described as more or less than 50% of the total myometrial thickness. 
Chapter 4 demonstrates that measuring the absolute depth of myometrial invasion and 
using a cut-off point of 4 mm predicts recurrence of disease and disease-free survival better 
than the currently used cut-off point of 50% of the total myometrial thickness. In literature, 
conflicting results about the best way of measuring myometrial invasion are reported. Some 
authors found absolute depth of myometrial invasion to be the best predictor,25 others 
found the tumor-free distance to be a better prognostic indicator.26-28 Nevertheless, we 
agree with these authors that an absolute cut-off value for myometrial invasion gives better 
predictive results than a percentage as cut-off value. Future research should sort out which 
way of measuring myometrial invasion is the best predictor of recurrence and which cut-off 
value should be used. 
Prognostic value of IHC markers
In order to identify immunohistochemical markers for the prediction of clinical behavior of 
endometrial carcinomas, we attempted to gain more insight into the metastatic process of 
EECs in Chapter 7. Vandenput et al recently revealed changes in expression of PR, p53, and 
p-mTOR in the recurrent tumor when compared to the primary tumor. These results show 
that endometrial carcinoma biology changes over time.29 We compared primary tumors 
with and without metastases, and primary tumors with the metastatic site to reveal how 
tumor biology changes in the metastatic process.  
A loss of ER expression was found in the primary carcinoma of EEC patients with proven 
metastases (locoregional and distant) when compared to EEC patients without metastases. 
In addition, within the metastatic group, loss of ER and PR expression and gain of MIB1 
expression was found in the primary tumor of patients with distant metastases in comparison 
with the primary tumor of patients with locoregional metastases. These findings emphasize 
again that hormone receptors play an important role in endometrioid carcinogenesis and 
are important predictors of survival. It also indicates that expression of cell-cycle regulator 
MIB1 seems to be an important step in the metastatic process for distant metastases.30-32 
The predictive use of ER, PR, and MIB1 is the most interesting for the clinician, as they 
contribute to the identification of carcinomas that have the potential to metastasize. 
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Gain of p16 and p21 expression was found in the metastatic site when compared to 
the primary tumor. P16 is a tumor suppressor gene and part of the Rb (retinoblastoma 
associated protein pathway), which is an important suppressor of proliferation.33 Changes 
in p16 expression were associated with aggressive endometrial carcinomas before. 
However, whether increased or decreased p16 expression is a predictor of poor survival 
is controversial.34-36 In addition, the inactivation of P21 leads to tumor progression, as it 
is a critical downstream effector in the P53 specific pathway.30,37,38 P53 is one of the most 
prominent suppressors of proliferation.39 Also for p21 results of expression patterns are 
conflicting in literature as both gain and loss of protein expression are associated with 
aggressive tumor behavior.40-43 Nevertheless, taking these studies and our results together, 
alterations in P16 and P21 seem to increase the metastatic potential of endometrial 
carcinoma. Furthermore, changes in the pathways of proliferation suppressors p53 and Rb 
seem to be important steps in the metastatic process of EECs. The conflicting results of 
p16 and p21 expression need to be sorted out in future research in order to determine the 
clinical use of the IHC expression of these two proteins. 
Chapter 8 focuses on a promising marker in the identification of aggressive endometrial 
carcinomas: L1CAM.44 L1CAM was recently identified to be an independent predictor of 
survival in EECs specifically.45 In this large multicentre cohort of over one thousand EEC 
patients, carcinomas with L1CAM expression showed a striking decrease in the disease free 
five-year survival rate when compared to L1CAM negative EECs. However, only 18% of this 
large cohort was L1CAM positive. As shown in Chapter 5, L1CAM was strongly associated 
with non-endometrioid histology in our series. It was previously shown that the percentage 
of L1CAM positive tumors was 75% in serous carcinomas and 16% in endometrioid 
carcinomas.46 Taking this together, a L1CAM positive endometrial carcinoma may be either a 
carcinoma with non-endometrioid histology, or an endometrioid carcinoma with aggressive 
behavior. This makes L1CAM a useful marker for the prediction of clinical behavior of 
endometrial carcinomas.
The association of L1CAM with EECs with a poor clinical course led to the presumption that 
more L1CAM expression could be found in EECs with atrophic background endometrium 
when compared to the EECs with hyperplastic background endometrium. We did not find 
this difference in Chapter 6, but we did find a significant gain of expression in the serous 
carcinomas in Chapter 7. The low prevalence of L1CAM expression in EECs is a possible 
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explanation for this. In Chapter 8, of the seven L1CAM positive EECs, only one carcinoma had 
atrophic background endometrium. Of the other six carcinomas one had premenopausal 
proliferative, four had hyperplastic, and one had no background endometrium. It would be 
interesting to know the nature of the background endometrium of the L1CAM positive EECs 
in the multicenter study of Zeimet et al.45    
Furthermore, up-regulation of L1CAM is associated with loss of E-cadherin, and loss of 
ER and PR expression.47 Since L1CAM expression is a predictor of poor clinical survival, 
an association with other predictors of poor survival is not surprising.14,31 A causal link 
between L1CAM and E-cadherin possibly lies within the Epithelial-Mesenchymal Transition 
(EMT) program. The EMT signaling pathway is identified to be the regulator of invasion 
and metastasis in cancer of epithelial origin. It is loosely defined by three major changes 
in cellular phenotype: (1) morphological changes from cobblestone-like epithelial cells to 
spindle-shaped mesenchymal cells which migrate more easily; (2) changes in markers of 
cell-cell junction such as E-cadherin; and (3) functional changes from stationary cells to 
motile cells.39,48 
Recently, EMT was described in endometrial cancer as well.49,50 These review articles can put 
the findings of Chapter 6, 7, and 8 in a broader perspective. The most common hallmarks 
of EMT have been found in endometrial carcinoma, either at the level of E-cadherin loss 
or at the induction of its repressors. Also other molecular alterations, consistent with 
the mesenchymal phenotype like L1CAM and MIB1 up-regulation, have been found in 
endometrial carcinoma. EMT inducer TGFβ1 was found to be one of the regulators of L1CAM 
expression, and MIB1 up-regulation has been found to contribute to the EMT-derived invasive 
phenotype in endometrial carcinoma cells.49 Taking this all together, carcinomas evaluated 
in this thesis which were associated with poor clinical features like poor progression-free 
survival or metastatic disease, expressed features of the EMT pathway.
Conclusions
The endometrium of asymptomatic postmenopausal women shows focal proliferation in 
a substantial part of the patients, which possibly indicates that some EECs arise in focal 
areas of proliferative endometrium. Nevertheless, carcinomas in atrophic background 
endometrium and carcinomas in hyperplastic background endometrium show partly the 
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same IHC pattern and profile of mutations, but partly there are differences. This means that 
the carcinogenic process of EECs with atrophic background endometrium could be different 
from the known stepwise carcinogenic model of EEC.
Immunohistochemical expression of features known to be involved in carcinogenesis 
and metastases of EECs could be useful in daily clinical practice. It could be helpful in the 
discrimination between carcinomas with and without metastatic potential, and thus in 
identifying patients in need of more aggressive treatment. 
Besides immunohistochemistry, conventional pathologic markers, such as cervical cytology, 
background endometrium, and depth of myometrial invasion could also be incorporated for 
prediction of the clinical course. This thesis gives new possibilities for the use of myometrial 
invasion and emphasizes the importance of looking at the tissue surrounding the tumor, 
since the nature of the background endometrium is a prognostic marker. 
Future Perspectives
Before the results of this thesis can be translated into clinical use, data should be confirmed 
in a larger, prospective, multicentre trial. A set of IHC markers could be incorporated in 
an algorithm for pre-operative clinical decision making together with the already used 
pathologic features tumor type and tumor grade. This set of markers could consist of ER, 
PR, p16, p21, p53, E-cadherin, MIB1, and L1CAM, and depending on the results of future 
studies of more markers. At present, other researchers are investigating the prognostic 
use of IHC markers in endometrial carcinoma. Recently, the MOMaTeC study group proved 
that double negative hormone receptor status in pre-operative biopsy is an independent 
predictor of poor clinical outcome and lymph node metastases.51 Other results of this 
multicenter, prospective trial are awaited. Currently, another prospective study investigates 
the usefulness of a set of IHC markers in the pre-operative setting of endometrial carcinoma 
patients (PIPENDO).52 
Furthermore, a substantial part of the carcinogenesis of endometrial carcinoma is still 
not fully understood. Comparison of more IHC markers and mutations between EECs with 
atrophic and hyperplastic background endometrium should be performed in future research 
to prove the existence of a separate carcinogenic pathway. In addition, mutation analyses 
of background endometrium could give more information on the carcinogenesis of EECs. 
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The individualization of endometrial carcinoma treatment still needs fine tuning. Currently, 
we are at a point where we have gained more insight into endometrial carcinogenesis, but 
these insights are hardly used in daily clinical practice. More understanding of the process of 
tumor progression gives the possibility of using IHC or molecular markers for risk assessment 
for metastatic or recurrent disease, and gives potential for targeted therapy. 
Suggestions for clinical practice
• In case of atypical or malignant endometrial cells in cervical cytology, the clinician 
should think about the possibility of a more aggressive endometrial carcinoma.
• Myometrial invasion should be measured in absolute millimeters of invasion instead of 
the currently used cut-off value of more or less than 50% of the myometrial thickness. 
• The background endometrium should be mentioned in the pathology report of 
endometrial carcinoma patients.
• A set of IHC markers with ER, PR, MIB1, E-cadherin, and L1CAM should be incorporated 
in pre-operative and post-operative setting for guidance in clinical decision making.
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SUMMARY
In the western world, endometrial cancer is the most common cancer of the female 
genital tract. In a generally accepted dualistic model of endometrial carcinogenesis two 
subtypes are distinguished based on clinical behavior and histopathologic presentation 
of the carcinoma. Type I carcinoma, representing 80% of all endometrial carcinomas, 
occurs around an average age of 60 years and bears in general a good prognosis. These 
endometrioid carcinomas are directly linked to unopposed estrogen stimulation, and show 
a background of hyperplastic endometrium. Type I carcinomas are characterized by ER and 
PR expression, Micro Satellite Instability, and alterations in KRAS, CTNNB1, PTEN, and the 
WNT-pathway. Type II carcinomas, on the contrary, occur at an average age of 70 years, 
and bear a relatively poor prognosis. These carcinomas show non-endometrioid histology 
like serous and clear cell type. The background endometrium of these patients appears 
atrophic, and carcinomas are characterized by aneuploidy, p53 and Her2/neu expression, 
and loss of E-cadherin expression. An outline of the treatment strategies and the currently 
known predictive markers for endometrial carcinoma is given in Chapter 1.
In order to investigate endometrial carcinogenesis, the physiological conditions of the 
(postmenopausal) endometrium should be clear. Chapter 2 gives a detailed description of 
the endometrium of 20 premenopausal and 48 postmenopausal women who did not have 
symptoms of (abnormal) vaginal bleeding. To this end, the endometrium of these patients 
undergoing a hysterectomy for symptoms of uterine prolapse was analyzed systematically 
using the SEE-END protocol. (Focal) proliferative endometrium or hyperplasia was found in 
33% of the postmenopausal women. Hyperplasia or disordered proliferative endometrium 
was found in 5% of the premenopausal women. This is a remarkable high prevalence of 
endometrial pathology in asymptomatic women, but the clinical relevance of these lesions 
has yet to be determined.
In Chapter 3, we found abnormal endometrial cells in cervical cytology in 87.5% of a cohort 
80 uterine papillary serous carcinoama (UPSC) patients, and in 37.8% of a cohort of 267 
endometrioid endometrial carcinoma (EEC) patients. Furthermore, abnormal endometrial 
cells in cervical cytology were associated with extra-uterine spread of disease in the UPSC 
group and with cervical involvement in the EEC group. These data indicate that the clinician 
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should be more alert for a non-endometrioid carcinoma or an endometrioid carcinoma in 
advanced stage when endometrial cells are found in cervical cytology. 
Currently, myometrial invasion is expressed as more or less than 50% of the total 
myometrium. In literature, the interobserver variability of assessing myometrial invasion 
is around 30%. In Chapter 4 the predictive value of expressing myometrial invasion as the 
absolute depth of invasion in millimeters was compared to expressing myometrial invasion 
in more or less than 50% of the myometrium, and to expressing invasion as the distance to 
the serosa in millimeters in a cohort of 335 EEC patients. The absolute depth of myometrial 
invasion was found to have a better predictive value than the other ways of measuring 
myometrial invasion. Whether the interobserver variability decreases with this way of 
measuring myometrial invasion has yet to be determined. 
Approximately 20% of the individual cases does not fit the dualistic model of endometrial 
carcinogenesis. This 20% includes endometrioid carcinomas associated with poor prognosis 
and atrophic background endometrium. In Chapter 5 the background endometrium of a 
cohort of 527 tumor grade 1 endometrioid endometrial carcinomas was analyzed. Seventeen 
percent showed atrophic background endometrium. In addition, atrophic background 
endometrium was an independent prognostic factor for patients with tumor grade 1 EEC. 
Possibly, these carcinomas with atrophic background endometrium do not follow the 
hypothesized progression model for type I tumors. They may arise trough a unique, third 
carcinogenic pathway.
With the intention to find more evidence for the existence of a third type endometrial 
carcinoma in Chapter 6, we compared the expression profile of a set immunohistochemical 
(IHC) markers, and the presence of BRAF, KRAS, and PIK3CA mutations in EEC patients with 
hyperplastic background endometrium (type I), with UPSC patients (type II), and EEC patients 
with atrophic background endometrium (type III). Expected differences between EEC (type 
I and III) and UPSC (type II) were found: EEC showed higher expression of ER and PR, and 
lower expression of L1CAM, p53, and MLH1. Within the EECs, the expression patterns of 
type I and type III carcinomas were mostly comparable. However, type III carcinomas did 
show significantly lower E-cadherin expression, and significantly less mutations in the KRAS 
gene than type I carcinomas. KRAS mutation comprises an important step in the type I 
carcinogenic model of hyperplasia turning into EEC. These findings might indicate that type 
III carcinomas lack a crucial step in the carcinogenic pathway of type I carcinomas. 
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In Chapter 7, in order to identify prognostic markers for EEC, a comparison of the expression 
profile of a set of 12 IHC markers was made between the primary tumor of EEC patients with 
metastatic disease and the primary tumor of a control group of EEC patients with FIGO stage 
I disease. Only ER expression was found to be significantly lower in patients with metastatic 
disease. This finding emphasizes that loss of ER expression is an important predictor of poor 
clinical outcome. A second evaluation in this chapter showed significantly more p16 and p21 
expression in the metastatic site when compared to the primary tumor. this indicates that 
these two effectors of the Rb and P53 pathway respectively, play a role in the metastatic 
process. The third comparison showed increased MIB1 expression and decreased ER and PR 
expression in the primary tumor of patients with distant metastases when compared to the 
primary tumor of patients with loco-regional metastases.
In Chapter 8, L1CAM was studied to determine if it was associated with clinicopathologic 
features in EEC. L1CAM, a membranous marker, regulating cell-cell interactions, has recently 
been reported by other authors to be an independent predictor of survival in EEC. In our 
study, 18 of a cohort of 103 EEC patients was L1CAM positive. However, after histologic review, 
11 of the 18 L1CAM positive cases turned out to be non-endometrioid carcinomas. L1CAM 
was associated with older age, poor tumor differentiation, lymphovascular space invasion, 
and was a predictor of poor survival in univariable analysis. In multivariable analysis non-
endometrioid histology, and advanced FIGO stage turned out to be independent predictors 
of survival, as L1CAM was not. We concluded from this study that L1CAM expression could 
support correct classification of endometrial carcinoma and that it carries prognostic 
information for endometrial carcinoma.
In Chapter 9 the results of the different chapters are discussed and put in perspective 
with results from literature. In addition, some clinical recommendations are done, and the 
possibilities for future research are discussed.       
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In de westerse wereld is het endometriumcarcinoom de meest voorkomende maligniteit 
van de vrouwelijke tractus genitalis. In een algemeen geaccepteerd, dualistisch model voor 
de carcinogenese van het endometriumcarcinoom worden twee typen onderscheiden. Dit 
onderscheid is gebaseerd op het klinische gedrag en de histopathologische presentatie van 
het carcinoom. Type I carcinomen, goed voor 80% van alle endometriumcarcinomen, ontstaan 
rond een gemiddelde leeftijd van 60 jaar en over het algemeen hebben deze patiënten een 
goede prognose. Deze endometrioïde carcinomen zijn het directe gevolg van stimulatie 
door oestrogenen en ontstaan in een achtergrond van hyperplastisch endometriumweefsel. 
Type I carcinomen worden gekarakteriseerd door expressie van ER en PR, Microsatelliet 
instabiliteit en veranderingen in KRAS, CTNNB1, PTEN en de WNT-signaaltransductiecascade. 
Dit in tegenstelling tot de type II carcinomen, die rond een gemiddelde leeftijd van 70 jaar 
ontstaan en over het algemeen een slechte prognose hebben. Type II carcinomen laten 
vaak het histologische beeld zien van een niet-endometrioïd type carcinoom zoals het 
sereuze carcinoom of het helder-cellige carcinoom. Het achtergrondendometrium van deze 
patiënten is atrofisch. Deze carcinomen worden gekenmerkt door  aneuploïdie, p53 en 
Her2/neu expressie en verlies van E-cadherine expressie. Hoofdstuk 1 geeft een overzicht 
van de behandelmethodes en de voorspellende markers voor het endometriumcarcinoom 
die we op dit moment kennen.
Om meer inzicht te krijgen in de carcinogenese van het endometriumcarcinoom, zouden we 
meer moeten weten over de fysiologie van het (postmenopauzale) endometrium. Hoofdstuk 
2 geeft een gedetailleerde beschrijving van het endometrium van 20 premenopauzale en 
48 postmenopauzale vrouwen die geen symptomen hadden van (abnormaal) vaginaal 
bloedverlies. Om dit te bewerkstelligen werd het endometrium van deze vrouwen, die een 
hysterectomie ondergingen vanwege een prolaps uteri, systematisch onderzocht volgens 
het SEE-END protocol. (Focaal) proliferatief endometrium of hyperplastisch endometrium 
werd gevonden bij 33% van de postmenopauzale vrouwen. Hyperplastisch endometrium, 
of abnormaal proliferatief endometrium werd gevonden bij 5% van de premenopauzale 
vrouwen. Dit is een opmerkelijk hoge prevalentie van pathologie van het endometrium van 
vrouwen zonder symptomen van (abnormaal) vaginaal bloedverlies. De klinische betekenis 
van deze bevindingen is echter nog niet geheel duidelijk. 
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In hoofdstuk 3 vonden we abnormale endometriumcellen in het cervixuitstrijkje in 87.5% 
van een cohort van 80 patiënten met sereuze carcinomen en in 37.8% van een cohort 
van 267 patiënten met endometrioïde endometrium carcinomen (EEC). Bovendien waren 
abnormale endometriumcellen in het cervixuitstrijkje geassocieerd met uitbreiding van het 
carcinoom buiten de uterus van de groep patiënten met sereuze tumoren en met uitbreiding 
van het carcinoom in de cervix van de groep patiënten met endometrioïde tumoren. Deze 
data geven een indicatie dat de clinicus gewaarschuwd moet zijn voor de mogelijkheid van 
ofwel een niet-endometrioïd carcinoom ofwel een endometrioïd carcinoom in een hoog 
stadium wanneer endometriumcellen worden gevonden in het cervixuitstrijkje. 
Volgens de huidige richtlijnen wordt invasie van de tumor in het myometrium uitgedrukt 
in meer of minder dan 50% van de totale dikte van het myometrium. Uit studies blijkt dat 
in ongeveer 30% van de gevallen de pathologen die de diepte van de myometriuminvasie 
beoordelen van mening verschillen. In hoofdstuk 4 wordt de voorspellende waarde van 
het uitdrukken van myometriuminvasie als absoluut getal in millimeters vergeleken met het 
uitdrukken van myometriuminvasie in meer of minder dan 50% en met het uitdrukken van 
de myometriuminvasie in millimeters naar de serosa in een cohort van 335 EEC patiënten. De 
myometriuminvasie uitgedrukt als absoluut getal in millimeters had een betere voorspellende 
waarde dan de andere manieren van meten en uitdrukken van myometriuminvasie. Het 
moet nog worden uitgezocht of de beoordelingen van verschillende pathologen beter met 
elkaar overeen zullen komen door deze andere manier van meten te gebruiken.
Ongeveer 20% van de individuele casus past niet in het dualistische model van de 
carcinogenese van het endometriumcarcinoom. Deze 20% behelst endometrioïde carcinomen 
die geassocieerd zijn met een slechte prognose en atrofisch achtergrondendometrium. In 
hoofdstuk 5 werd het achtergrondendometrium van een cohort van 527 patiënten met 
graad 1 endometrioïde endometriumcarcinomen (EEC) geanalyseerd. Zeventien procent 
had  atrofisch achtergrondendometrium. Daarnaast was atrofisch achtergrondendometrium 
een onafhankelijke voorspeller van de klinische uitkomst van patiënten met graad 1 
endometrioïd endometriumcarcinoom. Het is mogelijk dat deze carcinomen met atrofisch 
achtergrondendometrium niet het stapsgewijze model volgen voor de carcinogenese van 
het type I endometriumcarcinoom. Wellicht ontstaan deze carcinomen door een ander, 
derde model voor carcinogenese.
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Met de bedoeling om meer bewijs te vinden voor dit mogelijke derde type 
endometriumcarcinoom, hebben we in hoofdstuk 6 het expressiepatroon van een set 
van immunohistochemische (IHC) markers en de aanwezigheid van BRAF, KRAS en PIK3CA 
mutaties bij EEC patiënten met hyperplastisch endometrium (type I), patiënten met sereuze 
carcinomen (type II) en EEC patiënten met atrofisch endometrium (type III) vergeleken. We 
vonden de verwachte verschillen tussen EEC (type I en III) en sereuze carcinomen (type II): 
EEC liet een hogere expressie van ER en PR zien en een lagere expressie van L1CAM, p53 en 
MLH1. Bij de vergelijking tussen de EEC patiënten, waren de expressiepatronen van type I 
en III voor het grootste deel vergelijkbaar. Type III liet wel een significant lagere E-cadherine 
expressie zien. Daarnaast waren er significant minder mutaties van het KRAS gen dan bij het 
type I carcinoom. KRAS mutaties zijn een belangrijke stap in het model voor het ontstaan 
van type I carcinomen bij de overgang van hyperplastisch endometrium naar graad I EEC. 
Deze bevindingen geven een aanwijzing dat type III carcinomen een cruciale stap overslaan 
in het model voor carcinogenese van type I carcinomen.
In hoofdstuk 7 hebben we het expressie profiel van een set van 12 IHC markers in de primaire 
tumor van een groep patiënten met FIGO stadium I EEC vergeleken met het expressiepatroon 
in de primaire tumor van een groep EEC patiënten met metastasen. Het doel van deze 
vergelijking was het identificeren van prognostische markers voor EEC patiënten. Alleen ER 
expressie was significant hoger in de groep met metastasen. Deze bevinding benadrukt dat 
verlies ER expressie een belangrijke voorspeller is van een slechte klinische uitkomst. Een 
tweede vergelijking in dit hoofdstuk liet significant meer expressie van p16 en p21 zien in 
de metastase vergeleken met de primaire tumor van dezelfde patiënt. Dit kan betekenen 
dat deze twee effectoren van de, respectievelijk, Rb en P53 signaaltransductiecascade een 
rol spelen bij het metastaseringsproces. De derde vergelijking liet verhoogde expressie van 
MIB1 en verlaagde expressie van ER en PR zien in de primaire tumor van patiënten met 
metastasen op afstand, vergeleken met de primaire tumor van patiënten met lokale of 
regionale metastasen.
In hoofdstuk 8 werd L1CAM bestudeerd om te bepalen of deze marker geassocieerd is met 
klinische en pathologische uitkomsten bij EEC patiënten. L1CAM, een membraneuze marker, 
reguleert de cel- cel interactie. Het is recent aangetoond door andere auteurs dat het een 
onafhankelijke voorspeller van overleving is voor EEC patiënten. Wij vonden dat bij 18 van 
een cohort van 103 EEC patiënten de tumor L1CAM positief was. Echter, na revisie van de 
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histologische coupes bleken 11 van de 18 L1CAM positieve tumoren niet-endometrioïde 
carcinomen te zijn. L1CAM was geassocieerd met oudere leeftijd, slechte tumordifferentiatie 
en invasie van de lymfovasculaire ruimtes en was verder geassocieerd met slechte overleving 
na univariate analyse. Bij multivariate analyse bleken niet-endometrioïde histologie 
en gevorderd FIGO stadium de onafhankelijke voorspellers van overleving, L1CAM was 
geen onafhankelijke voorspeller. Wij concludeerden uit deze studie dat L1CAM expressie 
ondersteunend kan zijn bij het stellen van de goede histologische diagnose en dat L1CAM 
prognostische informatie kan geven over het endometriumcarcinoom.
In hoofdstuk 9 worden de resultaten van de verschillende hoofdstukken bediscussieerd en 
in perspectief geplaatst ten opzichte van eerdere resultaten uit de literatuur. Aanvullend 
worden een aantal klinische aanbevelingen gedaan en de mogelijkheden voor toekomstig 
onderzoek worden besproken.        
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